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CHAPTER ONE: SUMMARY.
1. SUMMARY
The present study aimed to evaluate two screening strategies, single strand conformation 
polymorphism (SSCP) and amplification mismatch detection (AMD) analysis, for the 
detection of point mutations in the retinoblastoma gene (RB). SSCP was optimised and 
applied to exons 12-22 of the RB gene which constitute the most important functional 
domain. Leukocyte DNA from 20 patients with bilateral retinoblastoma (Rb), tumour 
DNA from 40 patients with bladder carcinoma and tumour DNA from 39 patients with 
breast carcinoma were subjected to SSCP analysis. SSCP band shifts were found in 4 of 
20, 1 of 40 and none of 39 patients respectively. AMD was optimised and applied to 
exons 12-16 of the RB gene and also to reverse-transcriptase PCR in the 20 patients with 
bilateral Rb. Cleavage was found in 2 patients: one was found in a cDNA segment and 
the other was found in genomic DNA. Neither of these patients corresponded to the 4 
with SSCP band shifts. Thus in total, 6 patients with Rb and one with bladder carcinoma 
had mutations detected and proof was sought by sequencing.
Amplification of segment C of the cDNA of patients with bilateral Rb has revealed that 
patient EAS showed an additional band indicating either a deletion or a splice mutation. 
Analysis of exon 17 and the flanking intron of the same patient with AMD showed a 
cleavage with hydroxylamine. Sequencing of the exon revealed that the mutation is a C 
substitution of the A at position -2 of the acceptor site of intron 16, impairing normal 
splicing of the RNA. The mutation results in skipping of exon 17, because the short 
transcript band on the agarose gel was approximately 196 bp shorter than the original 
band and exon 17 was 196 bp in size. This leads in turn to the production of a truncated 
RB protein. By analogy to other published mutations, this aberrant, destabilised protein 
might not be able to bind the El A oncoprotein. In addition, the mutant RB protein may 
fail to complex with S V40 large T antigen.
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Analy sis of segment C of the cDNA from patient PC with bilateral Rb showed a cleavage 
with hydroxylamine reaction. Sequencing of the segment revealed the mutation to be a T 
-»G transversion at nucleotide position 1587 within exon 16 causing a substitution of 
histidine to glycine. The missense mutation may or may not have a functional effect. 
However, this residue lies within an RB domain (aminoacids 393-572) identified recently 
by in vitro deletion mutants to be required for oncoprotein binding. This mutation creates 
a restriction site for Nde I.
Sequencing of exon 21 from patient MH who had an SSCP band shift, revealed that an 
insertion of a G at nucleotide position 2251 within exon 21 resulted in a novel stop codon 
(TAA) at codon 719 (nucleotide position 2295) within exon 21 thus deleting the domain 
interacting with the SV40 T antigen. The translated protein is most probably too short to 
be functional. To confirm whether the observed SSCP pattern in the region of exon 21 of 
the RB gene was a new germ line mutation or inherited from one of the parents, 
heteroduplex analysis of the parents revealed either the mutation was de novo or one of 
the parents had germ line mosaicism. In addition, the change creates a restriction site for 
the restriction enzyme Fokl.
Another mutation detected (from patient AR) by SSCP analysis was an A to C 
transversion at position 1636 in exon 16 causing AGA to CGA codon change, both 
coding for the same amino acid: Arginine, this mutation abolishes a restriction site for the 
restriction enzyme Cvijl. The mutation site was located in the last base of the exon 16, 
although it has not been shown in this study in mRNA, it could affect splicing of the 
mRNA of RB gene.
Two mutations found were considered to be silent mutations, because they do not cause 
any amino acid change. Their RNA transcripts were found to be normal. These mutations
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were a T to C transition at position 1617 in exon 16 (Patient GM) which alters the codon 
GTT (GUU) to GTC (GUC) both coding for the same amino acid: Valine and an A-»G 
tra n s its  in intron 19 (patient EAS) which abolishes a restriction site for the 
restriction enzyme Tsp 509 I which may be useful in tracking this mutation in affected 
family members. Analysis of 100 samples (patients with bilateral Rb and other tumours) 
for this restriction site revealed that none of them has same change.
The mutation found from the patient with bladder carcinoma was a G to C transversion at 
position +1 of the donor site of intron 12, probably impairing normal splicing of the 
RNA. The second mutation was assumed to lie in a part of the retinoblastoma gene that 
was not analysed, since in somatic cases two hits in the RB gene are expected. Intact 
RNA could not always be recovered from the clinical material used in this study, 
therefore the diagnostic strategy for bladder carcinoma was chosen not to be based on the 
analysis of RNA transcript. The change creates a recognition site for the restriction 
enzymes MaeM, Bpu\0\, DdeI.
The seven mutations detected in this study were all novel and emphasise the 
heterogeneity of the molecular pathology in this gene. The screening approach each 
contributed to the identification of the region of interest, but there was no overlap 
between the two. This suggests that a single approach would fail to detect all mutations 
and that a combination of the two would be more effective. The failure to detect 
molecular pathology in 14 of 20 patientswith bilateral retinoblastoma was also
surprising and reflects the growing experience from other centres. This might be intrinsic 
to this gene given the success of screening strategies in other disorders, or it may be that 
mutations are present in areas of the gene not studied for instance promoter sequence.
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CHAPTER TWO: INTRODUCTION.
2. INTRODUCTION
2.1 Molecular pathology of single gene disorders.
The inheritance of single gene defects can be divided into autosomal dominant, 
autosomal recessive, sex linked and mitochondrial which are inherited as Mendelian 
traits (McKusick, 1990). Mutations in DNA sequence may occur by a variety of 
mechanism. The category of mutations that includes deletions and insertions accounts for 
5% to 10% of all known mutations (Cummings, 1994) but for most genes, point 
mutations appear to be of primary importance.
Point mutations may affect the transcription of the gene into mRNA or the processing 
of mRNA during the production of its mature form or the translation of mRNA into 
protein. On the basis of the amino acid or codon changes, point mutations have been 
classified into missense, nonsense and sense. Missense mutation is a single nucleotide 
change ihat causeSthe substitution of one amino acid for another in a protein. This 
substitution may or may not affect the function of the gene product. For example a 
single nucleotide substitution in codon 6 from GAG (glu)—>GUG (val) of beta globin 
results in sickle cell anaemia, an autosomal recessive disorder leading^&mormal red
j?cells and potentially lethal phenotype (Orkin and Kazazian, 1984). Another nucleotide 
substitution in the same codon from GAG (glu)-»AAG (lys) results in a condition 
known as HbC (Haemoglobin C), associated with mild clinical symptoms. In a third 
beta globin variant called HB Makassar, the codon at the sixth position is changed 
from GAG (glu)-»GCG (ala), causes no symptoms and is regarded as a harmless 
haemoglobin variant. Nonsense mutations cause a change from one of the 61 codons 
that specify an amino acid to one of the three termination codons (UGA, UAA, 
UAG). Since there are only three stop codons, therefore most of the point mutations 
are likely to be missense rather than the nonsense. Nonsense mutation usually lead to 
premature termination of translation and the formation of shortened polypeptide
4
chains. In thalassemia, a change at codon 39 from CAA (gln)-»UAA (termination) 
produces a nonfunctional shortened polypeptide only 38 amino acids long. In 
individuals homozygous for this mutation, no beta globin is produced, resulting in a 
condition known as beta-zero-thalassemia (Cummings, 1994). In the beta globin 
variant McKees Rock, the last two amino acids are missing and the protein is only 
143 amino acids long. The change in codon 144 UAU (tyr)—»UAA (termination) 
results in a beta chain that is shorter by two amino acids. This change has little effect 
on the function of the beta globin molecule as a carrier of oxygen (Cummings, 1994). 
Nonsense mutatioiSmay also arise, from insertion or deletion of one or more bases 
leading to a premature introduction of a stop. Sense mutation5produce longer than 
normal proteins by changing a termination codon into one that codes for amino acids. 
In Hb Constant Spring-1, the alpha chain termination codon UAA at position 142 is 
changed to CAA (gin), and as a result, 31 additional amino acids are added to the 
alpha chain before another termination codon is encountered in the mRNA 
(Weatherall, 1991).
Nucleotide substitutions have so far been the most common type of mutation in 
coding DNA sequence. Transitions, substitution of a pyrimidine by a pyrimidine, or a 
purine by a purine, are more frequent than transversions (substitution of a pyrimidine 
by a purine or vice versa). The excess of transitions is partly due to evolutionary 
instability of methylated cytosine residues. Cytosines which occur in the dinucleotide 
CpG are often methylated in human and vertebrate DNA to give 5-methylcytosine. 
Spontaneous deamination of 5-methylcytosine occurs over an evolutionary time-scale 
to generate thymine (Bird, 1986). Because the latter is^natural base in DNA, however 
it may not be recognised by DNA repair systems as being the product of an aberrant 
process (Strachan, 1992). The CpG sequence is effectively replaced in this process by 
TpG and CpA on the complementary DNA strand following DNA replication. Since 
the observed frequency of CpG in human genomic DNA is about 20% of the expected
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frequency, the CpG dinucleotide appears to be a mutational hot spot and contributes 
significantly to the molecular pathology of many disorders. For example, in a group of 
nearly 400 patients with haemophilia B showed that 50% of the mutations found 
in multiple unrelated patients were due to mutation of a CpG dinucleotide in over 
70% of cases (Cooper and Krawsak, 1990).
Sequence variation of human gene products reflects alterations of sequences in the 
nuclear DNA and at the level of gene expression, notably RNA processing. At the 
level of the genome differences between allelic sequences at a single chromosomal 
locus and also differences between related non-allelic sequences at different loci can 
contribute to sequence diversity. In the former case allelic sequence variation is 
traditionally described as polymorphism if more than one variant (allele) at a locus 
occurs in a human population with a frequency greater than 0.01. Although each 
individual possesses a maximum of only two different alleles at any one locus, a 
population survey of many individuals may reveal several different alleles at that locus, 
especially in the case of highly polymorphic loci. The small minority of DNA 
polymorphisms which lead to amino acid differences contribute to polymorphism at 
the protein level, as do differential transcription and RNA processing events 
(Strachan, 1992). For example the human dystrophin gene has two different 
promoters which are activated in different tissues; a brain specific promoter activates 
transcription at a location which is more than 90 kb upstream of the muscle-specific 
promoter (Strachan, 1992).
Translation begins at the 5' end of the mRNA with AUG (met). There is another 
sequence just upstream of the AUG codon that controls the rate at which translation 
occurs. In alpha thalassemia, a nucleotide substitution in this region reduces the rate 
of translation of mRNA (Weatherall, 1991). GeneSWhich are very actively transcribed, 
either at a specific stage in the cell cycle (e.g. histones) or in specific cell types (e.g. p-
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globin), always have a TATA box in their promoter. This element, often TAT AAA or 
a variant, normally occurs at a position about 30 bp upstream from the transcriptional 
start site. However, TATA boxes are absent from the promoters of many other genes, 
including housekeeping genes. Instead, the latter often have GC-rich sequence 
elements, especially variants of the consensus sequence GGGCGG. Other common 
promoter elements include the CAAT box, usually at about -80, which is often the 
strongest determinant of promoter efficiency. Several forms of p thalassaemia have 
been described in which point mutations were found upstream from the P globin gene 
either within or adjacent to the promoter boxes (Orkin et al., 1983; Weatherall, 1991). 
These mutations are associated with a variable reduction in output from the adjacent P 
globin chain loci. The activity of many promoters is modulated by an enhancer, which 
is a regulatory sequence that stimulateJtranscription. This is located on the same DNA 
molecule and can be situated, either upstream or downstream from the promoter 
region (Connor and Ferguson-Smith, 1991).
Correct processing of pre-mRNA molecules in the nucleus requires precise alignment 
of the coding regions. Nucleotide substitutions at intron-exon boundaries can interfere 
with normal splicing, resulting in an mRNA that retains an intron or is missing an 
exon. Single base substitutions within introns may result in preferential alternative 
splicing of the mRNA molecules at the site of the mutation. A common form of p 
thalassaemia that occurs in the Mediterranean population results from a single 
nucleotide substitution, G-»A, at position 110 of the first intervening sequence 
(IVS1) of the P globin gene (Weatherall, 1991). This change produces an AG 
sequence that happens to be preceded by a stretch of pyrimidines and thus forms a 
functional 3' acceptor consensus sequence. About 80% of the processed mRNA is the 
result of splicing into this site rather than the normal 3’IVS1 AG. The mRNA 
produced as the result of the abnormal splicing contains intron sequences and is 
therefore useless as a template for globin chain synthesis. Because this site is used
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preferentially, more abnormal than normal mRNA is produced and therefore there is a 
severe deficiency of P chain production (Weatherall, 1991).
2.2 Retinoblastoma gene structure and function.
The human retinoblastoma susceptibility gene is located within human chromosome 
13, band ql4 (Sparkes et al 1980; 1983). Using DNA probe H3-8 which is within 25 
kb of a cloned genomic sequence, Dryja et al.(1986) detected deletions involving this 
locus in three of 37 retinoblastomas. One probe from this region was found to contain 
a transcribed sequence and was used to successfully isolate a 4.7-kb human cDNA 
segment corresponding to the mRNA of the retinoblastoma gene (Friend et al., 1986). 
Other research groups also cloned similar cDNA fragments, using the H3-8 clone as a 
starting point (Fung et al., 1987; Lee et al., 1987a). The RB transcript is encoded in 
27 exons dispersed over approximately 200 kilobases of genomic DNA. The length of 
individual exons ranges from 31 to 1889 base pairs. The largest intron spans more 
than 60 kb and the smallest has only 80 bp. The cDNA sequence contains 4724 
nucleotides with an open reading frame (ORF) that codes for a protein consisting of 
928 amino acids (Friend et al., 1987; Lee et al., 1987ab).
The 5' end of the gene, which is directed toward the centromere, lacks a typical 
TATA box, but contains an unmethylated CpG-rich DNA sequence (CpG-island), 
which is characteristic of "house-keeping genes” (Friend et al., 1987). The RB gene 
codes for a nuclear phosphoprotein of 110 kd (pi 10*®). which is present throughout 
the cell cycle (Chen et al., 1989; Buchovich et al., 1989; DeCaprio et al., 1989)). In 
Gl, this protein lacks phosphate groups and this appears to block progression to S 
phase by binding transcription factors. When pi 10^® is phosphorylated by cell cycle 
kinase, it releases transcription factors, allowing them to activate the gene 
transcription necessary for progression through the cell cycle. In the absence of intact
8
pi lO^B cells are not blocked in G1 and unscheduled cell proliferation occurs. At this 
stage, the cells are not malignant.
Three biochemical activities of the RB protein have been discovered (Goodrich et al., 
1991). First, the carboxy-terminal half of pllO^® is capable of binding to DNA, 
though no sequence specificity for this binding has been demonstrated (Lee et al., 
1987b; Wang et al., 1990). Secondly, the transforming proteins of several DNA 
tumour viruses, including SV40 T antigen adenovirus E l A, can bind pi 10^® 
(DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al., 1988). Two regions, also 
within the carboxy-terminal half of the protein, are required for T antigen and E l A 
binding (Hu et al., 1990; Huang et al., 1990). Mutational analysis of the transforming 
proteins has demonstrated a correlation between their ability to transform cell 
binding pi 10®^ (Cherington et al., 1988; DeCaprio et al., 1988; Lillie et al., 1987; 
Moran, 1988; Moran et al., 1986; Smith and Ziff, 1988; Whyte et al., 1989), although 
some transformation-related properties are not dependent on binding pi 10^® 
(Thompson et al., 1990). Mutant RB proteins found in naturally occurring tumours 
fail to bind T antigen, and the mutations map to the regions required for binding in 
vitro (Hu et al., 1990; Huang et al., 1990). Thirdly, the transcription factor as well as 
several unidentified cellular proteins bind RB protein, apparently within the same 
binding domain used by T antigen (Bagchi et al., 1991; Bandara and La Thangue, 
1991; Bandara et al., 1991; Chellappan et al., 1991; Chittenden et al., 1991; Defeo- 
Jones et al., 1991; Huang et al., 1991; Kaelin et al., 1991). These observations 
suggest that the antigen-binding domain is critical to function of the protein. Although 
provocative, these biochemical properties have not yet provided a satisfactory 
explanation for the physiological effects of loss of RB function. The genetic events 
leading to malignant development appear to occur much latter. Certain viral 
oncoproteins such as adenovirus E l A and SV40 large T antigen can bind to 
unphophorylated pi 10^® and displace transcription factors, allowing these factors to
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active gene transcription. This mechanism appears to be an important step in the 
transformation of cells by DNA tumour viruses. Qian et al. (1992) identified two 
regions of pRb that are required for E2F binding and for hyperphosphorylation. E l A 
binding domains partially overlap but are distinct from both of these other two 
regions. Biological function of pRb is dependent on retention of the integrity of both 
of these biochemically defined domains. They speculated that these data support the 
model that pRb is a transducer of afferent signals (via the kinase that phosphorylates 
it) and efferent signals (through transcription factor binding), using distinct structural 
elements.
The genetic predisposition to retinoblastoma is transmitted by mutant alleles of the 
retinoblastoma susceptibility gene (Cavenee et al., 1983; Knudson, 1973). Inactivation 
of RB is both necessary and sufficient to form clonal proliferations of retinal cells 
(Friend, 1989). Few, if any, other cancers have such an apparently simple aetiology. 
Much more frequently tumour development is dependent on a number of genetic 
alterations in both oncogenes and tumour-suppressor genes. Of the genes involved in 
the development of cancer, many oncogenes have been identified but few tumour- 
suppressor genes, although may have been postulated (Stanbridge, 1990). RB (like 
p53) has been implicated in a tumour-suppressing role in a wide range of tumours 
including retinoblastoma, osteosarcoma (Friend et al., 1986; Fung et al., 1987; 
Reissmann et al., 1989; Toguchida et al., 1988; Yokota et al., 1988; Horowitz et al., 
1989; Kaye et al., 1990; Mori et al., 1990), breast cancer (Lee et al., 1988; T'Ang et 
al., 1988; Varley et al., 1989), bladder carcinoma (Dunn et al., 1989; Horowitz et al., 
1989) and leukaemia (Liu et al., 1992). Patients successfully treated for 
retinoblastoma have a higher incidence of certain second-site primary tumours, such 
as osteosarcoma and soft-tissue sarcomas (Abramson et al., 1984). Mutations of RB 
that ablate normal gene expression have been found in these tumours as well as in 
carcinomas of the breast, prostate, bladder, and small cell lung, as well as leukaemia
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(Bookstein et al., 1990; Liu et al., 1992; Friend et al., 1987; Harbour et al., 1988; 
Hensel et al., 1990; Horowitz et al., 1990; Lee et al., 1988; Shew et al., 1989,1990; 
Toguchida et al., 1988: Ahuja et al., 1991). Expression of normal RB protein in 
prostate carcinoma, osteosarcoma, breast carcinoma, and bladder carcinoma cells also 
suppresses their tumourigenicity in nude mice (Bookstein et al., 1990; Huang et al.,
1988). The risk of osteogenic sarcoma is increased 500-fold in patients with bilateral 
retinoblastoma, the bone malignancy being at sites removed from those exposed to 
radiation treatment for the eye tumour (Abramson et al., 1976). Francosis (1977) 
concluded that there is a special predisposition to osteogenic sarcoma, both 
radiogenic and nonradiogenic, in retinoblastoma patients and possibly in their relatives 
Expression of normal RB protein (Horowitz et al., 1990; Lee et al., 1987b) or mRNA 
(Dunn et al., 1988; Friend et al., 1987; Fung et al., 1987; Lee et al., 1987a) is lacking 
in all retinoblastomas examined to date. Replacement of the normal RB gene in 
cultured retinoblastoma cells by retrovirus-mediated gene transfer consistently 
suppresses their tumourigenic potential in nude mice (Huang et al., 1988; Sumegi et 
al., 1990).
2.3 Molecular pathology of the retinoblastoma gene.
The tumour exists in both hereditary and sporadic forms (Vogel, 1979). In the 
hereditary form one allele is inherited in a mutated form and the other is altered 
somatically, whereas in the sporadic form changes to both alleles occur somatically 
(Murphree and Benedict, 1984) (Figure 1). Hereditary predisposition to 
retinoblastoma is caused by a germline mutation at the retinoblastoma gene locus 
(RB) (RBI) and is transmitted as an autosomal dominant trait with 90% penetrance 
(Vogel et al., 1979). Approximately 40% of patients carry a germline mutation at this 
locus in all cells (Vogel 1979) (Table 1). Three quarters of these alterations represent 
de novo mutations. Most patients with hereditary retinoblastoma have bilateral
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disease. The average number of tumour foci in these patients is three to five. 10% of 
carriers develop no tumour (reduced penetrance)(Horsthemke, 1992). In 60% of all 
retinoblastoma patients, both alleles are inactivated by somatic mutations in a single 
cell (Vogel, 1979) (Table 1). These patients develop only a single tumour focus, and 
there is no risk to their offspring. However, 15% of patients with single tumours will 
have a germline mutation. Risk estimates for relatives of isolated cases of 
retinoblastoma are given in Table 2.
In 1971, from studies of age/incidence curves, Knudson (1971) postulated that the 
disease arose from two sequential events. In the hereditary form of the disease, one 
mutation is inherited in the germ-line and is phenotypically harmless. A second 'hit' 
occurring in the retinal cell causes the tumour. As there are a large number of 
retinoblasts in the eye (over 10^), which are all at risk because they already carry one 
mutation, a second 'hit' will occur frequently enough to cause a high proportion of 
tumours in at least one eye and often in both. In the sporadic form of the disease, both 
mutations occurring in the somatic tissue. The probability of two mutations occurring 
in the same cell is low, therefore the disease is both rare and unilateral (Macdonald 
and Ford, 1991). This 'two-hit' hypothesis has subsequently been confirmed by 
identification of mutations or deletions of the gene and more recently by analysis of 
the cloned retinoblastoma gene itself. Benedich et al. (1982) and Cavenee et al. 
(1983) obtained evidence that the two mutations necessary for tumour formation-one 
germline mutation and one somatic mutation in hereditary retinoblastoma or two 
somatic mutations in non-hereditary retinoblastoma-affect the two alleles of the same 
gene. Thus, homozygous loss of function of the RB gene initiates retinoblastoma 
tumour formation and the RB gene is termed a tumour suppressor gene.
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Genetic form Type of mutation Frequency (%) Type of disease
Hereditary
retinoblastoma
transmitted germline 
mutation 10 Bilateral
De novo germline 
mutation 30 Bilateral
Nonhereditary
retinoblastoma somatic mutations only 60 Unilateral
Table 1: Genetic forms of retinoblastoma*
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RB in Relation to Risk of carrying RB
proband proband mutation
Bilateral Offspring 50%
Bilateral Sibling or dizygotic twin 5%
Bilateral
Offspring of 
unaffected 
sibling
0.5%
Bilateral First cousin 0.05%
Bilateral Monozygotictwin 100%
Unilateral Offspring 7.5%
Unilateral Sibling or dizygotic twin 0.8%
Unilateral
Offspring of 
unaffected 
sibling
0.08%
Unilateral First cousin 0.008%
Unilateral Monozygotictwin 10%
Table 2. Risk of retinoblastoma in relatives of a child with retinoblastoma and no family 
history (Hodgson and Maher, 1993).
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In families with hereditary retinoblastoma, close linkage was demonstrated between 
esterase D alleles and retinoblastoma, suggesting that the two genes had to be close. 
In non-hereditary cases, approximately 20% of the retinoblastomas were shown to 
have an abnormality; usually absence or a deletion in one copy of chromosome 13, 
reduced levels of esterase D were detected in the tumours (Benedict et al., 1982). 
Patients with two detectable variants of esterase D in somatic tissues had only one 
variant present in their tumours. These studies suggested that in tumours there was 
loss or deletion of part of chromosome 13 and it was assumed that there was a 
mutation in the RB gene on the remaining copy of chromosome 13. These changes 
were confirmed at the molecular level by Cavanee and colleagues (Cavanee et al., 
1983) using the loss of heterozygosity test which has been widely used for detection 
of tumour suppresser genes. The loss of heterozygosity test depends on differences in 
the lengths of DNA fragments generated by digestion of genomic DNA with 
restriction enzymes. These restriction fragment length polymorphisms (RFLPs) 
present within the population can be detected by DNA probes specific for the DNA 
fragment of interest. In the case of retinoblastoma, the probes selected for use were 
located on 13q. Patients suitable for study were those who had different sized 
fragments of the DNA (alleles) on each of the two chromosome 13s in their somatic 
tissue, that is, they were heterozygous. When tumours from the same patients were 
analysed, only one of the two alleles was present. This loss of heterozygosity can 
occur by a number of possible mechanisms, including loss of the normal chromosome 
possibly followed by reduplication of the abnormal one, an interstitial deletion of the 
normal chromosome, or a recombination event resulting in two copies of the deficient 
allele. The tumour only occurs when both copies of the RB gene are altered or lost, 
therefore the tumour phenotype is recessive. However, the tumour is inherited as if it 
were dominantly expressed, because, the likelihood of the second mutation in the 
retinal cells is close to 100%.
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Since retinoblastoma results from the homozygous or hemizygous state of a gene at 
13ql4, retinoblastoma could either be as a recessive disease or the susceptibility 
could be is dominant. It is of interest that 90% of de novo mutations occur in the 
paternal germline (Dryja et al., 1989; Zhu et al., 1989); this may be because far more 
cell divisions occur between embryonic development and meiosis in males than in 
females. Ejima et al. (1988) showed that cytogenetically visible deletions resulting in 
a retinoblastoma are usually in the paternally derived chromosome. Such a bias would
Ab enot expected for sporadic retinoblastoma where both mutations occur in somatic 
tissue, but there had been some indication of a bias toward initial somatic mutation in 
the paternally derived gene on chromosome 11 in sporadic Wilms tumour. There was 
a growing body of data indicating a difference in behaviour of maternally and 
paternally derived autosomal genes. Germinal imprinting may be mediated by some 
epigenetic process such as de novo DNA methylation and carried over to postzygotic 
stages. Dryja et al. (1989) and Zhu et al. (1989) found that in bilateral retinoblastoma 
there is a preferential retention of the paternal chromosome in the process of loss of 
heterozygosity (LOH). They indicated that either mutation of RB is more common 
during spermatogenesis than oogenesis as a result of differences between male and 
female meiosis, DNA methylation or environmental exposure; or the paternal 
chromosome in the early embryo is more at risk for mutation, or deficient in DNA 
repair.
A few patients are mosaic for an RB gene mutation (Ribeiro et al., 1988; Greger et 
al., 1990). In these patients, the mutation occurred during early embryonic 
development. If the mutation arises before the germline is partitioned off from other 
cell lines, it may be transmitted to the offspring. One such case was analysed by 
Greger et al. (1990). A single mutation event during early embryonic development 
gave rise to two cell lines with related but different deletions. A different deletion was 
transmitted to each of the two children.
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Deletions and point mutations have also been observed as the result of somatic 
mutations. Local mutations at the RB locus occur in approximately 30% of patients. 
Most frequently, the second RB allele is lost by chromosomal mechanisms (Cavenee 
et al., 1983). These mechanisms can be detected by comparing the patient's 
constitutional genotype with the tumour genotype. Such comparisons are performed 
with the help of polymorphic DNA markers along chromosome 13. In approximately 
50% of patients, the second allele is lost by mitotic nondisjunction with or without 
duplication of chromosome 13 (Horsthemke. 1992). In these cases, tumour cells are 
either hemizygous or homozygous for alleles of the chromosome 13 that carries the 
first RB gene mutation. In approximately 20% of patients the second allele is lost by 
mitotic crossover. In these patients, tumour cells are heterozygous at loci proximal to 
the RB gene and homozygous at the RB locus and loci distal to it.
Early data, derived mostly from Southern blot analysis identified structural 
abnormalities of RB in 10%-40% of hereditary and sporadic Rb tumours (Cowell and 
Hogg, 1992). The vast majority of these abnormalities included deletions of all or 
part of the gene (Friend et al., 1986; Fung et al., 1987). It appears that deletion 
breakpoints can occur throughout the length of the gene (Canning and Dryja, 1989; 
Kloss et al., 1991). Canning and Dryja, (1989) found that 2 out of 12 deletions had 
breakpoints in the region containing exons 13-17, and 7 out of 12 deletions included 
that region. Others groups also found this region was involved in deletions and 
rearrangements (Fung et al., 1987) possibly indicating the location of a breakpoint 
cluster region. It is not known whether this is related to the chromosome 
abnormalities, but these DNA sequence can form stem and loop structures that 
possibly promote rearrangements (Cowell and Hogg, 1992). Canning and Dryja, 
(1989) reported that there was a direct repeat at the breakpoint site and one of these 
was always lost in 6 of 8 deletions. Cowell and Hogg (1992) also found short direct 
repeat associated with small deletions within RB. This observation is consistent with
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a slipped mispairing during DNA replication. In this model, pairing on one DNA 
strand occurs with the downstream sequence on the other strand creating a loop. 
When the replication loop is resolved, one copy of the repeat, plus the intervening 
sequence, is deleted.
Sakai et al. (1991a) investigated the methylation pattern at the 5* end of the 
retinoblastoma gene, including its promoter region and exon 1, in DNA purified from 
56 primary retinoblastomas. They found five tumors with evidence for 
hypermethylation, all from unilateral, simplex patients. No methylation abnormalities 
were detected in DNA purified from the leukocytes from these patients. They 
speculated that erroneous hypermethylation without alteration of nucleotide sequence 
occasionally plays a role in the genesis of this cancer. Cytosine methylation of CpG 
sites in the promoter region of eucaryotic genes is involved in the inactivation of 
expression of certain genes. Given that methylation can lead to reduced transcription, 
it is possible that expression of tumor-suppressor genes is also inactivated by 
hypermethylation, thereby contributing to the etiology of cancer. Recently 
OhtaniFujita et al. (1993) found five sporadic retinoblastoma tumors (16% of all 
unilateral cases) with hypermethylation of the 5’ end of the retinoblastoma gene 
without detecting any structural abnormalities. However, it is unclear whether the 
promoter of the retinoblastoma gene is actually inactivated by its hypermethylation. 
They showed that specific hypermethylation in the promoter region of the 
retinoblastoma gene reduces its expression to only 8% of the unmethylated control. 
Furthermore, they have found that two transcription factors important for the 
promoter activity, an activating transcription factor (ATF)-like factor and the 
retinoblastoma binding factor 1, do not bind when their recognition sequences are 
GpG methylated.
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Some patients have a somatic 13q- mosaicism (Ribeiro et al., 1988). Insertion and 
translocations involving band 13ql4 have also been observed (Turleau et al., 1985), 
but are much less frequent than deletions. Most patients with a deletion of the entire 
band of 13ql4 are mental and physically retarded: cytogenetic analysis is indicated 
only in patients with such stigmata. To date, the gene for esterase D is the only gene 
known to be close to the RB gene, it maps at least 200 (kb) proximal to the RB gene 
(Sparkes et al., 1980). Deletion of the esterase D gene, however, has no clinical 
phenotype. Deletions of 13ql4 are rare in retinoblastoma tumour cells. In some 
tumours monosomy 13 is observed. In contrast, tetrasomy 6p and trisomy lq are 
frequent findings (Kusnetsova et al., 1982; Benedict et al., 1983; Squire et al., 1984). 
In tetrasomy 6p, two additional chromosomes are often present in the form of an 
isochromosome of 6p, which is rare in other tumours (Hoersthemke, 1992). DNA 
polymorphism studies have indicated that mitotic nondisjunction leading to trisomy 6 
precedes isochromosome formation. The isochromosome is then formed by transverse 
division of centromere or intrachromosomal chromatid exchange (Horsthemke et al.,
1989). The functional role of tetrasomy 6p and trisomy lq  is unknown.
Anecdotal reports suggested that bladder carcinomas appear more frequently than 
expected in retinoblastoma families (Tarkanen and Karjalainen, 1984) and 
subsequent, larger studies have confirmed this observation (DerKinderen et al., 1988; 
Sanders et al., 1989). Where age at diagnosis was reported, this was markedly lower 
than the mean age of onset in the general population. Higher incidence and lower age 
of onset of a cancer in a particular subgroup points to a genetic predisposition and 
suggests that germline mutations in the RB gene may predispose to bladder cancer 
(Cairns et al., 1991). Horowitz et al. (1989) reported another mechanism of RB gene 
inactivation, namely, abnormal splicing due to a point mutation in the consensus 
sequence of the exon-intron junction in a bladder cancer cell line; the short RB 
transcript in this cell line does not contain the sequence of exon 21. A similar example
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was also reported by another group (Dunn et al., 1989). Murakami et al. (1991) 
found a novel RB gene transcript that does not contain the sequence corresponding 
to exon 2 of the gene in human lung carcinoma cell line suggesting the involvement of 
alternative splicing.
Evidence that RB may also be involved in the development of sporadic bladder 
cancer has come from the finding that a number of bladder carcinoma cell lines 
possess an altered RB protein or show no detectable RB expression (Horowitz et al., 
1989; 1990). Cairns et al. (1991) have examined 162 bladder tumours for evidence of 
structural alterations to the RB gene. Ninety-four patients were informative with one 
or more intragenic RB probes, 28 of these (29%) showed loss of heterozygosity 
(LOH). Of these, two tumours showed homozygous deletions with the 5* intragenic 
probe pl23M1.8. The 28 tumours with Rb LOH were screened with the RB cDNA 
probes pR3.8 and pR0.9 which revealed two homozygous deletion and one 
rearrangement. This is similar to the frequency at which abnormalities of the RB 
protein product have been detected in bladder carcinoma cell lines (33%) by 
Horowitz et al. (1990). Southern analysis of LOH is a relatively crude method of 
detecting gene inactivation and will not identify small internal deletions or point 
mutations. Indeed only 10-20% of retinoblastomas have obvious structural alterations 
of an RB allele which are detectable by Southern analysis (Yandell and Dryja, 1989b) 
and only 70% show loss of the other allele (Zhu et al., 1989), yet loss of function of 
RB is thought to occur in 100% of retinoblastomas.
More recently, loss of function of the RB gene has been associated with at least two 
different types of primary cancer. Structural abnormalities were detected in 13% of 
primary small cell lung carcinoma (SCLC), and in 18% of SCLC cell lines (Harbour 
et al., 1988). More significantly, loss of RB mRNA was seen in 60% of the SCLC 
lines. SCLC, like retinoblastoma, is a tumour of neuroendocrine origin, and Harbour
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et al. (1988) suggested that the involvement of the RB gene in two tumour types 
displaying phenotypic properties of neuroendocrine differentiation may be of 
significance. There seems to be no evidence for familial clustering of SCLC, nor for 
any association of SCLC with retinoblastoma or any of the mesenchymal tumours 
which also exhibit deletion of RB. Frequent aberration to the RB gene have also been 
detected in primary carcinoma of the breast (Lee et al., 1988; T'Ang et al., 1988). 
Breast carcinomas are not, however, of neuroendocrine origin, but they can show a 
strong familial trend, with some families showing a very strong genetic component 
(Sattin et al., 1985; Ottman et al., 1986; Newman et al., 1988). Whilst there is 
evidence that mothers of children with osteosarcoma and soft tissue sarcoma show a 
higher rate of breast cancer, there is no evidence of any association between breast 
cancer and retinoblastoma. Varley et al. (1989) have analysed the organisation of the 
retinoblastoma gene in 77 primary breast carcinomas using cDNA probes 3.8 and 0.9. 
They found deletions or rearrangements of the RB locus in 15 cases out of 77 
carcinoma samples indicating that the loss of RB function is important in the 
progression of human breast carcinoma. In 1988 T’Ang et al. reported that 25% of 
breast cancer cell lines and 7% of primary tumour samples showed a deletion or 
rearrangement of the RB gene. Varley et al. (1989) have shown that changes to the 
RB gene leading to loss of expression of both alleles occurred in 19% of primary 
breast tumours. Hovig et al. (1992) have examined RB exon 21 from 78 tumours 
included 11 breast carcinomas, 30 non small cell lung carcinomas, 6 colon 
carcinomas, and 31 sarcomas by constant denaturant gel electrophoresis (CDGE). 
They did not detect any mutations in the examined region in any of the tumours.
DeCaprio et al. (1989), Buchkovich et al. (1989), and Chen et al. (1989) 
demonstrated that the RB gene product has the properties of a cell cycle regulatory 
element and that its function is modulated by a phosphorylation/dephosphorylation 
mechanism during cell proliferation and differentiation. Goodrich et al. (1991) found
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that injection into cells of either full-length or a truncated form of the RB protein 
containing the T antigen-binding region inhibited progression from G1 into S phase. 
Coinjection of anti-RB antibodies antagonised this affect. The results indicated that 
RB regulates cell proliferation by restricting cell cycle progression at a specific point 
in G1 and established a biologic assay for RB activity. Coinjection of RB with a T 
antigen peptide or injection into cells expressing T antigen was accompanied with no 
inhibition of progression into S phase. This was interpreted as indicating that the 
transforming proteins of some DNA tumour viruses, including SV40 T antigen and 
adenovirus E l A, may promote cell growth, at least in part, by binding and 
inactivating RB. The RB gene has been shown to be inactivated in various way, such 
as by loss of part or all of the gene (Lee et al., 1987a; Fung et al., 1987; Friend et al., 
1987; Lee et al., 1988), disorders gene expression (Lee et al., 1987a; Fung et al., 
1987; Harbour et al., 1988) or dysfunction of the RB protein (Horowitz et al., 1989; 
Shew et al., 1990). Amino acid substitutions or creation of stop codons due to point 
mutations or shifts of the reading frame (Dunn et al., 1989) results in activation of the 
RB protein. Hu et al. (1990) generated a series of deletion mutants of the RB cDNA 
sequence that have been tested for their ability to interact with two viral 
oncoproteins, the adonevirus E l A and SV40 large T antigen. Two separate regions 
of RB are essential for association with El A or large T antigen. The two regions 
include a fragment of 180 amino acid residues (393-572) and one of 127 residues 
(646-772) which fall in exons 12-22 inclusive (Hu et al., 1990; Huang et al., 1990). A 
comparison of these binding sites on RB with the sites of naturally occurring 
mutations reveals that all of the RB mutations identified to date contain deletions 
either in one or both of the binding regions (Hu et al., 1990). This suggest that the 
DNA tumour virus transforming proteins are predicted to bind to and inactive normal 
RB function, thus removing a barrier to cell proliferation.
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2.4 Available methods used in the detection of point mutations.
2.4.1 Polymerase chain reaction (PCR).
The polymerase chain reaction (PCR) is a technique for the in vitro amplification of 
specific DNA or RNA sequences. The PCR method was devised and named by Mullis 
and colleagues at the Cetus Corporation (Mullis et al., 1987), although the principle 
had been described in detail by Khorana and colleagues over a decade earlier (Taylor, 
1993). The development of the PCR has led to a variety of new approaches for 
sequencing human genes.
The principle behind PCR is illustrated in Figure 2. The polymerase chain reaction 
(PCR) uses two oligonucleotide primers to direct the synthesis of specific sequences 
of DNA. One primer anneals to the coding strand of DNA and other to the noncoding 
strand. These primers are used to direct the enzyme DNA polymerase to copy each 
strand in opposite directions. The primers are added in great excess to the source 
DNA, in the presence of buffer, enzyme, and free nucleotides. The source DNA is 
denatured at 95°C and then cooled to 40-65°C. The requirements of the reaction are 
simple: deoxynucleotides to provide both the energy and nucleosides for the synthesis 
of DNA, DNA polymerase, primer, template, and buffer containing magnesium. 
Initially synthesis will go beyond the sequence complementary to the other primer, but 
with each cycle of heating and cooling, the amount of DNA in the region flanked by 
each primer will increase almost exponentially, whilst longer sequences will only 
accumulate in linear fashion, provided that the amount of starting DNA is present in 
limiting quantities. Thus, after several cycles the predominant reaction product will be 
that fragment of DNA which is flanked by the primers, and will include the primers 
themselves.
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Figure 2 .The principle o f polymerase chain reaction. In the first cycle, a 
fragment larger than the targeted DNA is synthesised However, after, tw o 
amplification cycles targeted DNA fragment is produced and eventually it 
becomes the predominant product.
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The heating and cooling cycles can be repeated and DNA will continue to accumulate 
exponentially until one of the reaction products is exhausted or the enzyme is unable 
to synthesis new DNA quickly enough. At high DNA concentrations, the DNA may 
also begin to prime itself and result in the synthesis of non specific products. Thus, it 
either stops the amplification or produces non-specific products. The number of 
cycles required for optimum amplification varies depending on the amount of starting 
material and the efficiency of each amplification step. After about 30 cycles of 
successive steps of denaturation, annealing of primers and DNA synthesis, the 
products of the PCR will include, in addition to the starting DNA, about 10^-10^ 
copies of the specific target sequence, an amount which is easily visualised as a 
discrete band of a specific size on agarose gel electrophoresis. Repeated cycles of 
enzymatic amplification increase the quantity of the targeted DNA region more than 
2000-fold. Generally, 25 to 35 cycles should be sufficient to produce 100 ng-lpg of 
DNA of single-copy human sequence from 50 ng of genomic DNA. A final incubation 
step at the extension temperature (usually 72^C) results in fully double-stranded 
molecules from all nascent products. The primers should be similar in length and 
composition, so that their predicted melting temperatures (Tm), the temperature at 
which 50% of the strands are separated) are within 5°C. For calculation of the 
approximate Tm of the oligonucleotide primers, a simple formula such as Tm = 
2(A+T) + 4(G+C) in °C can be used (Thein and Wallace, 1986). Furthermore, GC 
content should be similar to the GC content of the template and of the other primer, 
ideally 50-60% GC. They should not have self-complementarity, secondary structures 
or be complementary to each other. Computer programs are available to help identify 
such complementarity. Primers should also have no runs of three or more Gs or Cs at 
their 3' ends. If mismatches between primer and template are known or likely to 
occur, these should be minimised at the 3' end of the primer, i.e., where the DNA 
polymerase binds. Highly degenerate primers may work under non-stringent reaction 
conditions, provided that at least three bases match at the 31 end of the primer
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(McMahon et al., 1988). Restriction sites can be included in the primer to help in 
efficient and directional cloning of the amplified product. Lengths between 100 and 
2000 bp can, however, often be amplified efficiently.
There are several PCR based methods for detection of mutations. These are 
restriction fragment length polymorphism analysis (Saiki et al., 1985; Kogan et al.,
1987), single-stranded conformation polymorphism analysis (Orita et. al., 1989), 
denaturing gradient gel electrophoresis (Cariello et al., 1988; Traystman et al., 1990), 
electrophoresis of heteroduplex DNA (White et al., 1992), RNase cleavage analysis 
(Myers et al., 1988), chemical cleavage of mismatch (Cotton et al., 1988; Grompe et 
al., 1991), allele specific oligonucleotide hybridisation (Embury et al., 1987; Lo et al.,
1988) and direct genomic sequencing (Wrishchnik et al., 1987; Wong et al., 1987; 
Newton et al., 1988).
2.4.2 Amplification and mismatch detection (AMD) analysis.
AMD analysis is a combination of PCR and the chemical mismatch method (Cotton et 
al., 1988). To screen for mutation sites within the amplified PCR products, the AMD 
method described by Cotton et al. (1988) and Dahl et al. (1989) is used. In this 
technique, mutant DNA is allowed to form a duplex with a radiolabelled probe of 
control DNA. Where mutations are present, the mutant strand does not exactly match 
the control and fails to anneal correctly. The resulting mismatch is chemically more 
reactive than the surrounding DNA, allowing chemical cleavage at this site and 
detection of different-sized radioactive fragments. Because cytosine and thymine react 
specifically with hydroxylamine and osmium tetroxide (OSO4), respectively, the 
nature of the reactivity also gives information about the base change. Since only 
mismatched cytosines and thymines show marked reactivity, probes in both sense 
| and antisense strands
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must be used to ensure detection of the complimentary guanine and adenine 
mismatches (Howells et al., 1990) (Figure 3).
Sites modified by hydroxylamine and osmium tetroxide are more susceptible to 
cleavage by piperidine than unmodified base pairs. Piperidine is therefore used to 
cleave DNA fragments at the site of modified bases. Cleavage occurs on one strand of 
helix only. Products are resolved by denaturing electrophoresis to allow the 
identification and location of mutation sites. Chemical cleavage has been shown to be 
an excellent method for the detection and location of mutations, particularly because 
it is possible to easily scan up to 2 kb segments of DNA at a time and additionally, it 
can be used on either DNA or RNA templates (Cotton et al., 1988: Dahl et al., 1989). 
Improved resolution of larger cleavage products is possible by the use of ^ ^S-labelled 
dATP rather than [^^P] dCTP-labelled probes (Saleeba and Cotton, 1991). Mutation 
detection by chemical cleavage has been applied to the analysis of gene structure in 
human systems and in other organisms such as Caenorhabditis elegans (Han and 
Sternberg, 1990), Escherichia coli (Grompe et al., 1991), and dengue virus (Cotton 
and Wright, 1989). Example of human diseases investigated by this method include B- 
thalassaemia (Dianzani et al., 1991), osteogenesis imperfecta (Bateman et al., 1989; 
Lamande et al., 1989), dihydropteridine reductase deficiency (Howells et al., 1990), 
ornithine transcarbamylase deficiency (Grompe et al., 1989), pyruvate dehydrogenase 
deficiency (Dahl et al., 1990), colorectal cancer (Rodrigues et al., 1990), and 
phenylketonuria (Forrest et al., 1991).
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Figure 3. Analysis of sequence variation by AMD.
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2.4.3 Single stranded conformation polymorphism (SSCP) analysis.
In PCR-SSCP analysis, a DNA sequence of interest (or a cDNA that has been reverse 
transcribed from mRNA) is first amplified by PCR. Single-stranded DNA has a 
tendency to fold up and form complex structure stabilised by weak intramolecular 
bonds, notably base-pairing hydrogen bonds. The electrophoretic mobilities of such 
structures on non-denaturing gels will depend not only on their chain lengths but also 
on their conformations, which are dictated by the DNA sequence (Orita et al., 1989). 
Single strand conformation polymorphism (SSCP) analysis is most conveniently 
performed by PCR amplification of the desired region of genomic DNA to produce a 
labelled product (either by using end-labelled PCR primers, or by incorporation of 
labelled nucleotides during the PCR reaction) (Hayashi et al., 1989; Makino et al., 
1992). Amplified DNA samples are denatured and loaded on a non-denaturing 
polyacrylamide gel electrophoresis (PAGE) (Orita et al., 1989). A test DNA sample 
that differs by a single base from a standard DNA sample can be identified by a 
comparative mobility shift during electrophoresis. The base change results in a 
change of conformation.
2.4.4 Heteroduplex DNA analysis.
The PCR products of normal and mutant alleles can be separated from each other 
using hydrolink (non-denaturing) gel electrophoresis (Keen et al., 1991). 
Heteroduplex DNA is generated during PCR amplification when two homologous 
DNA segments, or alleles, which have sequence differences are amplified. Double 
stranded DNA is formed not only from identical complementary strands 
(homoduplexes) but also from the annealing of complementary strands from the 2 
different amplified segments (heteroduplex). Heterodublex DNA can also be formed 
by mixing two homologous DNA fragments together, heating to 95°C, and slowly
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cooling to room temperature. Although the effective size range for resolution of DNA 
containing single base pair mismatches is up to 1300 bp (Boyd et al., 1993), size from 
100-400 base pairs of DNA are optimal for effective resolution of heteroduplex. 
Separation of DNA fragments based on conformational differences induced by single 
base mismatches.
2.4.5 Denaturing gradient gel electrophoresis (DGGE).
DGGE analysis has been applied to screening of genes involved in several genetic 
diseases (Traystman et al., 1990; Sheffield et al., 1989). Denaturing gradient gel 
electrophoresis (DGGE) detects DNA sequence differences. Thus, it can be used to 
screen for point mutations or other types of mutations prior to DNA sequencing. The 
technique first described by Fischer and Lerman, (1979) entails electrophoresis of 
DNA fragments at high temperature in an acrylamide gel that contains a gradient of 
denaturant such as formamide and urea.
Denaturing gradient gel electrophoresis allows the separation of DNA molecules 
differing by as little as a single base change (Fischer and Lerman 1983: Myers et al., 
1985ab). The separation is based on the melting properties of DNA in solution. DNA 
molecules melt in discrete segments, called melting domains, when the temperature or 
denaturant concentration is raised. Melting domains vary from about 25 base pairs to 
several hundred base pairs in length, each melting cooperatively at a distinct 
temperature called Tm. Due to the considerable contribution of stacking interactions 
between adjacent bases on a DNA strand to double helical stability, the Tm of a 
melting domain is highly dependent on its nucleotide sequence. The Tms of DNA 
fragments differing by even very small changes, such as a single base substitution, can 
differ by as much as 1.5°C. In the DGGE system, DNA fragments are 
electrophoresed through a polyacrylamide gel that contains a linear gradient, from top
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to bottom, of increasing DNA denaturant concentration. DNA fragments enter the 
concentration of denaturant where its lowest temperature melting domain melts 
(equivalent to the Tm of the domain), the molecule forms a branched structure that 
has a retarded mobility in the gel matrix. If the gradient conditions are chosen 
properly, DNA fragments differing by single base changes begin branching, and hence 
slowing down, at different positions in the gel, resulting in the separation of the 
fragments at the end of the electrophoretic run.
2.4.6 Temperature gradient gel electrophoresis (TGGE).
The TGGE is based on the same principles as the DGGE (Meyer et al., 1991). Using 
a thermal instead of a chemical denaturing gradient, the preparation of gradient gels is 
avoided. The horizontal acrylamide gels fixed on a solid gel support make the 
handling of the gel very convenient. In contrast to DDGE analysis, only one gel 
condition is sufficient for TGGE. Similar to DGGE the TGGE results are easy to 
interpret because of the two heteroduplex bands are reproducibly observed when 
tumour tissue or peripheral blood harbouring a germline mutation is analysed. In 
contrast, interpretation of SSCP gels is often impaired by the presence of only three 
or more than four single-strand bands. Like all screening techniques, the detection of 
mutants by TGGE does not discriminate between mutations resulting in an amino acid 
change and silent mutations or natural polymorphisms.
The TGGE allows the separation of molecules depending on their different melting 
behaviour in temperature gradients and has already been applied to separation of HLA 
alleles (Meyer et al., 1991). Mixed wild-type and homozygous mutated fragments are 
denaturated and renaturated in the presence of 4M urea to get two kinds of 
heterodimers in addition to the wild-type and mutant homodimers. One of those 
samples is separated on a 5 % polyacrylamide gel (in 4 M urea, 20 mM MOPS, and I
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mM EDTA, pH 8.0 for 2 h at 250 V within a test temperature gradient (30°C—70°C) 
perpendicularly orientated to the electrical field in the TGGE. Due to the formation of 
two homodimers and two heterodimers, 4 melting profiles are observed. From these 
the temperature range of effective separation can be determined. This interval is 
defined by the highest temperature where all duplices remain double stranded and by 
the melting temperature of the most stable homoduplex. Then the optimal temperature 
gradient which overlaps effective separation is selected and orientated parallel to the 
electrical field in the following electrophoresis. The approximate running time of the 
parallel TGGE in order to get effective separation is also calculated. Aliquots of the 
control samples are loaded serially at different times at 20°C resulting in different ’run- 
in1 times. Then the parallel electrophoresis proceeds within the selected ideal 
temperature gradient. After that the optimal running time for effective separation of 
all kinds of duplices is selected for subsequent parallel TGGE experiments.
2.4.7 Restriction fragment length polymorphism (RFLP).
One of the most commonly used tools for following the inheritance of genes or gene 
markers is that of the linked restriction fragment length polymorphism (RFLP). 
Traditionally, this technique involved the digestion of approximately 5pg of genomic 
DNA, followed by electrophoresis, Southern transfer, radioactive (or, less commonly, 
non-radioactive) probing, followed by the exposure of the filters to X-ray film 
(Maniatis, Fritsch, Sambrook, 1982). The use of PCR has made it possible to amplify 
a short region of DNA surrounding the restriction site of interest which is then 
exposed to the relevant restriction enzyme. The amplified DNA is then visualised 
directly on an appropriate gel matrix. This method has many advantages over the 
traditional Southern analysis, not least of which is the great saving in time (Williams,
1988).
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In the case of retinoblastoma, the probes selected for use are located on 13q. Patients 
suitable for study are those who have different sized fragments of DNA (alleles) on 
each of the two chromosome 13s in their somatic tissue, that is, they are 
heterozygous. When tumours from the same patients are analysed, only one of the 
two alleles is present (Figure 4). This loss of heterozygosity can occur by a number of 
possible mechanisms, including loss of the normal chromosome possibly followed by 
reduplication of the abnormal one, an interstitial deletion of the normal chromosome, 
or a recombination event resulting in two copies of the deficient allele.
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35
2.4.8 The amplification refractory mutation system (ARMS).
The amplification refractory mutation system (ARMS) is a simple and rapid method of 
detecting point mutations, restriction fragment length polymorphisms (RFLP), and 
small nucleotide insertions or deletions. The method was first described by Newton 
(1989a) for analysing single DNA base differences in patients with a-antitrypsin 
deficiency and has since been applied to prenatal diagnosis and carrier detection of 
cystic fibrosis (Newton et al., 1989b). The technique is based on allele-specific 
priming of the polymerase chain reaction. To diagnose a specific mutation, two 
oligonucleotide primers are required that are identical in sequence except for the 
terminal 3' nucleotide. The normal primer has the 3' terminal nucleotide sequence 
complementary to the normal DNA sequence. Under the right conditions a primer will 
act as a template for DNA polymerase only when the terminal 5' nucleotide is 
perfectly matched to the target DNA sequence. Thus, the normal primer when 
hybridised to the mutant genomic DNA and, conversely, the mutant primer when 
hybridised to the normal DNA, will not function properly as a template for DNA 
amplification and no amplified product is observed at the end of the PCR process. To 
screen for a particular mutation, only the mutant ARMS primer is required (in 
combination with three others- a common primer and two control primers). However, 
for prenatal diagnosis of individuals homozygous for a particular mutation, both 
normal and mutant primers will be required. The design of the ARMS primers is very 
important. The technique is a combination of a PCR assay and examination of the 
amplification products by agarose gel electrophoresis and ethidium bromide staining. 
In this technique two polymerase chain reactions involving four primers in the one 
reaction mixture is required. Two of the primers are control primers that amplify a 
segment of the DNA some distance away from the site of the mutation so they do not 
interfere with the amplification of the DNA fragment produced by the ARMS primers 
and common primer. The control fragment indicates that the PCR reaction was set up
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properly. When it is not observed in an ARMS analysis, the result obtained with 
ARMS primers must be discounted and the analysis repeated. The other two primers 
are the ARMS primers that are allele-specific to either the mutant DNA sequence or 
normal DNA sequence as required, and a common primer, which matches the same 
sequence in both normal and mutant DNA. These two primers combine to produce 
the diagnostic ARMS DNA fragment in the amplification reaction. The success of the 
ARMS technique is dependent on the ARMS primers working specifically.
2.4.9 RNase cleavage analysis.
Single base changes in DNA can be detected by cleavage of mismatches in RNA:DNA 
duplexes with the enzyme RNase (Myers et al., 1988; Winter et al., 1985; Gibbs and 
Caskey 1987). A uniformly labelled single-stranded RNA probe is synthesised. The 
ssRNA probe is synthesised as run-off transcripts from a cloned DNA template. The 
probe is mixed with double-stranded test DNA, which can be cloned, genomic DNA 
or PCR-amplified DNA fragment, and the mixture is heated to separate the DNA 
strands. This is then followed by an annealing reaction whereby the labelled RNA 
probe is allowed to anneal with its complimentary strand in the test DNA fragment 
forming an RNA:DNA duplex. The presence of any base changes in the test DNA will 
cause base mismatches in the RNA:DNA duplex. The annealed mixture is then treated 
with the enzyme RNase A to cleave the RNA strand at the mismatched sites. After the 
cleavage reaction, the duplex is treated with denaturants to separate the strands and 
then run on a denaturing gel to separate the RNA fragments by size. If the test DNA 
had no mutation, a single band on the autoradiograph, corresponding in length to the 
full-length protected test fragment, is observed. If a mutation was present in the test 
DNA, two bands will be observed on the autoradiograph.
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By using this procedure, approximately 30 to 40% of all possible mismatches in the 
RNA:DNA duplexes can be efficiently detected. The detection rate can however, be 
improved to detect up to 60 to 70% of the possible base changes, by testing a DNA 
fragment with each of its two corresponding labelled RNA probes in separate 
cleavage reactions (Myers et al., 1985c). This method is most suitable for screening 
DNA fragments between 100 and 1000 bp long. Fragments longer than 1000 bp are 
difficult to screen because of random cleavages which occur even in perfectly 
matched bases and may be numerous enough to interfere with the results. Moreover, 
analysis of such long RNA fragments requires the use of denaturing agarose gels 
(Myers et al., 1988). Therefore, the most obvious limitation of this method is that it 
cannot detect all possible mismatches. Further more, the method requires extra 
cloning for probe production and the screening is limited to DNA fragments of up to 
1000 bp only.
2.4.10 Allele specific oligonucleotide (ASO) hybridisation.
A point mutation which does not produce a restriction site change may be detected 
using allele-specific oligonucleotide (ASO) probes (Studencki and Wallace, 1984). 
ASO probes are typically 15-20 nucleotides long and normally employed under 
hybridisation conditions at which the DNA duplex between probe and target is only 
stable if there is perfect base complimentary between them. A single mismatch 
between probe and target sequence is sufficient to render the short heteroduplex 
unstable. Oligonucleotide probes can therefore be designed to hybridise to specific 
alleles of a gene which differ by a single nucleotide at a diagnostic site. Although 
ASOs can be used in conventional Southern blot hybridisation, it is more convenient 
to use them in dot-blot assays.
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2.4.11 Direct genomic sequencing.
There are two popular methods for sequencing. One of them is the chemical method 
described by Maxam and Gilbert (1977), the other one is the enzymatic method of 
Sanger et al. (1977). Of the two methods, Sanger's method, known as dideoxy 
sequencing or the chain termination method of sequencing, is most widely used. In the 
Maxam and Gilbert method, the DNA is cleaved into fragments which are then 
radioactively labelled at one end, subsequently divided up into four batches, each of 
which is treated differently by chemicals to modify a particular base or bases resulting 
in very small DNA fragments, some of which will be end-labelled. The fragments are 
then resolved in denaturing polyacrylamide gels resulting in base specific bands on 
autoradiography.
The enzymatic method of sequencing involves the synthesise of a DNA strand by a 
DNA polymerase using a single-stranded DNA template. An universal oligonucleotide 
primer is annealed to the template and this followed by a period of extension where 
dTTP, dGTP, dCTP, and radioactively labelled dATP are incorporated into the 
growing strand. Reactions are terminated by addition of dideoxynucleotides into the 
strands in four separate reactions, one each for ddGTP, ddTTP, ddCTP, and ddATP 
(Dideoxynucleotides lack a 3' hydroxyl group and cannot form phosphodiester 
bonds). This results in the production of a family of DNA fragments of different 
lengths depending on the site of incorporation of dideoxynucleotide. High resolution 
gel electrophoresis separates the fragments, and because of the incorporation of 
radioactive dATP they can be visualised by autoradiograph. If the four termination 
reactions are run next to each other on the gel, then the sequence can be read directly 
from the order of the ladder of the bands (Watson et al., 1987).
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2.5 Aims of the present study.
The overall aim of this project was to compare different strategies in screening for 
molecular pathology using the RB gene as a model system.
Specifically this involved:
2.5.1. Optimisation of PCR, RT-PCR of retinoblastoma cDNA, single-stranded 
conformation polymorphism (SSCP) and amplification and mismatch detection 
(AMD) analysis.
2.5.2. Characterisation of mutations with direct genomic sequencing.
2.5.3. Application to breast and bladder carcinomas.
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CHAPTER THREE: METHODOLOGY.
3. Material and Methods.
3.1 Patients.
The Patients recruited were those with clinically confirmed bilateral retinoblastoma
referred to the Duncan Guthrie Institute of Medical Genetics, Glasgow. Blood samples 
| by Mair Crouch from The Duncan Guthrie Institute of Medical Genetics, Glasgow, 
were collected and immortalised lymphoblastoid cell line established^ Controls were
randomly selected from individuals who presented with problems other than
retinoblastoma. 20 patients with bilateral retinoblastoma and 3 of whom were related and
6 control subjects were included in this study. As well as patients with bilateral
retinoblastoma, 40 patients with bladder carcinoma and 39 patients with breast carcinoma
were screened for RB gene mutations. Tumour tissues from patients with bladder
carcinoma were provided from Pathology Department of Western Infirmary Hospital
Glasgow and obtained by transurethral resection. Tumour tissues from patients with
breast carcinoma were provided from The Duncan Guthrie Institute of Medical Genetics,
Glasgow. Additionally, to screen MCAD (Medium-Chain Acyl-CoA Dehydrogenase)
deficiency in Scottish population, 552 DNA from clotted bloods obtained from The
Duncan Guthrie Institute of Medical Genetics Alphafetoprotein Screening Laboratory
and postmortem livers of 233 SIDS (Sudden Infant Death Syndrome) patients
(representing most patients in the past 10 years in Scotland) obtained from Pathology
Department of the Royal Hospital for Sick Children in Glasgow.
3.2 Preparation of genomic DNA.
Genomic DNA was extracted from blood, tumour tissue, blood clots, liver tissue and 
Guthrie Cards. Extraction of DNA from blood was modified from methods described by
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Kunkel et al. (1977) whereas extraction of DNA from tissue was done with a method 
according to Hogan et al. (1986). Small scale DNA extraction method was used for the 
DNAs extraction from fresh blood clots (Williams et al., 1988).'
3.2.1 Extraction of DNA from blood.
DNA from patients with bilateral retinoblastoma was isolated from peripheral blood
fk
lymphocytes on the protocol by Kunkel et al. (1977). 20 ml of ice cold lysis buffer was 
added to 5 ml blood and mixed gently. This was incubated on ice for 10 minutes, 
centrifuged at 2800 9  for 10 minutes, and then the supernatant was discarded. The 
pellet was resuspended in 3 ml nucleic lysis buffer and the following solutions were added 
to the tube; 200pl 10% SDS and IOOjllI proteinase K. The solution was then incubated at 
37°C overnight. 1 ml of 6 M NaCI was then added to overnight incubation and the 
sample was centrifuged at 2.5 K for 15 minutes. The top layer was transferred into a 10 
ml tube. After this, the samples were extracted twice with phenol/chloroform, followed 
by a chloroform extraction to remove any traces of phenol. DNA was precipitated by
two volume of absolute ethanol. 
DNA was spooled out using sealed pasteur pipettes, washed in 70% ethanol, air dried and 
dissolved in 200-500 |il of TE buffer. The samples were stored at 4°C until required. 
Final DNA concentration was estimated by measuring the optical density at 260 nm in a 
Perkin Elmer 6000 spectrophotometer.
*Lysis buffer: 0.32 M Sucrose, 10 mM Tris-HCI pH 7.5, 5 mM MgCl2, 1% TritonxlOO. 
♦♦Nucleic lysis buffer: lOmM Tris-HCI pH 7.5, 0.44 M NaCI, 2 mM EDTA pH 7.2.
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3.2.2 Extraction of DNA from tissue.
©(■
To screening MCAD deficiency, extraction^DNA from postmortem liver tissue of 233 
SIDS was based on methods of Hogan et al. (1986). Same method was used for 
extraction of DNA from tumour tissue (breast carcinoma and bladder carcinoma) to 
screen RB gene mutations.
After thawing, the tissues (approximately the size of a pea) were minced with fine- 
pointed sterile scissors The following reagents were added; 3 ml lysis mix , 200pi 10% 
SDS, lOOpl proteinase K (10 mg/ml). Then they were incubated at 55°C for 4-16 hours. 
After incubation, 1 ml 6M NaCI was added and sample vigorously shaken. The samples 
were then centrifuged at 3000g for 10 min. The supernatant was transferred to another 
tube and an equal volume of phenol-chloroform was added to each tube ( 5 ml of each). 
After centrifugation at 3000 g for 10 min the supernatant was transferred to a fresh tube. 
DNA was precipitated by adding 2 volumes of ethanol, 1/10th volume 3M sodium 
acetate. DNA was spooled out using sealed glass pipettes. The DNA was rinsed in clean 
70% ethanol, air dried and resuspended in an appropriate small volume of TE buffer 
(about 500pl).
3.2.3 Small scale DNA extraction.
Small scale DNA extraction method was used for the DNA extraction from fresh blood 
clots which were obtained from pregnant western Scottish women undergoing 
alphafetoprotein (AFP) analysis for foetal abnormality. Two methods of small scale DNA 
extraction were performed to determine which was the most amenable to PCR 
amplification and which was also cost and time effective. The majority of the DNAs were
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extracted by the Proteinase K method of Williams et al. (1988), who have shown that the 
quantity and purity of the DNA is sufficient for the subsequent PCR amplification. The 
remainder of the DNAs were extracted by the alkali method of Ivinson and Taylor 
(1993), which is a much quicker and simpler procedure.
3.2.3.1 Proteinase K method.
Batches of 10-20 DNAs were prepared simultaneously. For each blood sample, a clot 
(approximately the size of a pea) was placed into a 1.5 ml eppendorf tube and minced 
with scissors. The following reagents were then added to each eppendorf; 375 \i\ Nucleic 
lysis mix ,25 jil Proteinase K (10 mg/ml). The reagents were mixed well by inverting each 
tube for approximately 30 sec. The reaction components were then incubated at 55°C or 
at 37°C for at least 4 hrs with mixing each hour or overnight* Phenol/chloroform 
extraction was performed three times on the resultant DNA mixture, followed by a single 
chloroform extraction (The upper layer in each extraction contained DNA). The DNA 
was then precipitated out of solution by addition of roughly 1 ml of ice-cold ethanol to 
the DNA solutions in each 1.5 ml eppendorf tube. If visible, the DNA was spooled out on 
a glass pipette, washed in ethanol and left to air dry. The DNA was subsequently 
redissolved in 200 (il of TE buffer. If the DNA was not visible on ethanol precipitation, 
the DNA/ethanol mixture was microfuged at 10.000 rpm (IEC Centra-4x). The ethanol 
supernatant was poured off and the pellet allowed to air-dry. The DNA pellet was then 
redissolved in solution, as above. The DNA solutions were stored at 4°C until required. 
The optical density (OD) of the DNA solutions was read at 260 nm using quartz cuvettes. 
The DNA concentration (jll/ml) was calculated by multiplying the OD reading by the 
dilution factor of the DNA solution in the cuvette (1/100) and also by multiplying by 50 
as 1 OD unit is equivalent to 50 jig of DNA. One |Xg of DNA was used in the PCR.
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3.2.3.2 Alkali method.
DNA blood clots were prepared as in the proteinase K method. To release the DNA into 
the solution, 0.1M NaOH (100 pi) was added to the minced clot and mixed thoroughly 
by vortexing for roughly 15 sec. The mixture was then boiled for 6 min on a preheated 
Dri-Block (techne DB-1) and afterwards microfuged (IEC Centra-4X) at 10,000 rpm for 
3 min. The supernatant was immediately removed from the underlying cell debris and 
stored at 4°C unless the PCR was performed immediately. Depending on the volume of 
supernatant recovered, 5-10 pi of the DNA solution were used for the PCR.
3.3 Total cellular RNA extraction.
Total cellular RNA was extracted from peripheral blood lymphocytes and lymphoblastoid 
cell lines. Extraction of RNA from lymphocytes was modified from methods described by 
Lench et al. (1988) and Sherman et al. (1989), whereas extraction of total cellular RNA 
from lymphoblastoid cells was based on the methods of Chomczynski and Nicoletta,
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(1987). The use of high-quality RNA is critical for the success of RT-PCR analysis. The 
RNA must not be degraded by ribonucleases, as determined by the intactness of 
ribosomal (rRNA) bands, and contaminating genomic DNA must be removed. Therefore, 
plastic used for the preparation and storage of RNA were treated in 0.1% 
diethyl pyrocarbonate (DEPC) in water for 14-16 hours
before being autoclaved to avoid contamination with RNases. All plastic-
ware for RNA use were kept aside from general use. Isolated RNAs were stored as an 
ethanol precipitate at -20°C or in aqueous solution at -70°C or below up to a year 
without appreciable deterioration. Repeated freeze and thaw cycles were avoided.
3.3.1 Extraction of RNA from lymphocytes.
10 ml of venous blood was collected in heparinised bottles The diluted blood was 
carefully layered over 10 ml of histopaque and centrifuged at 1400 rpm for 30 min at 
room temperature. After centrifugation the opaque interface mononuclear cells, including 
lymphocytes, was carefully removed with a pasteur pipette into a fresh tube and washed 
in 20 ml of cold PBS (phosphate buffered saline), then pelleted by centrifugation at 1400 
rpm. for 20 min. The supernatant was discarded in chloros and the cell pellet resuspended 
in phosphate buffered glucose (pH 7.4). j Approximately four million cells were
then removed and washed in PBS and pelleted in a microcentrifuge by centrifugation at 
1400 rpm for 10 min. The cell pellet was resuspended in 500 |il of solution D ( 4 M 
guanidinium thiocyanate, 25 mM sodium citrate, pH 7; 0.5% sarcosyl, 0.1 M 2- 
Mercaptoethanol). [To minimise handing of guanidinium thiocyanate (hazardous) a stock 
solution was prepared as follows: 250 g guanidium thiocyanate (Fluka) was dissolved in 
the manufacturer’s bottle (without weighing) with 293 ml water, 17.6 ml 0.75 M sodium 
citrate, pH 7, and 26.4 ml 10% sarcosyl at 65°C. This stock solution can be stored for at
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least 3 months at room temperature (Chomczynski and Nicoletta, 1987)]. The resultant 
mixture was transferred to an autoclaved and DEPC treated 1.5 ml eppendorf tube and 
the following solutions; 50jll1 of 3M Sodium Acetate, 500pl of phenol, lOOpl of 
chloroform-isoamylalcohol (49:1 ratio) were added and vortexed for 20 seconds. The 
tubes were placed on ice for 15 minutes. Then the tubes were centrifuged for 20 minutes 
at 10000 rpm. The aqueous phases of the mixtures were transferred into 1.5 ml eppendorf 
tubes. Then 1000 pi of isopropanol was added to the tubes, and mixed well. They were 
kept at -20°C for 1 hour. The tubes were then centrifuged, and the supernatant was 
discarded. 300 pi of solution D was added to the pellets and the pellets were dissolved. 
300 pi of isopropanol was added to each tube and then the solution quickly chilled at - 
20°C. After an 1 hour, the tubes were centrifuged for 10 min. The pellet was washed in 
250 pi of 75% ethanol, then dried. Finally the pellet was dissolved in DEPC treated 
water.
3.3.2 Extraction of total cellular RNA from lymphoblastoid cell line.
The most common and consistently successful method for isolating pure, intact total 
RNA are modifications of the original guanidinium thiocyanate method of Chirgwin et al. 
(1979). To each cell pellet in a 30 ml Sorvall tube, 3 ml of Solution D was added. 2- 
mercaptoethanol was added to a final concentration of 1% (0.14 M) only just before use. 
Homogenisation was done by carefully vortex mixing the cell pellet in the homogenisation 
buffer and then passing the homogenate several times through a 23-gauge needle until the 
cell lysate was no longer viscous. After homogenisation, the protocol was carried out as 
described above.
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3.3.3 Determination of RNA concentration.
RNA quantitation was carried out by spectrophotometry. The optical density (OD) of the 
RNA was determined both at 260 and 280 nm. To carry out determination of the optical 
density (OD) of RNA, 10 pi of RNA solution was diluted in 990 pi of TE buffer in a 1 ml 
cuvette. An OD of 1 at 260 nm corresponds to approximately 40 pg/ml of RNA. The 
ratio of 260 nm and 280 nm was used to determine the purity of the RNA solution. The 
value of the ratio was expected to be 2 to determine good RNA (Gurr and McPherson, 
1993).
3.3.4 Qualitative assessment of RNA.
The quality of RNA was evaluated by agarose gel electrophoresis. To prepare the gel, 
0.45 g agarose was weighed out in 22 ml of water in a flask . The flask was weighed and 
boiled until the agarose had dissolved. The flask was then re-weighed and the evaporated 
water replaced. The gel was cooled to 55°C. After cooling, in a fiime hood, the following 
reagents were added; 5 ml formaldehyde, 3 ml lOxMOPS buffer [3-(A-morpholino) 
ethanesulphonic acid] and the gel quickly poured before setting. 1 pi of RNA solution 
was mixed with 5 pi of formamide, 1.65 pi of formaldehyde, 1 pi of 10X MOPS and 1.3 
pi of dH02 The mixture was heated to 55°C for 10 min, quenched on ice and 2 pi of gel 
loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 40% sucrose in 
water) was added. The samples were then immediately loaded with lpg  Escherichia coli 
ribosomal RNA (Boehringer) as markers and electrophoresed at 75 V until the 
bromophenol blue reached the bottom of the gel. lxMOPS was used as a running buffer. 
After running the samples, the gel was soaked in water for 1 hour to wash out the 
formaldehyde. The gel was stained for 5 min in a 1/1000 solution of ethidium bromide,
48
then destained for 2 hr or overnight in H2O and viewed under U. V. light to check for the 
integrity of ribosomal bands and to estimate the concentration.
3.4 Polymerase chain reaction.
3.4.1 Amplification of DNA from retinoblastoma gene.
Primers flanking exons 12-22 of the retinoblastoma gene, designed by Thompson and his 
co-workers (1991) (Table 3), were used in this study for the amplification of DNA from 
the retinoblastoma gene. The synthetic oligonucleotide primers were prepared by on a 
Applied Biosystems DNA synthesiser. Amplification was performed by adding 1 pi of 
DNA to a 15 pi reaction mixture containing 50 mM KC1, 10 mM Tris.HCl (pH 8.4), 1.5 
mM MgCl2, 100 pg/ml gelatine, 10 pM of each dNTP (dATP, dCTP, dGTP, 
dTTP)(Boehringer Mannheim) and 0.5 pM of each primer. The mixture was then put in 
an U.V. box (Amplirad II, high intensity shortwave cabinet with 4xG875 germicidal 
lamps, 1.8 watts each, 254 mm wavelength) for 5 min. After U.V. treatment DNA was 
added and thoroughly mixed by vortexing. To this 1.25 units of Taq DNA Polymerase 
was added, the mixture overlaid with 15 pi of light mineral oil and amplified for 30 
cycles. Denaturation was carried out at 94°C for 45 sec, annealing was performed at 52- 
57°C (Table 5 in the results section) for 2 min and extension at 72°C for 1.5 min except 
for the last extension which was carried out for 10 min. At the end of the PCR, samples 
were briefly centrifuged and 5 pi of each product was taken below oil and 
electrophoresed on a 1% agarose gel in IX TBE buffer. Electrophoresis was carried out 
at 10-15 V/cm until the bromophenol blue in the loading mixture migrated two thirds of 
the distance of the gel. The gel was stained by soaking for 30 min at room temperature in
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the running buffer containing 0.5 pg/ml of ethidium bromide. When necessary the gel was 
destained for 20 min before visualisation under U.V. light.
3.4.2 Amplification of DNA from medium-chain Acyl-CoA dehydrogenase
(MCAD) gene.
A 0.5 ml sterilised tube was used for the PCR reaction. The reaction mix, which was 
made up to a total volume of 100 pi with double distilled water, was set up using lOpl of 
lOxPCR reaction buffer (50 mM KC1, 10 mM Tris (pH 8.4), 1.5 mM MgCl2, 100 mg/ml 
gelatine), 10 pi dNTP's mix containing 50pM of each nucleotide and 50 pmol of each 
oligonucleotide primer (Gregersen et al., 1991). The concentration of each 
oligonucleotide primer was calculated according to the method described by Thein and 
Wallace, (1986). All reagents were kept at -20°C, vortexed briefly after thawing and 
spun down before pipeting with positive displacement pipettes (Lab systems). The mix 
was irradiated for 5 minutes in an Amplirad before the addition of lpg of template. The 
samples were than heated at 95°C for 5 minute, 60°C for 5 minutes, and 2 units of Taq 
DNA polymerase (Boehringer Mannheim, 5 U/pl) were added. Each PCR reaction mix 
was overlaid with lOOpl of light mineral oil (Sigma), and centrifuged for 3 seconds before 
it was placed in Techne PHC 1 automatic thermocycler. Amplification conditions 
consisted of 30 cycles of the following: denaturation at 94°C for 1 min, annealing at 
60°C for 2 min, and primer extension at 72°C for 2 min. The PCR cycles were followed 
by a final 10 min extension step at 72°C. The products were directly digested with Ncol 
and analysed in 8% polyacrylamide gels.
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Primer set Sequence
12A 5'-GAT ACA TTT AAC TTG GGA GA-3
12B 5'-CAT GTT AGA TAG GAG ATT AG-3'
13A 5'-GAT TAC ACA GTA TCC TCG AC-3'
13B 5-TAC AACTGGA AGATGC TG-3'
14A 5'-AAA CAG TGA GAC TCC ATC TC-3'
14B 5-TGG CCA GGA TGA TCT TGA TG-3'
15A 5-TAA GGT TTC AAT TAA ACA AC-3'
16B 5-CTT TAA ATT GAA CAA AAG TG-3'
17A 5-TAC CTAGCT CAAGGGTTA AT-3’
17B 5-TAG CCA TAT GCA CAT GAA TG-3'
18A 5-AAT TAT GCT TAC TAATGT GG-3'
18B 5-ATT TGC AGT TTG ATGGTC AA-3*
19A 5'-TGT GAT TCT TAG CCA ACT TG-3’
19B 5'-TCA GAG TCC ATG CTC TTG AA-3'
20A 5'-AGA GGT TTC TGT TAA AAT GC-3'
20B 5-AGAAGG TGA AGT GCT TGA TT-3'
21A 5-ATT CTG ACT ACT TTT ACA TC-3'
21B 5'-ATG AGA TCA AAT GAA TTA CC-3'
22A 5'-TTT ACT GTT CTT CCT CAG-3’
22B 5-GTG GAC CCA TTA CAT AG-3'
Table 3. Sequence of PCR primers for the exons studied (Thompson et al., 199 !)♦
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3.4.3 PCR primer design.
Primers for RT-PCR were designed using computer program OLIGC)TM(MEDPROBE). 
Segments were designed which overlapped each other and almost covered the entire 
cDNA. Oligonucleotide primers were generally synthesised in the range 21-22 bases. 
Primers were stored in the ammonia eluant used for deprotection which stays liquid at - 
20°C, enabling the dispensing of primers without repeated freeze-thawing. Before use, 
20-30 jil of this stock was heated to 95°C for 3 minutes to drive off the ammonia. Total 
cellular RNA from samples was used to synthesise cDNA using oligonucleotide primers 
with nucleotide sequences complementary to various regions of the RB mRNA. The 
single-stranded cDNA segments carrying portions of the RB mRNA thus obtained were 
then amplified by PCR to double-stranded DNA segments using sets of two primers one 
of which was the same oligonucleotide as that used for reverse transcription. The regions 
thus amplified, designated as segments A to E (Table 4), with nucleotide lengths of 302 
bp to 1433 bp, are shown in Figure 5. These 5 segments overlap each other and cover 
almost the whole coding sequence of the RB cDNA of 3938 kb. Amplified products 
were then subjected to AMD analysis.
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5 RB cDNA 4.7 kb
A B
||U -‘.giA.Jumw? 
432 734 794 1L94
3290
1361 2068 3127 4497
Figure 5. The strategy for amplification, o f RB cDNA, and the positions o f the 
segments used for RT-PCR in the gene is shown.
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POSITION SYMBOL POSITION 
AND LENGTH
SEQUENCE
Sense A5 432 (21) 5’GTG GGG AAT CTG TAT CTT TAT-3'
Antisense A3 734 (21) 5 -ATA CTT CCC CTT TAG CTA ATA-3'
Sense B5 794 (21) 5'-TGC TAT GTG TCC TTG ACT ATT-3'
Antisense B3 1199 (21) 5-TAC TTT TTC GTG GTG TTC TCT-3'
Sense C5 1361 (22) 5-CAG TGA ATC CAA AAG AAAGTAT-3’
Antisense C3 2068 (22) 5-AAA ACA GTG AAA GAG AGG TAG A-3'
Sense D5 1857 (21) 5 -TAA ACA ATC AAA GGA CCG AGA-3'
Antisense D3 3290 (21) 5-AAA AAC AAG AGC AAA CAT CAC-3’
Sense E5 3127 (21) 5-TTG AAA ATC TTG TGT AAA TCC-3’
Antisense E3 4497 (21) 5-CCC TTG ACC TAA AAA CTA ACT-3’
Table 4. Sequences of the oligonucleotide primers used in various amplifications and their 
positions in retinoblastoma cDNA are shown.
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3.4.4 Asymmetric PCR amplification of retinoblastoma cDNA.
The PCR technique allows the rapid isolation of specific DNA targets for sequencing. 
Asymmetric PCR reaction was performed according to the protocol developed by Mgone 
(1992). By this method single-stranded DNA was generated during the PCR reaction. 
Primers were included in a ratio of 50:1 to 100:1, one primer at the usual concentration 
and one diluted. The best ratio was generally determined by trial and error. 5 jxl of a 10 \l 
M and 0.1 |iM dilution of each primer were used in a PCR reaction in a total volume 100 
pi. Other components were the same as for the standard reaction. The reactions were 
checked for the production of single-stranded DNA on a 1% TBE agarose gel, and 
visualised by staining with ethidium bromide (lOpg/ml).
3.4.5 Reverse-transcriptase PCR (RT-PCR).
Reverse transcription of RNA followed by the polymerase chain reaction (RT-PCR) is a 
sensitive method to detect specific mRNAs. RNA was first isolated from
cells and then used as a template for reverse transcription to complimentary DNA 
(cDNA). The cDNA in turn was used as a template for PCR, using primers designed to 
amplify the selected cDNA region. Following PCR, the product was typically analysed by 
agarose gel electrophoresis. The amplified cDNA was identified by the size of the PCR 
product, which is predicted from knowledge of the cDNA nucleotide sequence.
3.4.6 Reverse-transcriptase PCR using downstream primers.
A 3’ (antisense) gene-specific primer was annealed to the mRNA and extended with 
reverse transcriptase, thus generating a cDNA template for the 5' (sense) primer, allowing
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PCR amplification to occur. To accomplish this, 0.5-1 pg of RNA was heated at 95 °C 
for 5 min, quenched on ice and then 20 pmol of antisense primer was added. To anneal 
the primer, the samples were heated at 65 °C for 10 minutes and quenched on ice again 
and then reverse transcribed in a 20 pi reaction mixture containing 20 Units Ribonuclease 
inhibitor (RNasin; Boehringer Mannheim Biochemica; 2,000U/50pl), 50 mM Tris-HCI, 
pH 8.3, 3 mM MgCI2, 75 mM KCI, 10 mM dithiothereitol (DTT), 200pM each dNTP 
(dATP, dCTP, dGTP, dTTP), 200 units of Moloney Murine Leukaemia Virus Reverse 
Transcriptase (M-MLV RT; Gibco BRL) for 1 hour at 42°C. At the end of the reverse 
transcription the mixture was heated to 95°C for 5 min and then quenched on ice. To this 
solution 30 pmol of the antisense primer and 50 pmol of the sense primer were added 
with a final concentration of 0.5 pM of each primer. The volume of the reaction mixture 
was adjusted to 100 pi and 2 units of Taq DNA polymerase added. The samples were 
then briefly vortex mixed and capped with 100 pi of light mineral oil. Amplification 
conditions consisted of 40 cycles of the following: denaturation at 94°C for 1 minute, 
annealing at 52°C for 2 minutes, and primer extension at 72°C for 2 minutes. The PCR 
cycles were followed by a final 10 minutes extension step at 72°C.
The samples were loaded onto 1% agarose gels and electrophoresed in TBE buffer. The 
products were then visualised under U.V. light by staining with ethidium bromide (lOp 
g/ml). The appropriate band was excised and the cDNA eluted by soaking for 24 hours in 
100 pi of TE buffer at -20°C. The cDNA in solution was removed from the agarose by 
pipetting and stored at -20°C or used directly in asymmetric PCR or AMD analysis.
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3.4.7 Reverse-transcriptase PCR using Oligo (dT).
mRNA molecules were first converted into cDNA by priming with 0.2 Jig of oligo(dT) 
(d(T)i2-l& Pharmacia). At the end of the reverse transcription two gene-specific primers 
were added for amplification. The amplification was carried out as described above.
3.4.S Purification of PCR products.
At the end of PCR, the amplified DNA or cDNA was purified by removing excess 
dNTPs, primers and salts. Various techniques were used. These included Geneclean 
purification (Vogelstein and Gillespie, 1979), and selective alcohol precipitation 
(Gyllensten and Ehrich, 1989; Brow, 1990).
3.4.8.1 Geneclean™ purification.
Chemical cleavage of PCR products requires elimination of primers, dNTP's, PCR 
buffer, and Taq polymerase, since these would interfere with the reaction. At the end of 
PCR amplification, the purification was carried out according to the manufacture's 
protocol (BIO 101). The paraffin oil was removed. 2-3 volumes of the supplied stock 
solution of Nal were added to the products giving a final concentration of at least 4 M 
and to this, 15 jil of the provided 'glassmilk' suspension was added, mixed and the 
mixture kept on ice for 15 min to bind the DNA molecules. The mixture was then 
centrifuged in a microcentrifuge for 5 seconds and the supernatant removed. The pellet 
was then resuspended in 300 pi of the New Wash provided, centrifuged for 5 seconds 
and the supernatant discarded. This washing was repeated three times and after the third 
wash the pellet was resuspended in 20 pi of TE buffer and incubated at 65°C for 10 min.
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The mixture was then centrifuge for 3 minutes and the supernatant containing eluted 
DNA was transferred to a fresh microfuge tube.
3.4.8.2 Selective alcohol precipitation.
Precipitation was performed according to the protocol modified by Mgone (1992). The 
method used was based on the fact that 2.0-2.5 M ammonium acetate reduces the 
coprecipitation of dNTPs with DNA (Okayama and Berg, 1982). Mineral oil was 
removed. An equal volume of 4 M ammonium acetate (pH 5.2) was then added, mixed 
and to this 2 volumes of ethanol added and again mixed. The mixture was left at room 
temperature for 10 min, then centrifuged at 12,000 rpm for 10 min. The DNA pellet was 
washed in 70% alcohol, dried in air and dissolved in 14 pi of TE buffer (pH 7.4).
3.5 Single-stranded conformation polymorphism (SSCP) analysis.
SSCP analysis was applied to screen functionally important RB gene regions. Exons 12 to 
22 (Table 3) of the RB gene were screened for sequence change with PCR-SSCP 
analysis. A 30 cycle PCR was performed on the target DNA sequences using 100 ng of 
genomic DNA. 20 pmol 32p dCTP (60 gCi) was included in the reaction mixture to label 
the PCR products. After thermal cycling, the amplified product was diluted 1:7 in gel 
loading buffer (95% formamide, 10 mM NaOH, 0.05% bromophenol blue and 0.05% 
xylene cyanol). The sample was heated at 95°C for 2 minutes to denature the DNA. The 
denatured DNA was then placed directly onto ice for several minutes. Then, the samples 
were loaded on to 0.5XMDE nondenaturing gel (20cmx40cmx0.4cm) containing 5% 
glycerol. Electrophoresis was carried out at 5 W for 14-24 hours, with a fan heater, set 
on cold, directed at the gel as a cooling device. The gels were dried on a gel dryer
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(Biorad model 543). After drying, the gels were placed on a sheet of Kodak XAR-5 film 
in an autoradiographic cassette with "Dupont lightning plus" intensifying screens 
(Hoeffer) and exposed for 3-16 hours at -70°C.
3.6 Heteroduplex analysis of the retinoblastoma gene.
After the final thermal cycle of PCR was completed, the reaction was inactivated by 
adding EDTA to 5 mM (1 jxl of 0.5 M EDTA per 100 pi reaction). Amplified DNA 
fragments were heated to 95°C for 3 minutes, and cooled slowly (20-30 minutes) to 
room temperature to form heteroduplexes (Keen et al., 1991). A sequencing plate was set 
up with 0.4 mm spacers and filled with gel solution including 25 ml of MDE gel, 69 ml of 
dH2 0 , 6 ml of 10X TBE buffer, 0.4 ml of 10% APS, 0.04 ml of TEMED. Appropriate 
DNA size markers were also included on each gel as well as control homologduplex 
DNA. Approximately 100-200 ng of DNA was loaded per lane. Before loading the 
samples, 1 pi of gel loading buffer (95% formamide, 10 mM NaOH, 0.05% bromophenol 
blue and 0.05% xylene cyanol) for each sample was added and mixed well. 
Electrophoresis was done at a maximum constant voltage of 20 Volts per cm of the gel. 
So, for 40 cm gel, 800 Volts was used.
3.7 Amplification and mismatch detection (AMD) analysis.
This technique was developed to screen for point mutations, but deletions and insertions 
too small to be recognised by gel electrophoretic techniques are also detected (Howells et 
al., 1990). In this method, a reference DNA probe was mixed with excess test DNA or 
RNA. The mixture was then heated to denature the double strands of the DNA, and 
followed by cooling to allow reannealing and, thus, heteroduplex formation occurred with
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mismatched or unmatched C and T bases detected by reactions with hydroxylamine and 
osmium tetroxide, respectively. Cleaved by piperidine treatment was followed. The 
samples were then run on a 8% polyacrylamide/urea denaturing gel. 5 segments shown in 
Figure 5 of the RB gene and some of exons of the RB gene from patients with bilateral 
Rb were subjected to AMD analysis.
3.7.1 Probe preparation.
The purified PCR product chosen as the probe was end labelled or internally labelled. End 
labelling was done either by 3 -end labelling or 5-end labelling. Approximately 5ng of 
probe DNA per target sample per modification reaction was used. Radiolabelling of the 
probe was done by using either T4 polynucleotide kinase (5' end labelling) or the Klenow 
fragment of DNA polymerase I (3-end).
3.7.1.1 32p internal labelling and probe preparation.
Probes for each of the PCR products were prepared by PCR amplification between the 
sense and antisense oligonucleotides using an unaffected sample in the presence of 20 
pmol of 32p dCTP (60 jiCi). To allow efficient incorporation of label, the final 
concentration of non radioactive dCTP in the reaction was reduced from 200 pM to 6 
pM. To prevent misincorporation of alternate dNTPs as [dCTP] fell, only 25 PCR cycles 
were performed. The probe was then isolated from an agarose gel and resuspended in 
lxTE (lOmM Tris-HCl, ImM EDTA, pH 7.4) buffer at l,000cpm/pl.
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3.7.1.2 5'-end-labelIing and probe preparation.
10 pi of Geneclean PCR product of unaffected control were mixed with 0.5pl of (y-32p)_ 
ATP (3000 Ci/mmol; 10 Ci/ml), 5pl of 10X kinase buffer (freshly made; 500mM Tris- 
HCI pH 7.6, lOOmM DTT, lOOmM magnesium chloride), lpl of 10 units/pl T4 
polynucleotide kinase and 33.5pl of TE buffer (10 mM Tris-HCI, 0.1 mM EDTA, pH
7.4). This mixture was incubated at 37°C for 30 minutes. After that, it was placed on ice 
or stored at -20°C.
3.7.1.3 Probe preparation using 5'end-labelling primers.
Either the sense or the antisense strand of the wild-type cDNA was labelled by 
incorporation of radiolabelled oligonucleotide primer during the PCR reaction. 20-50 
pmol of primer was labelled as follows: To a final volume of 50pl of TE buffer; 5 pi of 5X 
kinase buffer, 5pi of diluted primer, 50-70 pCi (y-32p)ATP (6000 Ci/mmol), and 30 units 
of T4 polynucleotide kinase were added. Then it was incubated at 37°C for 45 minutes. 
End-labelled primers were used in the PCR reaction. After that, the reaction mixture was 
purified using Geneclean and used as a probe.
3.7.1.4 3'-end-IabeIling and probe preparation.
3 -end labelling can be used to selectively label each strand of the probe separately, but 
this requires that the appropriate restriction sites are present in the oligonucleotide 
primers. 6.5 pi volume probe DNA was mixed with lp l of (a-32p)-dNTP(s) (3000 
Ci/mmol; 10 Ci/ml), 1 pi of TM (100 mM Tris-HCI pH 8.3, 50 mM Magnesium 
chloride), 1 pi of 0.1 M dithiothereitol (DTT), 0.5 pi of 5 units/pl Klenow fragment
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(Boehringer-Mannheim) to a final volume of 10 pi of To jE. Then it was incubated at 
room temperature for 15 minutes and placed on ice or stored at -2°C.
3.7.2 Duplex formation.
By means of siliconized eppendorf tubes, homoduplexes and heteroduplexes were 
prepared with 28,000 cpm 32p control DNA (approximately 10.5ng) and a 10-fold 
excess of the unlabeled test DNA (105ng) in 162pi of TE buffer. 18pi of 10X 
hybridisation buffer (3M NaCI, 1M Tris-HCI, pH 8.0) was added, and the tubes were 
boiled for 5 minutes and transferred to 65°C. After 5-16h incubation, the tubes were 
removed and the DNA duplex was precipitated in 750pl of stop solution (63 mM sodium 
acetate, 20pM EDTA, 80% ethanol) as well as 4pi of 20 mg/ml mussel glycogen 
(Boehringer-Mannheim). After mixing well, the samples were chilled on dry ice for 10 
minutes. The samples were then spun at 14000g in a microcenrifiige for 10 minutes 
and the supernatant was discarded. The pellets were then washed with 70% v/v ethanol, 
and resuspended in 14pl of TE buffer. Two reactions were carried out for each duplex.
3.7.3 Hydroxylamine reaction.
20 pi hydroxylamine solution (1.39 g hydroxylamine (BDH) in 1.6 ml distilled water, 
adjusted to pH 6.0 by addition of approximately 1.6 ml diethylamine), was added to 7 pi 
of the duplex solution and the mixtures incubated for 10 and 60 min, respectively, at 
37°C. After incubation, 750 pi "stop solution” was added, and the DNA precipitated on 
dry-ice for 10 min. After centrifugation the DNA pellets were rinsed with 70% 
ethanol, and all liquid was removed after brief centrifugation. Finally the pellets were 
dried.
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3.7.4 Osmium tetroxide (OSO4) reaction.
18 jllI of osmium tetroxide solution (pyridine 6.75 pi (BDH), 4% w/v osmium tetroxide 
(Aldrich; 4% solution), 154 pi of Tq i E) was added to 7 pi of the duplex solution and the 
tubes mixed and incubated at 37°C for 2 hours. After incubation the reactions were 
stopped by the addition of 750 pi stop solution, and the DNA precipitated and was dried
as for the hydroxylamine reactions] Osmium tetroxide irritates mucous membranes, 
(therefore it should be used in a fume hood. ___________________
3.7.5 Piperidine cleavage of mismatches.
Fifty microliters of 10% piperidine (Fluka chemica) solution was added to each of the 
dried pellets and vortexed for 10 seconds, and the tubes then incubated at 90°C for 30 
min and 300 pi of stop solutions were added and the DNA was precipitated on dry-ice 
for 10 minutes and centrifuged, washed with 70% ethanol, dried, and resuspended with 7 
pi formamide dye (10 mg bromophenol blue, 10 mg xylene cyanol FF, and 0.2 ml of 0.5 
mM EDTA dissolved in 10 ml deionized formamide). The samples were boiled for 2 min 
and cooled on ice, and then the sample was subjected to electrophoresis on a 0.4-mm- 
thick 8% polyacrylamide/urea denaturing gel run at 35 W until the bromophenol blue 
marker had run 30 cm.
3.7.6 Radioactive labelling of 1 kb ladder.
The DNA fragments of the 1 kb ladder (BRL) were labelled by filling in of the 3* recessed 
ends with Klenow enzyme using the dATP, dGTP and dTTP nucleotides included in the 
Random Primed DNA labelling Kit (Boehringer Mannheim), lpg of 1 kb ladder was 
mixed with 1 pi of each dNTP, 2pl React 3 buffer (BRL), 2 pi of 32p dCTP (Amersham
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Life Science, 10 mCi/ml), 2 units of Klenow enzyme and made up to a final volume of 20 
jllI with distilled water. After then, the sample was incubated at 37 °C for 45 minutes. 
Then the labelled fragments were separated from other radioactive material on a pre­
packed Nick Column (Pharmacia), containing Sephadex G-50, eluted in 200 pi lx SSC 
buffer. The radioactively labelled 1 kb ladder was with loading mix before being applied 
on a gel.
3.8 Genomic sequencing.
The analysis of genetic variation in sequences amplified by PCR was carried out by 
sequencing the PCR product. The PCR amplified DNA and cDNA were directly 
sequenced using single-stranded templates (Mgone et al., 1992). Prior to sequencing, the 
PCR products were purified by removing excess deoxyribonucleoside triphosphates 
(dNTPs), salts and primers as described above. 7 pi of purified PCR product was mixed 
with 2 pi 5 X sequencing buffer giving a final concentration of 40 mM Tris-HCI (pH
7.5), 20 mM MgCl2 and 50 mM NaCI; 1 pmol of sequencing primer, either limiting or 
nested and complementary to synthesised single-stranded cDNA or DNA, was used. The 
template-primer mix was annealed by heating to 65°C for 2 minutes and then allowed to 
cool slowly, to less than 35°C over a period of 30 minutes. The mixture was then placed 
on ice and 1 pi of 0.1 M DTT, 2 pi of a 1/5 dilution of labelling mix (7.5 pM of each 
dNTP except dATP), 0.5 pi oc^S-thio dATP (1000 Ci/mmol: 10 pCi/pl) and 2 pi (1.5 u) 
of a 1/8 dilution of T7 DNA polymerase (Sequenase; version 2.0, protocol no. 70770) 
were added and incubated at room temperature for 5 minutes. After incubation, 3.5 pi of 
the mix was added to 2.5 pi of each termination mix prewarmed to 37°C, and incubated 
for another 5 minutes. The termination mixes contained 80 pM of each dNTP and 8 p  M 
of the appropriate dideoxyribonucleoside triphosphate (ddNTP). The reactions were
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terminated by the addition of 4 pi formamide-dye stop solution (95% formamide, 20 mM 
EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) and denatured at 75°C for 2 
minutes; 1.5 pi of each reaction mixture was immediately loaded onto an 8% 
polyacrylamide gel containing 7 M urea. The gels were run at a temperature of 50°C for 
2-4 hours, then fixed in 10% methanol/10% acetic acid, dried and exposed for 16-18 
hours to Kodak X-Omat AR film using intensifying screens .
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CHAPTER FOUR: RESULTS.
4. Results
4.1 Amplification of DNA from postmortem liver tissue and blood clots.
Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, is an autosomal 
recessive inborn error of metabolism associated with sudden unexplained death in 
young children. The DNAs from clotted bloods and postmortem livers of patients 
dying of sudden infant death syndrome (SIDS) were subjected to a modified PCR 
(Gregersen et al. 1991), whereby DNA fragments of 199 bp, including position 
985 were synthesised. The sense and antisense primers used were (5-TTT ATG 
CTG GCT GAA ATG GCC ATG-3')(bp 961 to 984 of the cDNA) and (5'-CAG 
GAT ATT CTG TAT TAA ATC CAT GGC CTC-3')(bp 1130 to 1159 of the 
cDNA) respectively (Gregersen et al. 1991). The sense primer contains a C:T 
mismatch at position 981, thus introducing a Ncol restriction site (CCATGG) 
when the mutant sequence is amplified. The antisense primer introduces a G:A 
mismatch at position 1135, creating another Ncol site. A Ncol site is not created 
and therefore cleavage does not occur when the PCR product is derived from the 
A985 allele. The other Ncol site is a control site, which is cleaved in both cases. 
G985 can therefore be distinguished from A985 because Ncol digestion of the PCR 
product results in a 158 bp band (G985) instead of a 178 bp band (A985) (Kolvraa 
et al., 1991) (Figure 6). 552 DNAs extracted from fresh blood clots of women 
from the West of Scotland were analysed two heterozygotes and no homozygotes 
were found. In addition, there were 3 G985 heterozygotes in a sample of 233 
Scottish patients dying from SIDS from same geographical area and no 
homozygotes found. This means that the heterozygous frequency of the G985 
mutation is 1/276 (95% Cl: 1/76-1/2279) in the Scottish population and 1/74 (95% 
Cl: 1/27-1/377) in Scottish patients with SIDS (Dal.,y et al., 1991),
66
1 2 3 4 5 6 7 8 9  10
200
bp^
1 5 4
bp^
1 9 9
Nbp
>«158
bp
1 7 8
«bp
Figure 6. Amplification o f DNA from tissues and blood clots,
Genomic DNA fragments (199 bp) o f the MCAD gene were amplified and digested 
with Ncol and subjected to electrophoresis in an 8% polyacrylamide gel. Lane 1; 
size marker (1 kb ladder), lane 2; control (undigested), lane 3; heterozygous 
control, lane 4; heterozygous individual, lanes 5-10; normal individuals.
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4.2 Application of PCR-SSCP analysis in regions of the retinoblastoma 
gene.
In PCR-SSCP analysis, a DNA sequence of interest was amplified by PCR. For 
efficient detection of the product, isotopic label was coupled with the PCR primers or 
was incorporated into the PCR product itself (Hayashi et al., 1989; Makino et al., 
1992). Generally in 100 pi of PCR reaction for SSCP analysis, 2 pi of a-^^PdATP 
(3000Ci/mmol) and 2-3 unit of Taq polymerase are used. In order to save Taq 
polymerase and radioactive isotope PCR amplification was carried out in 15 pi of 
reaction solution. PCR in the small amount of reaction solution resulted in more 
efficient amplification and low expose radioactivity. On the other hand, when 
amounts of DNA from patients is limited for analysis, PCR can be carried out in small 
PCR reactions. In 100 pi of PCR reaction, the amount of DNA required is about 1 p 
g, whereas using this approach, only 10-100 ng DNA used in the PCR reaction can 
yield about 1-1.5 pg of product which is more than enough for SSCP analysis. The 
optimal amount of DNA per lane for SSCP analysis was found to be 100 ng. The 
product was then heated to dissociate the strands, and analysed by non-denaturing 
MDE gel electrophoresis (Orita et al., 1989). In the present study non-denaturing 
MDE gels were used instead of polyacrylamide gels. The advantage of using MDE 
gels instead of polyacrylamide gels was that the separation of single strand of the 
DNA was better and clearer. This resulted in easier analysis of the samples. Under 
non-denaturing conditions, single stranded DNA fragments will fold into unique 
conformations determined by their primary sequence because the structure is 
stabilised by intramolecular interactions. This secondary structure is difficult to 
predict theoretically and is highly dependent on variables such as temperature and 
ionic concentrations. Experience in many laboratories has confirmed that even a 
single-base substitution in PCR fragment several hundred nucleotides in length can 
induced a conformational change that is detectable as altered mobility on non­
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denaturing gel electrophoresis and that the technique requires relatively less labour 
and expense than most other approaches (Hayashi et al., 1993). The presence of low 
concentration of glycerol also affects folding and differences in the gel matrix can 
have a dramatic effect on mobility. In the present study 5% glycerol was used in the 
gel. Overloading sometimes results in abnormal migration of the bands and reduced 
resolution. For this reason, radioisotopic labelling of PCR products to a high specific 
activity can be recommended.
The full sequence of the coding region of RB gene, together with approximately 
200 bp of the introns flanking each exon, has been reported by McGee et al. 
(1989). Since not all the mutations occur within exons, the sequences used for the 
oligonucleotide primers (Thompson et al., 1991) extend into the intron region. 
Details of primer sequences are given in Table 3 in the methodology section. The 
size of the flanking intron region included in the amplified product varied between 
69 and 220 bp depending on the exon. The size of PCR products range from 182 
to 300 bp. Details of annealing temperature of the primers are given in Table 5.
Following PCR amplification, the amplified DNA was analysed on a 1% agarose 
gel to check both the size and specificity of the product (Figure 7). The location of 
primers was important to get specific amplification. Single base pair mutations can 
be detected following SSCP analysis of PCR products up to 350 bp. However, 
subtle changes in nucleotide sequence are more readily detectable in smaller 
molecules (Orita et al., 1989). An additional factor which influenced the location of 
the primers was the GC-AT ratio. The higher the AT content, the lower the 
annealing temperature and the greater the likelihood of non-homologous pairing 
which results in background amplification. Generally, the higher the GC content of 
the primer, the higher the annealing temperature. The 3* primer for exon 20 is 
situated upstream of the highly polymorphic tandem repeat (VNTR) region
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comprising variable numbers of CTTT(T) repeats (McGee et al., 1991). Since 
exons 15 and 16 are separated by only an 80-bp intron sequence, a single pair of 
primers was used to cover both exons (Thompson et al., 1991). All of the primers 
listed in table 3 were tested and their efficiency confirmed using a variety of DNAs 
from blood cells of normal individual and patients with bilateral Rb in whom a 
heterozygous mutation might be expected. After amplification, the samples were 
loaded on to 0.5XMDE gels containing 5% glycerol. Electrophoresis was carried 
out at 5 W for 14-24 hours, with a fan directed at the gel as a cooling device.
SSCP analysis was applied to screen functionally important RB gene regions. 
Exons 12 to 22 (Table 3) of the RB gene were screened for sequence change with 
PCR-SSCP analysis. This covers 1198 bp of the cDNA. Systematic screening was 
performed using DNA as a template from 20 patients with bilateral retinoblastoma, 
40 patients with bladder carcinoma (primary bladder carcinoma) and 39 patients 
with breast carcinoma (primary breast carcinoma). The DNA fragments which 
presented a shift in the electrophoretic mobility were demonstrated in five patients; 
four patients with Rb and one patient with bladder carcinoma (Table 5). For those 
exons showing band shifts with SSCP analysis, direct sequencing of the PCR 
products was performed.
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Primer set for 
exons and 
correspondence 
flanking intonic 
region
Size of 
amplified 
product (bp)
Temperature 
of PCR 
reaction
<°C)
Conformation
polymorphism
detected
Exon 12 290 52 1
Exon 13 236 57
Exon 14 276 57
Exon 15 and 16 285 55 2
Exon 17 300 52
Exon 18 206 55
Exon 19 234 53
Exon 20 295 57 1
Exon 21 216 55 1
Exon 22 182 52
|of amplified fragment
Table 5: SizeAand annealing temperature of the primers used for the amplification of 
the DNA fragments of the RB gene. First column: primer set used. Second column: 
size of the products. Third column: details of annealing temperature of the primers. 
Fourth column: results of PCR-SSCP analysis in regions of RB gene flanking exon 12 
to 22.
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Figure 7: PCR amplification o f exons 12-22 o f the RB gene.
A schematic representations o f exons studied in the upper part o f the figure.
a) Lane 1: The DNA marker used is the 1 kb ladder (BRL). Lane 2: amplification
of exon 12. Lane 3: exon 13. Lane 4: exon 14. Lane 5: exons 15-16. Lane 6: exon
17. b) Lane 1: 1 kb ladder. Lane 2: exon 18. Lane 3: exon 19. Lane 4: exon 20.
Lane 5: exon 21. Lane 6: exon 22.
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4.3 SSCP analysis of patients with retinoblastoma.
To investigate the nature of RB mutations in patients, an exon-by-exon analysis of 
DNA from samples from 20 unrelated individuals was performed. Exons 12-22 and 
flanking intron sequences were analysed in all cases. 4 different mutations from 
patients with bilateral Rb were detected by SSCP and confirmed by sequencing.
Two of these were in exon 16, one was in exon 20 and one was in exon 21. A 285- 
bp fragment containing exon 15 and exon 16 was amplified using DNA purified 
from the blood of patients with Rb. One additional band was present in the 
amplified products from patient AR and patient GM. Both patients have a different 
SSCP pattern (Figure 8). Analysis of exon 20 showed an abnormal SSCP banding 
pattern (Figure 9) for patient E.A.S. When compared with DNA from a normal 
individual, E.A.S. had an additional band which migrated faster than the other 
normal bands. Since I all 3 have two normal bands as well as an additional band, it 
can be predicted that these patients are heterozygous for the mutation. Analysis of 
exon 21 showed an abnormal pattern for patient M.H. When compared with DNA 
from others individuals M.H. showed an additional faster moving band below the 
two normal pattern bands (Figure 10). The results clearly indicate that onty M.H. 
contains (the mutated allele from exon 21.
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Figure 8: SSCP analysis o f exons 15-16 o f the RB gene from patients with bilateral 
retinoblastoma. A 285-bp fragment was amplified with the primers 5'-TAA GGT TTC 
AAT TAA ACA AC-3' and 5'-CTT TAA ATT GAA CAA AAG TG-3V PCR 
products were run on a 0.5XMDE gel (AT Biochem.) containing 5% glycerol at 8 W 
at room temperature for 17 hours. Lane 2: DNA from patient AR showed an 
abnormal SSCP banding pattern, Lane 5: DNA from patient GM showed an abnormal 
SSCP banding pattern when compared with DNA from other patients, Lanes 1, 3, 4, 
6, 7: DNA from other patients showed no conformation polymorphism.
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Figure 9: SSCP analysis o f exon 20 and the flanking intronic region o f the RB gene 
from patients with bilateral retinoblastoma. A 295-bp fragment was amplified with 
the primers 5'-AGA GGT TTC TGT TAA AAT GC-3' and 5-AGAAGG TGA AGT 
GCT TGA TT-3V PCR products were run on a 0.5XMDE gel containing 5% glycerol 
at 8 W room temperature for 16 hours. DNA from the patient EAS in lane 5 shows an 
additional band when compared with DNA from other patients.
1 2 3 4 s
Figure 10: SSCP analysis o f exon 21 o f the RB gene from patients with bilateral 
retinoblastoma. The DNAs were amplified with the primers 5'-ATT CTG ACT ACT 
TTT ACA TC-3' and 5'-ATG AGA TCA AAT GAA TTA CC-3\ PCR products, 216- 
bp in length, were analysed on a 0.5X MDE gel containing 5% glycerol and run for 14 
hours. DNA from patient MH in lane 1 shows an additional band when compared with 
DNA from other patients.
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4.4 SSCP analysis of patients with bladder carcinoma.
To determine the efficiency of SSCP technique in bladder carcinoma, DNA 
extracted from tumour tissue of 40 patients with bladder carcinomas were screened 
for point mutations. 30 cycles of PCR were performed on the target DNA 
sequences using 10 ng of genomic DNA in 15 pi reaction solution. 5 pmol ^2p 
dCTP (60 pCi) was included in the reaction mixture to label the PCR products. 
After thermal cycling, the amplified product was diluted 1:7 in gel loading buffer. 2 
pi of the samples were loaded on to 6.5% non-denaturing MDE gels 
(20cmx40cmx0.4cm) containing 5% glycerol. Electrophoresis was carried out at 5 
W for 14-24 hours. Exon 12-22 and flanking intron sequences of the RB gene 
were analysed in all cases. 39 out of 40 samples analysed for 11 exons and flanking 
intron sequence showed no shift in the electrophoretic mobility, indicating no 
structural alterations including point mutations. The only exception was sample 
no.32 which showed a shift in the electrophoretic mobility (Figure 11).
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Figure 11: SSCP analysis o f exon 12 o f the RB gene from patients with Bladder 
carcinoma. A 295-bp fragment was amplified with primers 5'-GAT ACA TTT 
AAC TTG GGA GA-3 and 5'-CAT GTT AGA TAG GAG ATT AG-3'. 3 jil o f 
each PCR products was run on a 0.5XMDE gel containing 5% glycerol for 16 hr. 
DNA from a patient no. 32 (lane 2) shows an abnormal SSCP pattern when 
compared with DNA from other patients.
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4.5 SSCP analysis of patients with breast carcinoma.
The 11 regions amplified by the primers listed on Table 3 were analysed for 
sequence variations by means of single strand conformation polymorphism analysis 
(SSCP). A systematic screening was performed using genomic DNA as the 
template for the PCR reaction from thirty-nine breast tumours by SSCP. A 30 
cycle PCR was performed on the target DNA sequences using 10 ng of genomic 
DNA in 15 pi reaction solution. 5 pmol 32p dCTP (60 pCi) was included in the 
reaction mixture to label the PCR products. After thermal cycling, the amplified 
product was diluted 1:7 in gel loading buffer. The sample was heated at 95°C for 2 
minutes to denature the DNA. The denatured DNA was then placed directly into 
ice bath for several minutes. Then, 2 pi of the sample was loaded on to 6.5% non­
denaturing MDE gel (20cmx40cmx0.4cm) containing 5% glycerol. Electrophoresis 
was carried out at 5 W for 14-24 hours. The RB gene from 39 breast carcinoma 
was analysed exon-by-exon by the PCR-SSCP technique. No unusual SSCP 
pattern was found in any of the tumours indicating no structural alterations or 
point mutations detected.
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4.6 Heteroduplex analysis of the family] of patient MH.
In the current study a modified heteroduplex detection protocol using MDE gel 
electrophoresis was used to evaluate its efficiency in the detection of a point 
mutation in the RB gene. The heteroduplex technique was applied to PCR- 
amplified exon 21-containing DNA from the patient showing a positive SSCP 
result which was found to be a G insertion by sequence analysis. To confirm 
whether the observed SSCP pattern in the region of exon 21 from patient MH with 
Rb was a new mutation or inherited from one of the parents, heteroduplex analysis 
was also performed on parents DNA.
This technique takes advantage of the formation of heteroduplexes in the PCR 
between different alleles from heterozygous individuals. These heteroduplexes can be 
detected on non-denaturing gels because they migrate slower than their corresponding 
homoduplexes due to a more "open" double-stranded configuration surrounding the 
mismatched bases. Heteroduplexes containing a single base deletion or insertion are 
easier to detect than single base substitutions. The reason for this a most likely 
because a larger opening is created by the absence or addition of a nucleotide on one 
strand than by two mismatched bases opposing on another (White et al., 1992).
After the final thermal cycle was completed, the reaction was inactivated by adding 
EDTA to 5 mM. Amplified DNA fragments were heated to 95°C for 3 minutes and 
then allowed to cool down to room temperature over a period of 30 minutes to form 
heteroduplexes (Keen et al., 1991). Since Rb is an autosomal dominant disease, 
heteroduplex formation will occur by PCR amplification in the presence of mutations. 
1 kb ladder as a size marker was also included on the gel as well as control 
homoduplex DNA. Approximately 100-200 ng of DNA was loaded in each lane. 
Before loading the samples, 1 (il of gel loading buffer (described in the methodology)
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for each sample was added and mixed thoroughly. The electrophoresis was performed 
at a maximum constant voltage of 800 Volts for 15 hr. The gel was then stained with 
ethidium bromide to visualise the bands on the gel without using any radioactivity. 
Typically the heteroduplex band migrated slower than the homoduplex. Analysis of 
the family with this technique showed that only the patient MH (the son) has the 
mutation but not the parents as shown in Figure 12, indicating either the parents are 
not carriers or one of the parents has gonadal mosaicism.. In order to evaluate its 
efficiency, this region from all family members was screened by direct sequencing in 
the presence of the patient as a control. No other member of the family showed the 
mutation. Screening the family for this known mutation using this technique was 
found to be very fast, easy and reliable.
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Family pedigree o f patient MH
O - T - O
k
*  2
HETERODUPLEX
HOMODUPLEX
Figure 12: Result o f the het^oduplex technique applied to PCR-amplified exon 21- 
containing DNA from MH showing a positive SSCP result and his parents. The 
slower moving heteroduplex DNA in lane 2 stains with ethidium bromide to about 
1/3 o f the intensity o f  the faster moving homoduplex DNA. The MDE gel was run 
at about 800 Volts for 16 hours. Lane 1: father; lane 2. patient MH; lane 3: 
mother; lanes 4 and 5: homoduplex normal controls.
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4.7 RNA extraction and quantitation.
RNA was extracted from lymphoblastoid cell lines and lymphocytes in all
patients and controls. The extraction was performed by the guanidium thiocyanate 
method (Chomczynski and Nicoletta, 1987). The basic principle of RNA extraction is 
very similar to that for DNA but the methods used are different in many specific 
aspects. In general, the cells are lysed, the cell lysate de-proteinized and the RNA 
separated from DNA. However, RNA is much more liable than DNA and more 
susceptible to nuclease degradation. Furthermore, RNases are much more resistant to 
protein denaturants than DNases. These factors make the isolation of undegraded 
RNA relatively difficult. Therefore, in order to obtain good quality RNA, it is 
necessary to lyse the cells and inactivate RNases simultaneously. Guanidium 
thiocyanate is among the most effective protein denaturants, thus disintegrating 
cellular structures causing nucleoproteins to dissociate from nucleic acids as the 
protein secondary structure lost. As a strong inhibitor of ribonucleases, guanidium 
thiocyanate as well as P-mercaptoethanol were included in the primary extraction 
buffer to protect the RNA from degradation by RNase (Chirgwin et al., 1979). Since 
there is a significant amount of RNase on the skin, gloves were worn during isolation 
of RNA. Whenever possible all water used was treated with DEPC and RNase 
inhibitors was used in the extraction solutions, the subsequent steps in the 
experiments, and for short-time storage of RNA in aqueous solution.
This extraction method was found to be satisfactory and convenient. Usually the 
extraction was performed in a day. The concentration of RNA ranged from 300-1000 
pg/ml with a mean of 700 pg/ml. RNA quantitation was carried out by 
spectrophotometry. The optical density (OD) of the RNA was determined both at 
260 and 280 nm. The purity as determined by the mean value of OD260/OD28O was 
2 indicating it was free of protein contamination. The preparations were run on RNA
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checking gels with formaldehyde to determine the integrity of the RNA. The RNA 
was denatured by heating in the presence of formamide and formaldehyde in order to 
disrupt aggregates and hydrogen bonded structures. After running the samples, the 
gels were soaked in water for 1 hour to wash out the formaldehyde for better 
resolution of the rRNA bands. Undegraded RNA typically shows a 2:1 ratio of 
28S:18S. Results of fractionation of the RNA preparations are shown in Figure 13. 
The RNA samples were found to be ideal. The extraction provided high yield and the 
extracted RNA was both pure and undegraded. Due to its simplicity and elimination 
of ultracentrifugation, the guanidium thiocyanate method allows simultaneous 
processing of a large number of samples. The method proved to be useful for RNA 
isolation from as few as 10^ cells or 3 mg of tissue. The degradation and loss of RNA 
was minimised by the limited handling involved in the technique.
The RNA was divided into two aliquots. To one tube, 0.1 volume of 2 M potassium 
acetate and 2.5 volumes of ethanol were added, the mixture was then stored at -70°C 
until required. To recover the RNA the mixture was centrifuged at 13000 g for 10 min 
and washed in 75% ethanol to remove the salt and the pellet was then dissolved in TE 
buffer. The other aliquot was kept at -20°C to be used for RT-PCR. Repeated freeze 
and thaw cycles were avoided. The amplified RB cDNA was also stored at -20°C 
until required in the second round of amplification.
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Figure 13: RNA electrophoresis ofR b patients and normal control. Lane 1: 1 pg o f 
Esherichia coli ribosomal RNA used as a marker. The other lanes are RNA 
samples from patients and control representing 28S rRNA, 18S rRNA.
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4.8 RT-PCR of the retinoblastoma gene mRNA.
Total cellular RNA from lymphoblastoid cells of patients with bilateral Rb was 
used to synthesise cDNA using oligonucleotide primers with nucleotide sequences 
complementary to various regions of RB mRNA. The single-stranded cDNA 
fragments carrying portions of the RB mRNA thus obtained were then amplified by 
the PCR to double-stranded DNA products using sets of two oligonucleotide 
primers, one of which was the same as that used for reverse transcription. The 
regions thus amplified, designated as fragments A, B, C, D, and E, with nucleotide 
lengths of 302 bp to 1433 b, are shown in Figure 5. These 5 fragments overlapping 
each other and almost cover the whole coding sequence of the RB cDNA. 
Approximately 3938 bp were amplified, then subjected to AMD analysis. Oligo^M  
(MEDPROBE) computer program was used to design primers set to amplify 
cDNA fragments. Even with this guideline, the construction of successful PCR 
primers can be empirical, and more than one primer set needed to be tested before 
a good combination was found. As a result, several sets of primers were designed 
for some segments before a single band was seen on an agarose gels (Figure 14). 
Details of annealing temperature of the primers are given in Table 6.
Amplification of segment C of the cDNA of patients with bilateral Rb has revealed 
that one of the patients (namely EAS) has an truncated transcript, as shown in 
Figure 15, indicating either a deletion or a splice mutation.
86
Figure 14: Amplification o f segments o f RB cDNA.
Lane 1: 1 kb ladder. Lane 2: RT-PCR amplification with primers A5 and A3. Lane 
3 RT-PCR amplification with primers B5 and B3. Lane 3: RT-PCR amplification 
with primers C5 and C3. Lane 4: RT-PCR amplification with primers D5 and D3. 
Lane 5: RT-PCR amplification with primers E5 and E3.
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Segment of
cDNA of the RB
Gene
Size of amplified 
product (bp)
Temperature of 
PCR rx (°C)
A 302 53
B 400 50
C 707 52
D 1433 53
E 1370 53
Table 6 Size of amplified segments of cDNA of the RB gene and their annealing 
temperature.
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Figure 15: Amplification o f C segments from patients with bilateral retinoblastoma 
Lane: 1 kb ladder. Lane :2 patient with normal size o f 707 bp C segment. Lane 3: 
patient EAS with 707 bp and 5J 1 bp product Lane 4: patient with normal size o f 
707 bp C segment. Lane 5: patient with normal size o f 707 bp C segment.
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4.9 Mutation detection using amplification and mismatch detection 
(AMD) analysis.
AMD detects all classes of point mutations (Cotton et al., 1988). AMD analysis was 
used to screen all cDNA fragments (A, B, C, D, E) from patients with Rb, as well as 
12-16 exons and the flanking intron regions. PCR-generated probes can be prepared 
by incorporating labelled dNTP either during PCR, or after amplification in a separate 
labelling reaction (as described in the methodology section). When comparing these 
two methods, the latter approach can be preferred for several reasons. Synthesis of 
probes with high-specific activities it is necessary to keep the concentration of 
unlabelled counterparts of the ^2p dNTP as low as possible. However, PCR 
amplification becomes inefficient when any of the dNTPs are in low concentration. 
Generation of high specific activity probes labelled during PCR amplification required 
the use of a full 250 jiCi of labelled dNTP in a single PCR reaction to achieve an 
adequate concentration of all four dNTPs. This is generally undesirable due to cost. 
In contrast, one standard PCR amplification can provide nearly 0.5 to 1 jig of cDNA 
fragment, more than enough material for numerous post-PCR probe preparations 
using 50-100 ng of cDNA with only 50 |iCi of labelled dNTP per probe. A critical 
step in preparing high specific activity probes by PCR amplification was the removal 
of unincorporated dNTPs from the PCR reaction. For this purpose, the geneclean 
method was found to be effective and rapid.
In the current study, the use of PCR amplification in the presence of suitable end- 
labelled primers yielded substrates for chemical cleavage reactions was found to be 
more efficient than using internally-labelled probes. In order to prepare 5' end-labelled 
probe, PCR reaction was carried out in the presence of two end-labelled primers as 
described before. The advantage of this method is that one of the strands of the wild- 
type cDNA can be labelled by the incorporation of radiolabelled oligonucleotide
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primer during the PCR reaction: either the sense or the antisense strand can be 
labelled. This strategy can be used to locate the position of the cleavage. After 
amplification of the probe by 5' end-labelled primers, the product was purified by 
Geneclean. Reference DNA or cDNA probe was mixed with excess test DNA or 
cDNA in ratio of 1/10; the mixture was then melted and then cooled to allow 
reannealing and thus heteroduplex formation with mismatched or unmatched base 
pairs at the position of the mutation. The probe is modified at mismatched C and T 
bases by reaction with hydroxylamine and osmium tetroxide, respectively, and 
subsequently cleaved by piperidine treatment. Fragments are sized on gels to locate 
the point of cleavage and hence, the mutation. In the cases of point mutations, 
mismatched G and A will not be directly detected, but they are transposed to 
mismatched C and T bases, respectively, by the use of probes of the opposite sense 
for detection. However, matched bases adjacent or close to mismatched or 
unmismatched bases become reactive by transmission of the distortion (Cotton et al., 
1988; 1989), and can signal the presence of the mutation and hence allow indirect 
detection. This allows detection of insertions (Cotton et al., 1989). Unmatched C and 
T bases are also reactive, allowing detection of deletions. It should be emphasised 
that this is a screening method developed to avoid the need for sequencing kilobases 
of DNA to detect a single mutation. Once the site of the mutation is detected, only a 
small portion of the mutated gene needs to be sequenced. For subsequent detection in 
individuals, families or populations, one of a series of simple mutation detection 
methods, such as oligonucleotide hybridisation can be used.
Because all classes of C and T mismatches (C.C, C.T, C.A, T.T, T.G, and T.C) are 
cleaved (Cotton et al., 1988), complete screening of double-stranded target for point 
mutations can be achieved using probes of both strands. Deletions will be detected by 
a cleavage of mutation of unmatched C and T bases or indirectly because of reactive 
bases nearby. Insertions will be detected indirectly by the increased reactivity of
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nearby matched C and T bases in the probe next to or near the loop of the unlabelled 
DNA in the heteroduplex (Cotton et al., 1991).
The technique has two modes of use with either uniformly labelled probe or end- 
labelled probe. Either mode can be used when the variation expected is minimal, such 
as one mutation in the region covered by a probe. However, if multiple differences 
are expected, e.g., 1 base in 10 is likely to vary, an end-labelled probe will generated 
a single and unique band for each reactive C or T in the probe, thus generating a 
pattern of difference between the pieces of nucleic acid. When using end-labelled 
probe, the low reactivity of all matched C and T bases with hydroxylamine and 
osmium tetroxide, respectively, offers a background C and T track to help locate the 
mismatch.
When screening kilobase lengths, probes need to be overlapped by 20-30 bases to 
avoid missing mismatches at the overlap. This is because of considerable breathing of 
the duplex at each end (Cotton et al., 1989). Pilot work needs to be done on the time 
needed for analysis of particular quantities of unlabelled DNA/DNA probe. If most of 
the probe remains uncleaved, there has been too little reaction, and if it is all cleaved, 
there may be too much reaction. This is because matched bases are modified and 
cleaved at a rate of about 1/100 of that of mismatched bases, allowing nonspecific 
probe destruction if the incubation time is too long (Cotton et al., 1991). Formation 
of a heteroduplex with a known mismatch should be included as a control that will be 
cleaved if in fact that heteroduplex has been formed. Potency of osmium tetroxide 
between two laboratories has varied. A range of concentrations should be tried when 
setting up the method. Solutions should be freshly made each three months before the 
solution takes on a green hue, although it is still active at this time. Eppendorf tubes 
darken as a result of the reaction.
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Analysis of fragment C from a patient (PC) with Rb showed a hydroxylamine
reaction. It is logical that cleavage kinetics should be different when mismatches are
present in one or both alleles. Thus, in the case of homozygotes, the probe band
should disappear to nothing at a uniform rate, but in the case of heterozygotes, the
probe band should rapidly diminish to half intensity and then diminish more slowly and
in parallel with the band signalling the mismatch (Cotton, 1991). This situation was
observed in the heterozygous mutation. However, a test has recently been developed
for testing allele status (Dianzani et al., 1991). This involves making the probe from
the test DNA and hybridising it with unlabelled test DNA. If the wild-type allele is
present in the test sample, it is heterozygote and cleavage will occur, hut not if it is
| (Figure 17)
homozygous for the mutation in question. The band at 481 bpA represents direct 
detection of a mismatched G found in the heteroduplex as a result of a T—»G 
mutation. It is notable that this mutation is heterozygous, since Rb is an autosomal 
dominant condition. As mentioned above, the kinetics of the band change is typical of 
a heterozygote.
The fragments of the RB cDNA from patients with bilateral Rb and some of the exons 
amplified from genomic DNA were subjected to AMD analysis. In order to determine 
point mutations by the mismatch technique, PCR amplified wild type DNA or cDNA 
was either end-labelled or internally-labelled and annealed to cold target DNA or 
cDNA. The resulting heteroduplex was treated with either hydroxylamine or osmium 
tetroxide and treated with piperidine. The samples were then subjected to 
electrophoresis.
4.9.1 AMD analysis of cDNA fragments
Since the coding region is too large (4.7 kb) to routinely sequence in its entirety, in 
order to determine the mutations, AMD technique was applied to scan PCR-
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amplified cDNA from RB mRNA for mismatches relative to the wild-type 
molecule. Before its application on clinical cases. AMD analysis of PCR amplified 
products was first performed on a panel of 14 patients with acute intermittent 
porphyria (AIP) to determine the efficiency of this method for mutation screening 
and to evaluate its potential for accurate carrier screening. Those patients had been 
previously studied and their molecular pathologies were described by Mgone et al. 
(1992). AIP is an autosomal disorder caused by partial deficiency of the enzyme 
porphobilinogen deaminase (PBG-D) (Mgone. 1991). Analysis of these known 
mutations was necessary to establish, develop and optimise the various procedures 
used in the detection of mutations. Initially the study concentrated on AMD 
analysis of cDNA templates. The patients included in this study were known to 
carry the following mutations: 1. Two patients with G(606)—>T (V202V); 2. 
G(135)-»A; 3. ACT(730-731); 4. C(100)->A (Q34K) and G(606)->A; 5. C(100) 
—>A; 6. C(610)—»T(Stand) (unpublished data); 7. G(848)—>A (Kennedy) 
(unpublished data); 8. T(761)—>C (Bossdow) (unpublished data); 9. G(754)-»A 
(Roberts) (unpublished data); 10. G(789)—>A (Boubou) (unpublished data); 11. 
G(1002)—>A (Olifant) (unpublished data).
Approximately 1.1 kb of cDNA from the PBG-D gene was synthesised and 
amplified by RT-PCR as described (Mgone, 1991) and then Geneclean used to 
purify the PCR products. These purified PCR products served as the unlabelled 
test cDNA to be used in the preparation of heteroduplexes. Control cDNA was 
labelled at the 5' end using 25 pM of each primer in a PCR reaction solution and 
used as a probe. It was purified using the Geneclean. 10 ng of labelled probe and 
100 ng of each test cDNA was mixed in a 1 X annealing buffer, boiled for 5 
minutes and incubated at 65°C overnight. After precipitation of the 
heteroduplexes, they were treated with osmium tetroxide and hydroxylamine as 
described in the methodology section. 50 |il of 10% piperidine were added to each
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tube which was immediately closed and kept on ice to prevent evaporation of the 
piperidine. The tubes were heated at 90°C for 30 min and then precipitated. 
Finally the pellet was dissolved in 10 jil of loading buffer and loaded onto an 8% 
denaturing polyacrylamide gel. Analysis of the patients with porphobilinogen 
deaminase (PBG-D) deficiency by the AMD technique revealed that three of them 
had heteroduplexes cleaved by hydroxylamine. One cleavage was at the expected 
position of 754 of the cDNA product and two of them at position 100 (Figure 16).
After optimisation of the technique, AMD analysis was applied for detection of 
mutations in patients with bilateral retinoblastoma. Analysis of all 5 fragments of 
cDNA of the RB gene from patients with bilateral Rb revealed no cleavage, 
indicating no structural alterations or point mutations. The only exception was 
fragment C. Analysis of fragment C from patient PC showed that the patient had a 
band represents a cleavage at position of 481 bp of the C fragment (707 bp) after 
hydroxylamine modification (Figure 17).
In order to compare the efficiency of end-labelling versus internal-labelling of the 
probes, AMD analysis of wild-type/mutant duplex RT-PCR amplified DNA was 
performed using either 5'end-labelled or internally labelled probes. Internally 
labelled probe was derived from an RT-PCR reaction in the presence of 20 pmol 
32p dCTP (60 pCi). Patient PC shows a cleavage product at expected position in 
lane 2 of Figure 18. Comparison of the results obtained are shown in Figures 17 
and 18.
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Figure 16: Detection o f  mutations by AMD analysis of patients with 
porphobilinogen deaminase (PBG-D) deficiency. Lane 1: Size marker (1 kb 
ladder). Lane 2: patient with G(606)—>T mutation. Lane 3: patient with G(135)—» 
A. Lane 4: patient with ACT(730-731) mutation . Lane 5: patient with C(100)—>A 
and G(606)—>A mutations shows a cleavage at position o f 100 bp. Lane 6: patient 
with C(100)-»A mutation shows a cleavage at position o f 100 bp. Lane 7: patient 
with C(610)—>T mutation. Lane 8: patient with unknown mutation. Lane 9: patient 
with unknown mutation. Lane 10: patient with G (606)->T mutation. Lane 11: 
patient with G(848)—»A mutation. Lane 12: patient with T(761)—»C. Lane 13: 
patient with G(1002)—»A mutation shows a cleavage at position o f 754 bp. Lane 
14: patient with G(754)—»A. Lane 15: patient with G(789)—>A mutation.
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Figure 17: AMD analysis o f segment C from patients with retinoblastoma using 
hydroxylamine reaction with 5'end-labelling.
A schematic representation o f cleavage site in the RB cDNA is shown in the upper 
part o f the figure. Lane 1: Size marker (1 kb ladder) Lane 4: patient PC shows a 
band represents a cleavage at 481 bp, Lanes 2, 3. 5 and 6 show no cleavage.
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Figure 18. Hydroxylamine reaction with internal labelling o f theC fragment o f RB 
gene. Lane 2: cleavage product present at the expected position o f 481 bp, Lanes 1, 3, 
5, 6, 7, show no cleavage. Lane 8: Size marker (1 kb ladder) (not technique o f choice),
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4.9.2 AMD analysis of DNA fragments.
Since not all mutations occur within the coding sequence, AMD analysis was used in 
order to screen for splice mutations and other mutations in the RB gene in patients 
with bilateral Rb by analysing the DNA exon by exon. Exons 12 to 16 including the 
flanking intronic region (Table 3) of the RB gene were screened for sequence changes 
with AMD analysis. Systematic screening was performed using DNA as a template in 
20 patients. PCR amplified wild type DNA was end-labelled and annealed to cold 
target DNA using the method described in methodology. The resulting heteroduplex 
was treated with either hydroxylamine or osmium tetroxide and treated with 
piperidine. The samples were then subjected to electrophoresis. Analysis of DNA 
fragments from 20 patients revealed that patient E.A.S showed a cleavage in the 
hydroxylamine reaction. (Figure 19)
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Figure 19: AMD analysis o f exon 17 and the flanking intronic region from patients 
with retinoblastoma by hydroxylamine reaction with 5'end-labelled probe. A 300- 
bp fragment was amplified with the primers shown in Table 3 and subjected to 
AMD analysis. Lane 1: Size marker (1 kb ladder) Lane 15: (patient EAS) cleavage 
product present at 245 bp, other lanes show no cleavage.
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Mutation Sequence Location of 
mutation
Restriction
enzyme
1 A—>C transversion wt GAAGgattt 
mt GAAGgcttt
-2 of acceptor 
site of intron 16
CvijI
2 T—Kj  transversion wt TTTCATATG 
mt TTTCAGATG
nucleotide 
position 1587 
within exon 16
Nde I
3 lbp insertion wt TGTAG *TATT 
mt TGTAGGTATT
nucleotide 
position 2251 
within exon 21
FokI
4 A—»C transversion wt aatgACGA 
mt aatgCCGA
nucleotide 
position 1636 in 
exon 16
CvijI
5 A—>G transition wt ttttaacgag 
mt ttttagcgag
intron 19 Tsp 5091
6 T—>C transition wt AATGTTGGA 
mt AATGCTGGA
nucleotide 
position 1617 in 
exon 16
None
7 G—>C tranversion wt gaatgCAATT 
mt gaatcCAATT
+1 of the donor 
site of intron 12
Maell, 
BpulOl, 
Dde I
Table 7: 1-6; Mutations of the RB gene, detected in retinoblastoma patients. 
7; Mutation of the RB gene, detected in bladder carcinoma*
| (Capitals: exonic, lower case: intronic)
101
4.10 Sequencing of DNA fragments in which a shift was present in 
electrophoretic mobility.
Sequencing of DNA fragments in which a shift was present in electrophoretic mobility 
was performed in order to detect sequence alterations. Direct sequencing of double­
stranded PCR products is usually more difficult than single-stranded templates, 
because artefacts are seen more often in the sequencing of double- rather than single­
templates. Templates have a strong tendency to reanneal which is responsible for the 
high background seen in the sequencing of double-stranded templates (Mgone, 1991). 
Single-stranded PCR products were generated using an asymmetric PCR amplifying 
exons of the RB gene. The homogeneity of the asymmetric PCR product was 
increased by reamplification of 1 pg of the product of a standard PCR. In these 
experiments, a standard PCR was run on an agarose gel and the gel was stained with 
ethidium bromide and the appropriate band was then excised. The amplified DNA was 
eluted by soaking overnight in TE buffer. The amplified product was used directly in 
asymmetric PCR without further purification. The most common source of 
contamination is the products of previous PCRs, and the best solution to the problem 
is extreme caution when handling the PCR reagents. To check for contaminants, a 
negative control reaction without any DNA template was run in parallel with all PCR 
reactions.
In asymmetric PCR, the amplification primers were included in a ratio of 50:1 to 
100:1, one primer at the usual concentration and one diluted in order to generate an 
excess of ssDNA complementary to the limiting primer. The best ratio was generally 
determined by trial and error. Since the efficiency of asymmetric PCR is low when 
compared with standard PCR, the number of PCR cycles was increased to 40 instead 
of 30. To overcome the low efficiency of asymmetric PCR, more Taq DNA 
polymerase was added in the late cycles of the PCR.
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In order to sequence both strands, two PCR reactions were carried out with
reciprocal ratios of the limiting primers. Prior to sequencing, the amplified DNA was
purified by removing excess dNTPs, primers and salts because of their interference in
sequencing reactions. This purification was done by selective alcohol precipitation in 2
M ammonium acetate (pH 5.2) and 2 volume of propan-2-ol as described in
methodology. The presence of excess primers interferes with annealing and extension
steps in sequencing reactions. Excess of primers leads to unlabelled primers which
compete with radiolabelled primers for binding sites on the templates. Excess of
dNTPs can serve as substrates that can interfere with the reaction. Ammonium acetate
which used in precipitation works by inhibiting the co-precipitation of dNTPs. It is
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also necessary to remove Awhich interfere with the reactions by inhibiting the 
sequencing enzyme. Regions of DNA with strong secondary structure may give rise to 
two problems: first, low efficiency of the PCR, due to the high frequency of templates 
that are not being fully extended by the Taq polymerase, second, compression of the 
DNA sequences in the sequencing reaction.
One of the major problem in sequencing regions close to the primers is the presence 
of faint bands. To avoid this problem, two approaches were employed. In the first 
approach, less nucleotide was used in the labelling step. The labelling mix was diluted 
in a ratio of 1/10 or 1/20 of the stock reagent and both reaction times kept at 3-5 min 
as described before. When reading sequences within 20 nucleotides of the 3' end 
primer, the amount of template DNA and primer concentration was increased. In the 
second approach, the MN buffer (0.15 M Sodium Isocitrate, 0.1 M MnCl2) provided 
with the Sequenase Version 2.0 DNA sequencing kit was used. This reagent takes 
advantage of the activity of the Sequenase enzyme in the presence of Mn^+ jons 
(Tabor and Richardson, 1989). The addition of Mn^+ to normal sequencing reactions 
reduces the average length of DNA synthesised in the termination step, intensifying 
bands corresponding to sequences close to the primer.
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Asymmetric PCR and direct sequencing of fragments showing an altered mobility 
on PCR-SSCP analysis were performed in all 4 cases: patient AR with Rb, patient 
GM with Rb, patient MH and patient no.32 with bladder carcinoma. The sequence 
obtained was compared with the sequence of normal controls and with the 
published sequence ((McGee et al., 1989). Single-stranded PCR products were 
generated using an asymmetric polymerase chain reaction amplifying the exons of 
the RB gene. Results of both asymmetric and standard PCR are shown in Figure 
20. PCR products were purified by selective precipitation in 2 M ammonium 
acetate and propan-2-ol. Sequencing was performed with Sequenase Version 2.0 
DNA polymerase using 50% of each purified PCR product and 1 pmol of the 
limiting primer as a sequencing primer in a 10 |il reaction mixture containing 40 
mM Tris.HCI (pH 7.5), 20 mM MgCl2 and 50 mM NaCI and annealed by heating 
to 65°C for 2 min and allowed to cool down to below 30°C over a period of 20 
min. Thereafter the rest of the reactions were carried out as described in the 
methodology section. The sequencing reactions were stagger loaded and 
electrophoresed for 3 h. Both the sense and anti-sense strands were generated and 
sequenced. From these experiments, it emerged that the optimal amount of PCR 
products to be used in sequencing reactions was 50% of each PCR reaction 
sequenced with 1 p mol of the sequencing primer.
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Figure 20: Agarose gel analysis o f  DNA generated by asymmetric PCR.
Lane 1: 1 kb ladder, Lane 2: double stranded DNA, Lane 3, 4: single and double 
stranded DNA.
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Sequencing of exon 20 and flanking intron regions from patient EAS with bilateral Rb 
revealed mutation an A->G (transition i at position 77 towards exon 20 of the 19th 
intervening sequence (IVS19) (Figure 21). The change abolishes a recognition site for 
the restriction Tsp 5091 enzyme. Although this exon and flanking intronic region was 
screened by SSCP analysis using samples from 20 patients with Rb, 40 patients with 
bladder carcinoma and 39 patients with breast carcinoma, analysing of the restriction 
site recognised by Tsp 509 I was also performed for the same samples. In the normal 
allele Tsp 5091 digests the region into 6 segments of 9 bp, 27 bp, 30 bp, 36 bp, 83 bp 
and 108 bp. In the mutation, the abolition of the recognition site leads to the 
production of 27 bp, 36 bp, 39 bp, 83 bp, 108 bp. In heterozygosity, carrier will carry 
mutant products as well as 9 bp and 30 bp products originate from normal allele 
(Figure 22). Screening was performed by amplifying the exon and flanking intronic 
region and fractionated the products on agarose gels. Following ethidium bromide 
staining, the PCR products were visualised under UV. light. No other samples were 
found to have this mutation. This screening can be performed to help in counselling of 
affected family members. Using two different approaches for the same change proves 
that SSCP analysis is an effective method to screen for known mutation. On the other 
hand, single base substitutions within introns could result in preferential alternative 
splicing of the mRNA molecules at the site of the mutation. A common form of p 
thalassaemia that occurs in the Mediterranean population results from a single 
nucleotide substitution, G—»A, at position 110 of the first intervening sequence 
(IVS1) of the p globin gene. This change produces an AG sequence that happens to 
be preceded by a stretch of pyrimidines and thus forms a functional 3' acceptor 
consensus sequence (Weatherall, 1991). The mRNA produced as the result of the 
abnormal splicing contains intron sequences and is therefore useless as a template for 
globin chain synthesis. Therefore it was necessary to check the mRNA product 
including this region from the patient with bilateral Rb. The single-stranded cDNA 
fragment carrying a portion of the RB mRNA (fragment D shown in Figure 5) was
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amplified by PCR to double-stranded DNA products using sets of two 
oligonucleotide primers, one of which was the same as that used for reverse 
transcription. This amplification revealed no shorter RNA transcript. Therefore this 
mutation does not effect splicing of the mRNA and can be considered a silent 
mutation. In some cases, these so called silent mutation may be responsible for 
pathology. This especially occurs in highly expressed genes where despite degeneracy 
of the code, a particular codon may be preferred for a certain amino acid than others. 
In a such cases, changing one codon to another, even if still codes for same the amino 
acid, may lead to inefficient incorporation of that particular amino acid residue. While 
analysing this region by sequencing, two base pair mistakes in the published sequence 
by McGee et al. (1989) were found. The sequence at positions 78 and 79 towards 
exon 20 of the IVS19 was AAC(78)GA(79)GATTAA, whereas the published 
sequence was AAT(78)GT(79)GATTAA (Appendix A). On the other hand, one of 
these sequence differences could be a polymorphism.
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Figure 21: Partial sequence o f intron 19 o f  the RB gene from patient EAS with 
bilateral retinoblastoma, showing a A-»G transition. The wild-type sequence on the 
right reads, AGAGCAATTTCAT, whereas the mutant is, AGAGCGATTTCAT. The 
change creates a recognition site for the restriction Tsp 509 I enzyme.
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Figure 22: Screening for the recognition site o f the restriction enzyme Tsp 509 I. 
Lane 4: A heterozygote patient shows 9 bp, 27 bp, 30 bp 36 bp, 39 bp, 83 bp, 108 
bp, Lane 1, 2, 3, 5, 6, 7, 8, 9: show 6 segments o f  normal allele o f 9 bp, 27 bp, 30 
bp, 36 bp, 83 bp and 108 bp. Lane 10: 1 kb Ladder.
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A +G225l(Exon 21) mutation was detected from patient MH with bilateral Rb. 
Sequencing of the exon and flanking intronic region revealed an insertion of a G at 
nucleotide position 2251 within exon 21 resulting in a novel stop codon (TAA) at 
codon 719 (nucleotide position 2295) within exon 21 (Figure 23) thus deleting the 
domain interacting with the SV40 T antigen. The translated protein is most probably 
too short to be functional. In order to screen the mutation in the family, the 
heteroduplex technique was applied to PCR-amplified exon 21-containing DNA from 
the patient and the parents. Neither of the parents was a carrier indicating that the 
mutation occurred as a new germinal change (Figure 12). To determine the efficiency 
of the heteroduplex analysis, the parents were also screened by direct sequencing 
which showed no change in the region. No other samples from the patients show the 
same SSCP pattern. On the other hand, the mutation abolishes a restriction site for the 
restriction enzyme Fok I which could be used to screen the population for this 
mutation.
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Figure 23: Sequence analysis o f exon 21 o f patient MH with bilateral 
retinoblastoma. The mutant sequence arises from an insertion o f a G at nucleotide 
position 2251 resulting in a novel stop codon (TAA) at codon 719. The mutation 
abolishes a restriction site for the restriction enzyme Fokl.
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A R507^(A] 636~>C) mutation found from patient AR with bilateral Rb was an A to 
C transversion at position 1636 in exon 16 causing AGA to CGA codon change 
(Figure 24), both coding for the same amino acid: Arginine, therefore this mutation 
does not cause an amino acid substitution. The mutation site is located in the last base 
of the exon 16, therefore it could affect splicing of the mRNA of RB gene. The 
location of the mutation lies within an RB domain (aminoacids 393-572), therefore 
the mutation could be the cause of the disease. SSCP analysis was performed for 
about 100 patients, none of them had the same change. The mutation abolishes a 
restriction site for the restriction enzyme Cvijl.
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Figure 24: Sequence analysis o f exon 16 o f the RB gene from patient AR with 
bilateral retinoblastoma in which a shift in the electrophoretic mobility was 
detected. The mutation is an A to C transversion at position 1636 in exon 16. The 
mutation changes the codon AG A to CGA, both coding for the same amino acid: 
Arginine. The sequence on the right, AGCAGTAA is from a normal control and 
the one on the left from an Rb patient (AR). The mutant sequence reads, 
AGCCGTAA. The mutation creates a restriction site for the restriction enzyme 
Cvijl.
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V500->V(Ti6i 7^ C )  caused by a T to C transition in exon 16, changes codon GTT 
(GUU) to GTC (GUC) both coding for the same amino acid: valine (Figure 25). This 
mutation does not lead any change or recognition sites for restriction enzymes. 
Analysis of a cDNA from the patient GM revealed no alteration or rearrangement of 
the region. Analysis of all patients with SSCP showed none of the patients carry this 
mutation. Therefore, this mutation is very unlikely to be the cause of Rb. In addition, 
since the mutation does not alter a recognition site for restriction enzymes, this is not 
useful in the diagnosis or linkage studies for tracking of this condition in affected 
family.
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Figure 25: Sequence analysis o f exon 16 o f the RB gene from patient GM with 
bilateral retinoblastoma. The mutation is a T to C transition at position 1617 in 
exon 16. This altered the codon GTT (GUU) to GTC (GUC) both coding for the 
same amino acid: valine. The mutant sequence reads TTGAGGTCGTAAT. This 
mutation, which was observed in one individual, does not result in any change, 
either in the amino acid pattern or recognition sites for restriction enzymes.
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The only mutation found from a patient with bladder carcinoma was a G to C 
transversion at position +1 of the donor site of intron 12 (Figure 26). This mutation 
represents a somatic mutation in heterozygous form and most probably causes 
abnormal splicing of the RNA. A second mutation was assumed that it lie in a part of 
the retinoblastoma gene that was not analysed, since in somatic cases two hits (Figure 
1) in the RB gene are expected. On the other hand, the sample was obtained by 
transurethral resection, it could be contaminated with non tumour tissue resulting in a 
heterozygote mutation. Intact RNA cannot always be recovered from the type of 
clinical materials used in this study, therefore the diagnostic strategy for bladder 
carcinoma was chosen not to be based on the analysis of RNA transcript. In order to 
determine the role of RB gene in tumourogenesis, 40 DNAs extracted from bladder 
carcinoma were screened with SSCP analysis. Horowits et al., (1990) found that 
inactivation of the retinoblastoma protein, p i05^®, which is universal in 
retinoblastoma cells, is present in most small cell lung cancers and in one-third of 
bladder cancers but is infrequent in other tumours. RB (like p53) has been implicated 
in a tumour-suppressing role in a wide range of tumours including bladder carcinoma 
(Dunn et al., 1989; Horowitz et al., 1989). Horowitz et al. (1989) reported a splice 
acceptor mutation at the 5' end of exon 21 from bladder carcinoma cells J82. This 
mutation resulted in fusion of exon 20 into exon 22. In the current study only 12 
exons of the RB gene were analysed. If the entire gene could be analysed, more 
mutation may be detected. In this individual mutation of RB found may represent the 
initiating event in tumour development.
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Figure 26: Sequence analysis o f exon 12 o f the RB gene from a patient with bladder 
carcinoma. The mutation arises from a G to C transversion at position +1 o f the donor 
site o f intron 12. The normal sequence is, TTTTAACGTAAGC whereas the mutant 
sequence reads, TTTTAACCTAAGC. The mutation abolishes a restriction sites for 
theM *eII, Bpu 101, DdeI restriction enzymes.
117
4.11 Sequencing of DNA and cDNA fragments in which a cleavage was 
detected.
RT-PCR was performed with the primers a standard manner to produce double­
stranded products. The desired band was then excised and the cDNA eluted and 
reamplified with the same primers used for RT-PCR. Such eluted cDNA could be 
stored at -20°C for several months. The cDNA was then reamplified 
asymmetrically. The adequacy of the single-stranded products was monitored by 
running on 1% agarose gels as described earlier. It was possible to produce both 
cDNA strands with equal efficiency. The products were purified by selective 
alcohol precipitation. Sequencing reactions were performed with Sequenase T7 
DNA polymerase with chain termination and extension reactions being carried out 
at 37°C. Sequencing was carried out with one of the sequencing primers at 1 
pmol. The amount of the template cDNA was varied. In some reaction whole 
purified product was used in a sequencing reaction whilst sometimes half of the 
product was enough to get result. This was varied for each of the cDNA segments. 
40 amplification cycles were carried out. The single-stranded products were 
subsequently sequenced directly.
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The first mutation involved -2 of the acceptor site of intron 16. The mutation was 
caused by an A-*0 transversion, One PCR amplification utilising primers Cl and C2 
yielded a truncated transcript, indicating a deletion associated with the reading 
frame (Figure 15). This amplification reaction jdelineatedl a deletion in RNA of 
approximately 65 nucleotides between bases 1361 and 2068. This deletion was 
more precisely defined by AMD analysis of exons and flanking intron regions of 
the region. Analysis of exon 17 and the flanking intronic region revealed a cleavage 
by hydroxylamine modification. This exon, together with the flanking intronic 
sequence was subjected to detailed sequence analysis. The observed mutation 
converts a canonical splice acceptor sequence, 5-TTTTTAG-3’, present in the 
wild-type allele into the sequence 5-TTTTTCG-3’ (Figure 27). This indicated that 
the short RNA transcript was not due to a deletion. Presumably, the point mutation 
found in the RB gene abrogates normal splicing at this site. As a consequence, 
exon 17 is discarded during the biogenesis of the RB mRNA, resulting in the fusion 
of exon 16 directly to exon 18. Because the short transcript band on the agarose 
gel was approximately 196 bp shorter than the original band and exon 17 is 196 bp 
in size. This leads in turn to the production of a truncated RB protein. In contrast 
to wild-type pl05-RB, this aberrant, destabilised protein is unable to bind El A 
oncoprotein. In addition, the mutant RB protein may fail to complex with SV40 
large T antigen. It is likely that this defective RB protein is also deficient in 
carrying out its normal function within the cell. No similar mutant allele was 
recovered when genomic DNAs from 19 unrelated individuals were screened by 
AMD analysis and sequenced in this region. The mutation abolishes a restriction 
site for the restriction enzyme Cvijl.
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Figure 27 Sequence analysis o f exon 17 o f the RB gene from patient EAS with 
bilateral retinoblastoma. The normal sequence reads, GAAGGGATTTTT whilst 
the mutant reads GAGGCTTTTTT because o f a substitution o f C for A at position 
-2 o f the acceptor site of intron 16. The change causes the skipping o f exon 17. 
The change creates a restriction sites for the restriction enzyme Cvijl.
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A second mutation, namely H502—»Q (T15S7—»G) was detected by AMD analysis of 
segment C of the RB mRNA. The mutation, caused by a T to G transversion at 
nucleotide 1587 (Figure 28), was seen in one patient with bilateral RB. This changes 
codon CAU (CAT) to CAG thus substituting histidine for glutamine at amino acid 
residue 483 (McGee et al., 1989). The missense mutation identified within exon 16 
suggests, may or may not have a functional effect.. This residue lies within an RB 
domain (aminoacids 393-572) identified recently by in vitro deletion mutants to be 
required for oncoprotein binding (Hu et al., 1990). The His-483—>Gln substitution 
appears to simultaneously abrogate RB phosphorylation and affinity for viral 
oncoproteins. Since the patient is the only affected member of the family, the 
substitution has occurred as a new germinal change, not present in the father which 
was the only parent available to analysis. Analysis of 19 unrelated patients with 
bilateral RB by AMD analysis showed no other patient carrying this mutation. In 
addition, this mutation abolishes a recognition site for the Nde I restriction enzyme 
allowing this to be used for screening purposes.
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Figure 28 Sequencing of the cDNA fragment o f  the RB gene o f patient PC who has 
shown a cleavage after hydroxylamine modification. The mutation arises from a T to 
G transversion at nucleotide position 1587 within exon 16. This changes codon CAU 
(CAT) to CAG thus substituting conserved amino acid, histidine for glutamine. The 
mutant sequence, TTTTTCAGATGTCTTT on the left arises from a T to G 
transversion. This mutation creates a restriction site for the Nde I. restriction enzyme.
\
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4.12 Mutations of the RB gene, detected in patients with retinoblastoma 
and other tumours in the current study.
The techniques of single strand conformational polymorphism (SSCP) analysis, 
amplified mismatch detection (AMD) analysis and heteroduplex analysis together 
with direct sequencing were used to detect mutations in 20 patients with 
retinoblastoma. Analysis revealed six mutations in patients with bilateral RB and one 
mutation from a patient with bladder carcinoma. Of those patients with RB, one had 
two different mutations. The six mutations from patients with RB were : a G insertion 
at nucleotide position 2251, a missense mutation (T to G transversion) at nucleotide 
position 1587, a splice site mutation (A to C transversion) at position 1636 in exon 
16, a splice acceptor site mutation at position -2 of intron 16, an A—»G transversion in 
intron 19 and a T to C transition at position 1617. A G to C transversion at position 
+1 of the splice donor site of intron 12 was detected in a patient with bladder 
carcinoma (Table 8).
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Patient Mutation Resulting Change The technique 
used
1. EAS A->C (-2 acceptor site 
of IVS16)
truncated RNA transcript, 
skipping exon 17
RT-PCR, 
AMD analysis
2 .E A S An 77->G (IVS19) does not result in any change SSCP analysis
3. PC H 483-*Q(T158 7 ->G) mutation causing the substitution 
of histidine to glutamine
AMD analysis
4 .M H +G2 2 5 1  (Exon 21) frameshift in exon 21 leads to a 
stop codon at codon 719 
(nucleotide 2295)
SSCP analysis
5. AR R500R (A 1 6 3 6 ^ C) does not cause any amino acid 
substitution, affecting splice site
SSCP analysis
6 .G M V4 93“*V ^ 1617 - * ^ causes no change in the amino 
acid pattern
SSCP analysis
7. Bladder 
no.32
G-*C (+1 donor site of 
IVS12)
affected splice site SSCP analysis
Table 8. Analysis of the RB structural changes likely to arise from detected mutations 
and the techniques used.
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CHAPTER FIVE: DISCUSSION
5. DISCUSSION.
5.1. Comparison of screening strategies; SSCP and AMD analysis for 
detection of point mutations in the RB gene.
The present study focused on application of screening strategies in the RB gene in 
patients with retinoblastoma, bladder carcinoma and breast carcinoma. The 
techniques of single strand conformational polymorphism (SSCP) analysis, amplified 
mismatch detection (AMD) analysis were applied for screening mutation on PCR 
amplified samples of cDNA and DNA from blood samples in 20 patients with 
retinoblastoma and in tumour genomic DNA from 40 patients with bladder carcinoma 
and 39 patients with breast carcinoma. In those patients who showed a band shift on 
SSCP analysis or a cleavage with AMD analysis, direct sequencing of the PCR 
products was performed. This approach revealed six mutations in patients with 
bilateral Rb and one mutation in the tumour from a patient with bladder carcinoma.
There are very few comparable published studies. Various methods have been 
employed for screening large numbers of constitutional mutation carriers in 
retinoblastoma (Cowell et al., 1992, Horsthemke et al., 1992, Sakai et al., 1991a; 
Kloss et al., 1991), but no single approach has detected mutations in more than 10- 
15% of the germ line cases investigated. For instance Blanquet et al. (1993) used 
denaturant gradient gel electrophoresis (DGGE) to detect mutations in a pool of 120 
unrelated retinoblastoma patients including 15 patients with familial form, 65 patients 
with sporadic bilateral, and 40 patients with unilateral. They characterized 10 
sequence alterations. The majority of mutations were found either in tumour tissue or 
in established tumour cell lines. This could suggest a different mutation rate in germ 
cells versus tumour cells. No specific region or hot spot has been identified and the 
mutations seem to vary in both type and location. This lack of any common mutation 
for the carriers is major drawback for informed genetic counselling.
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Janson and Nordenskjold, (1994) used pulsed-field gel electrophoresis and cDNA 
probes in screening 20 unrelated cases with bilateral Rb. They found one patient with 
aberrant fragments due to a mutation as well as a normal allele for a number of 
restriction endonucleases. Cytogenetic analysis revealed a balanced translocation 
t(4; 13)(q21 q 14).
Published mutations that have been detected using SSCP technique in RB gene 
include base substitution, small insertions and deletions, and rearrangements (Hogg et 
al., 1992). This technique has also been applied to the detection of DNA 
polymorphisms at various other loci of the human genome (Orita et al., 1989). 
Shimizu et al. (1994) and Kreipe et al. (1993) have also screened the RB gene exon- 
by-exon using SSCP analysis. These two group found mutations in 14 of 24 and 12 of 
12 Rb tumours respectively. PCR-based single-strand conformation polymorphism is a 
simple and fast method of screening for the presence of sequence changes. However, 
SSCP does not detect all sequence changes; Sarkar et al. (1992) reported that an 
average of 83% of single-base changes were detected in a segment of 183 bp, and 
only 58% were detected for a segment of 307 bp. They found only 35% of the 
mutations when segments of the factor IX gene ranging from 180-497 bp were 
screened in a prospective fashion in nine segments. They also described dideoxy 
fingerprinting (ddF), a method that detected 100% of single-base changes in the 
human factor IX gene when tested in retrospective and prospective manners. Dideoxy 
fingerprinting provides information about the location of the sequence change, and the 
efficiency of detection is independent of the length of the amplified product. In this 
technique, a ladder of bands is generated by performing one of the four standard 
dideoxy sequencing reactions and resolving the products by electrophoresis on a 
nondenaturing polyacrylamide gel. But the efficiency of this technique for RB gene is 
unknown. Murakami et al. (1991) have used PCR-SSCP analysis in combination of 
reverse transcriptase reaction for analysis of cDNA fragments of the RB gene
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obtained from mRNAs. They found a transcript with a mutated exon 2 sequence, but 
not a transcript carrying the normal sequence of exon 2 in small cell lung carcinoma 
(SCLC) cells and confirmed its loss by SSCP analysis of genomic DNA.
The inheritance of a disease causing gene can be determined either indirectly, by 
studying the segregation of DNA markers closely linked to the mutant allele, or by 
direct identification of a disease causing mutation carried by individual subject. The 
linked marker approach is valuable when there is a family history of a disease or when 
the disease is caused by a small number of mutant alleles present at relatively high 
frequency in the general population. Generally, a study of linked markers is not 
helpful when a new mutation has occurred in a previously unaffected family, and 
hence has only limited application in detecting disorders associated with high rates of 
new mutation. The results of AMD and SSCP analysis of the presence of a disease- 
causing mutation are more applicable in the study of disease such as retinoblastoma, 
which are characterised by high rates of new mutations. Many autosomal dominant 
and X-linked recessive disorders are most often caused by new mutations and the 
lesions responsible for these new familial cases may be very heterogeneous. Although 
RFLP analysis remains the method of choice in studying families predisposed to 
retinoblastoma that have more than one affected member, the diagnostic strategy 
used in this project is not dependent on a positive family history and thus can be 
routinely applied to a disease with no family history. Southern blotting can serve the 
same purpose, but its application is limited to the 10-20% of all cases of 
retinoblastoma caused by relatively large DNA rearrangements or deletions in the 
retinoblastoma gene. Allele-specific oligonucleotide (ASO) hybridisation and 
restriction fragment length polymorphism (RFLP) can be used to identify known 
genetic variations over relatively short stretches (one to 20 nucleotides) in the 
amplification products.
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Direct sequencing of either single- or double stranded PCR amplified DNA (or 
cDNA) fragments is highly accurate method for detection of essentially all genetic 
variations that may occur within the amplified fragment. With recent improvements, 
sequences can be read more consistently than before. However, all forms of direct 
sequencing are labour-intensive per base pair analysed when compared to the other 
techniques. This approach is especially expensive when it is necessary to analyse large 
numbers of samples for rare genetic variations. However, direct sequencing remains 
the method of choice for characterising the variant sequences that are detected by 
more rapid techniques, such as SSCP analysis (Hogg et al., 1992), AMD analysis 
(Cotton et al., 1988).,
In the current study, SSCP analysis was applied to screen functionally important RB 
gene regions. The oncoprotein binding sites of pi 10^® are known to lie between 
aminoacids 393-572 and 646-772 which fall in exons 12-22 inclusive. Therefore exons 
12 to 22 and flanking intron sequences of the RB gene were screened for sequence 
change with PCR-SSCP analysis. This technique was carried out to screen for point 
mutations. All mutations detected by SSCP were confirmed by sequencing. The five 
mutations detected by SSCP analysis were AD77—»G (IVS19) from patient EAS, 
+G225l(Exon 21) from patient MH, R507R(Al636_^ 'C) from patient AR, V500—> 
V(Tl617->C) from patient GM, G-»€(+l donor site of IVS12)( patient with bladder 
carcinoma). No false-positive results from SSCP analysis were observed although 
false negatives were not excluded because, as with most methods, the sensitivity is not 
100% (Hayashi et al., 1993). The mobility shifts cannot determine either the precise 
position or the exact nature of the base changes. Nevertheless, SSCP analysis is useful 
for screening for point mutations as it is simple, fast, and efficient. When mutated 
cases are identified, other methods such as direct sequencing must be used to 
determine the base substitution. It is still not clear whether this approach will 
successfully identify all mutations in the RB gene. However, in addition to the initial
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studies on the ras oncogenes (Orita et al., 1989), it has been used successfully to 
detect mutations in the cystic fibrosis gene (Dean et al., 1990) and the p53 gene 
(Mazars et al., 1991). Multiplex SSCP could provide a quicker way to screen a gene. 
However, digestion of the samples following co-amplification is not feasible because 
enzyme sites are often present in an inappropriate position and an extremely complex 
gel pattern would be generated. Hence, full-length PCR products must be used and 
sensitivity may be decreased for fragments >200 bp in length (Hogg et al., 1992). 
Although this approach can be applied only to disease loci for which the intron-exon 
structure and surrounding DNA sequences are known, the number of monogenic 
disorders that fail into this category is increasing rapidly (Kidd et al., 1989). A 
particular advantage of this method is that it does not require the presence of intact 
RNA transcript or functional protein, and therefore it can be used to examine tumours 
or other tissues in which no transcripts or gene products are expressed or from which 
RNA cannot be recovered. This is important because a relatively large fraction of 
retinoblastoma tumours produce no RNA transcript from the retinoblastoma gene 
(Friend et al., 1986; Fung et al., 1987; Goddart et al., 1988). In addition, direct 
sequencing of genomic DNA allows the detection of mutations that may occur at 
splice sites or other sequences that are excluded from the RNA transcript (Horowitz 
et al., 1989; Wong et al., 1987; Tromp et al., 1988).
Like all screening techniques mentioned in the introduction section, the detection 
of mutants by AMD analysis does not discriminate between mutations resulting in 
amino acid change and silent mutations or natural polymorphism. To answer this 
questions, direct sequencing of PCR products or of the excised and reamplified 
mutant band need to be done. As shown by its use for detection of point mutations, 
both AMD and SSCP analysis are sensitive enough to detect small changes of 
nucleotide sequence. AMD technique could be used in various kinds of mRNA 
analyses.
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To characterise all types of mutations in the coding sequence of the RB gene, the 
entire cDNA has to be analysed. In this study AMD analysis was applied to screen for 
mutations. This required amplification of cDNA and mRNA of the RB gene with at 
least 5 primer sets to cover almost the entire gene. Although AMD analysis can detect 
all types of mutations, in the current study only one mutation could be detected by 
analysing cDNA with this technique. The other mutation (A—»C, -2 acceptor site from 
patient EAS) found with AMD analysis was detected by amplification of an exon and 
its flanking intron region. Since Southern blot analysis identified structural 
abnormalities of RB in 10%-40% of the hereditary and sporadic Rb tumours (Cowell 
and Hogg, 1992) and approximately 10% of mutations affect splice junction sites 
(Bookstein et al., 1990), the chance of detecting mutations by AMD analysis is less 
than 100%, unless the segments of cDNA do not contain the beginning of the 
abnormalities. Two mutations detected by AMD analysis were an A—>C (-2 acceptor 
site of IVS16)(patient EAS), H502-»Q (T i587-»G)(patient PC). Weir-Thompson et 
al. (1991) also used AMD analysis and identified a point mutation in the RB gene in a 
small-cell lung carcinoma. There have been no false positives identified so far using 
this technique. The main disadvantage of the method is the highly toxic reagents 
which are dangerous to handle and difficult to dispose of. This technique also proved 
its efficiency when three mutations were found in 14 AIP patients with known 
mutations. This strategy, greatly saved time and labour and in addition, was found to 
be reliable. Furthermore this procedure of AMD analysis of PCR amplified of cDNA 
can be used as a prototype to investigate the molecular pathology of any other single 
gene disorder as shown in this study by being applied to demonstrate the mutations in 
acute intermittent porphyria. PCR-SSCP analysis was found to be a rapid and 
effective method for detecting point mutations because it was carried out on DNA. 
Simplicity is the major advantage of the PCR-SSCP analysis. However, in one case a 
mutation (T—»G transversion at nucleotide position 1587 within exon 16 ) was not 
found using SSCP analysis which was identified later by AMD analysis. The
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advantage of SSCP analysis in screening mutation is that analyse exon by exon and 
short segments can be analysed. AMD analysis probably more sensitive but slower 
and uses toxic reagents such as osmium tetroxide, hydroxylamine and piperidine. 
Strategy for mutation analysis for another disorders would be rapidly screened by 
SSCP analysis and use AMD analysis in those patients who have no mutation found 
with SSCP analysis.
5.2. Heterogeneity of molecular pathology in retinoblastoma gene.
At the time (1991) this project was initiated only a few point mutations had been 
discovered in the RB gene. The RB gene was cloned and mapped in 1987. Although 
the gene is well characterised, over a period of 7 years nearly 80 mutations including 
small insertion and deletions have been published (Appendix B) involving all or part of 
the retinoblastoma gene but, most of this type of work has been done on tumour 
material. Still very few germline mutations have been characterised.
Of the seven mutations found in this study one was due to a base insertion leading to a 
frameshift, six were due to single base substitutions. All mutations are novel, 
emphasising the heterogeneity of this condition. Among the mutations found, three 
mutations affect splice sites, one of which was detected from a patient with bladder 
carcinoma. One mutation causes an amino acid substitution. Of those patients with 
Rb, one had two different mutations which were a C substitution of the A at position - 
2 of the acceptor site of intron 16 and an A—»G | transition i in intron 19. a G 
insertion at position 2251 mutation resulting in a novel stop codon (TAA) at codon 
719 (nucleotide position 2295) within exon 21 and a T to G transversion at nucleotide 
position 1587 within exon 16 which results in substitution of conserved amino acid 
histidine to glutamine. All these are likely to be the cause of Rb in these individuals. 
Two mutation are considered to be silent mutations.
131
Deletion of exons 13 to 17 is a frequent observation in various types of tumours, 
including retinoblastoma, breast cancer, and osteosarcoma (Hong et al., 1989). Based 
on this observation, Hong (1989) suggested the presence of a potential ’’hot spot" for 
recombination in this region. Data (Figure 29) constructed from published mutations 
in exons 1-27 and flanking intronic region of the RB gene fail to show bias towards 
mutation in the two regions of suspected oncogene binding site. Uniform 
heterogeneity of the mutation distribution is clearly demonstrated (Figure 29).
Kaye et al. (1990) found a single point mutation within exon 21 that resulted in a 
nonconservative amino acid substitution (cysteine to phenylalanine) at codon 706. 
Stable expression of this mutant RB cDNA in a human cell line lacking endogenous 
RB demonstrated that this amino acid change was sufficient to inhibit 
phosphorylation. In addition, this mutation also resulted in loss of RB binding to the 
SV40 large tumour and adenovirus E1A transforming proteins. Yandell and Dryja 
(1989) have screened 3,712 bp of genomic DNA from each of nine individuals and 
found four DNA sequence polymorphism using PCR amplification and direct 
genomic sequencing. They found all four polymorphisms in introns.
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Scries 1 3
Mutations in each exons (1-27) 
■  Series 1
Figure 29. Distribution of germ-line and somatic mutations o f the RB gene.
This demonstrates the considerable heterogeneity o f the mutation in this gene. Bars 
represent the number (Series I) of mutations, which have been reported in the 
literature, in each exon (upperline numbers 1 -27) and intron.
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Bookstein et al. (1992), analysed mRNA from a prostate carcinoma cell line, 
identified an in-frame deletion of exon 21, but the splice junction sequences were 
normal. Mori et al. (1990) showed that the mRNA from an SCLC cell line was 
missing exon 22. A two base pair mutation GC-»TT, within the exon, apparently 
converted a glutamine to a stop codon, but, in fact, resulted in the entire exon being 
spliced out. Presumably these mutations generate cryptic splice sites that result in the 
endogenous splice sites being ignored (Cowell and Hogg, 1992).
Sakai et al. (1991) screened DNA samples from 111 patients with retinoblastoma for 
mutations of the 5' untranslated region or the promoter region of the RB gene using 
SSCP technique. DNA was derived from lekuocytes from patients known to have a 
germ-line mutation (bilateral disease or a positive family history) or from primary 
tumour fragments. Two cases showed a sequence variation within the region 
extending 327 bases, upstream of the initiation codon. In both instances, the variation 
was present in leukocyte DNA from all affected members or obligate carriers of 
families with hereditary retinoblastoma that they examined. In one family, the 
mutation was a G to T transversion 189 bp upstream of the initiating methionine 
codon, and in other family, it was due to a G to A transition 9 bp further upstream. 
The penetrance of these mutations appeared to be low: both cariers in one family had 
only unilateral Rb, and there was at least three obligate carriers who had no Rb in 
other family. A concurrent analysis of the majority of the coding region of the RB 
gene also using SSCP technique has revealed no other abnormalities in the DNA 
sequence in these two cases.
Deletions as small as 1 bp can be detected by enzymatic DNA amplification of short 
gene segments and high-resolution acrylamide gel electrophoresis (Lohmann et al., 
1992). Small deletions appear to comprise another 35% of germline mutations. Point 
mutations, which exist in approximately 50% of patients with hereditary
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retinoblastoma, can be detected by single-strand confirmation analysis (Sakai et al., 
1991), and sequencing of amplified gene segments (Yandell and Dryja, 1989). In 
contrast to the results of Yandell et al. (1989) and Onadim et al. (1992) reporting C 
to T transition as germline mutations and other studies in different disease in which 
the RB gene is involved, no missense mutations were found in the population which 
Blanquet et al. (1993) screened with DGGE. Blanquet et al. (1993) characterised 10 
sequence alterations generating stop codons, leading to amino acid substitution, or 
affecting splice sites in the RB gene, as well as four polymorphisms. Among them, 
five were alterations of the reading frame generating premature stop codons and 
hence aborted proteins. Because four of the premature stop codons appear in exon 
3,6 and 7, they speculated that the translated proteins were most probably too short 
to be functional. In the fifth case the stop codon was generated in exon 19 thus 
deleting the domain interacting with the SV40 T antigen. The sixth putative causal 
mutation is an A substitution of the conserved G at position +1 of the donor site of 
intron 6, probably impairing normal splicing of the RNA. The three other nucleotide 
changes occurring in splice sites do not modify the consensus specificity. Hogg et al. 
(1992) used the single strand conformation polymorphism (SSCP) technique to 
screen for mutations, exon by exon, in the RB gene and characterised two mutations. 
These are 1 bp insertion of a T in the coding strand of exon 20 and a G to A 
transition in the coding strand of exon 14. Dunn et al. (1988, 1989) used tumour cell 
lines to isolate RNA and, with the use of RNase protection, identified mutations in 
50%-60% of cases. They found that small deletions were the most common 
abnormality but suggested this may reflect limitations in the RNase protection 
procedure. Small deletions were also found most frequently in a proportion of SCLC 
cell lines studied by Mori et al. (1990). Murakami et al. (1991) identified a mutation 
C->A transversion in exon 2 causing a stop codon. They speculated that the mutation 
caused a short polypeptide of 81 residues instead of the complete RB protein.
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Kato et al. (1994) found two intragenic deletions (exon 18-19 and exon 24) and two 
point mutations (one missense mutation in exon 21 and one mutation at splice-donor 
site for exon 13) in the RB gene in somatic and tumour cells of patients with 
hereditary Rb. They found that three mutations were located in a domain essential for 
binding to oncoproteins encoded by DNA tumour viruses (Hu et al., 1990; Huang et 
al., 1990). One mutation (deletion of exon 24) was outside this domain but it is in the 
region essential for binding to transcriptional factor E2F, and for suppression of 
malignant phenotypes (Qian et al., 1992). A minisatellite-like sequence and short 
repeated sequences were located at the breakpoint of the deletion of exon 24, and 
they speculated that two deletions on both sides of the minisatellite-like sequence 
may be generated by a DNA slippage and misalignment mechanism. Shimizu et al. 
(1994) screened 12 patients with bilateral Rb and 12 patients with unilateral Rb by 
PCR-SSCP analysis in the entire coding region and promoter region. They identified 
mutations in 14 of 24 tumours, of which 6 were single base substitutions, 4 were 
small deletions, 3 were small insertions, and 1 was a complex alteration due to 
deletion-insertion. A majority (57%) of mutations were found in E l A binding 
domains.
Kreipe et al. (1993) have also screened the RB gene exon-by-exon using SSCP 
analysis. They found mutations in all 12 Rb tumours and one-third of the tumours had 
independent mutations in both alleles neither of which were found in the germ line, 
confirming their true sporadic nature. In the remaining two-thirds of the tumours only 
one mutation was found, consistent with the loss of heterozygosity theory of 
tumourigenesis. Point mutations, the majority of which were C—»T transitions, were 
the most common abnormality and usually resulted in the conversion of an arginine 
codon to a stop codon. Small deletions were the second most common abnormality 
and most often created a downstream stop codon as the result of a reading frameshift. 
They found that deletions and point mutations also affected splice junctions and
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direct repeats were present at the breakpoint junction in the majority of deletions, 
supporting a slipped-mismatch mechanism
Too few naturally occurring mutations in the Rb patients have been identified, so far, 
to allow correlations to be drawn between genotype and phenotype. One issue that is 
still virtually unaddressed is how pRB controls the differentiation of immature retinal 
cells into mature photoreceptors. Hong et al. 1989 found that the sequence extending 
from 196 to 249 bases upstream of the initiation codon is essential for transcription. 
Additional evidence that this region is important comes from the report of a prostate 
carcinoma with a deletion of 103 bases that overlaps this region (Bookstein et al., 
1990)
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C to T 42.4%
A to G
Figure 30. Point mutations in the RB gene.
Analysing of point mutations reported in Fig 29, according to base changes, showing 
dominance of C—>T transition.
T to C 9.1%
T to A 3.0%  
to G  6.1%
AtoT 3.0% 
C to A 3.0%
G to A 12.1%
9.1%
G to T 12.1%
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1 bp deletion /  insert 
25.7%
deletion
25.7%
splice mutation 
18.6% missense
5.7%
nonsense
24.3%
Figure 31: Categorization of the mutations of the RB gene
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Documentation of over 72 published mutations revealed that point mutations (70% of 
all mutations in the gene), the majority of which are C—>T transition, are the most 
common types of mutation in the RB gene (Figure 30). Hogg et al. (1993) analysed 
the RB gene from 12 Rb tumours using SSCP analysis. They found that one-third of 
the tumours had independent mutations in both alleles neither of which were found in 
the germ line, confirming their true sporadic nature. In the remaining two-third, of the 
tumours only one mutation was found, consistent with the loss-of-heterozygosity.
Point mutations (Appendix B), the majority of which were C—»T transitions, were the 
most common abnormality and usually resulted in the conversion of an arginine codon 
to a stop codon. Nearly fourty three percent of all mutations were C—»T transitions 
(Figure 30), which is consistent with observations in other genes and presumably due 
to the high mutability of 5-methylated cytosines in CpG dinucleotides (Yandell et al., 
1989). This suggest that T—»G mismatch repair is error-prone during both 
spermatogenesis and mitosis (Yandell et al., 1989). In RB tumours, it appears that 
premature stop codons are required to inactivate the RB protein. Otherwise, a larger 
proportion of amino acid substitutions, caused by C—»T mutations in CpG 
dinucleotides, would be observed (Hogg et al., 1993). The C—»T mutation in a CGA 
arginine codon is the only way a single base pair change in a CpG dinucleotide can 
convert an amino acid codon directly to a stop codon and is the most common 
finding. The CGA mutation in exon 11 has been reported in a different RB tumour 
(Yandell et al., 1989). However, mutations of either of the two CGA residues in exon 
27 or the two CGA residues in exon 8 has net been reported. This may simply reflect 
the small number of tumours which have been studied so far.
A shorter transcript is usually consistent with decreased gene activity. On the other 
hand, less than six percent of the mutations described were due to missense point 
mutation (Figure 31). How such mutations could effect gene activity is still unclear.
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They may creat a new splice site or they may be critical to the conformational 
structure of RB protein. Blanquet et al. (1993) found a single missense mutation 
occuring in exon 4 in a patient with bilateral Rb. In this patient, a A to T transition 
found at codon 137 and resulted in a glutamic acid to aspartic acid change. Although 
the charge and the type of amino acid remains unchanged, the folding and therefore 
the structure and the stability of the protein could be altered. In vitro studies are 
necessary to confirm the oncogenetic nature of this amino acid substitution. Yandell 
et al. (1989) reported another missense mutation which was a serine residue in exon 
18 replaced by a leucine residue. This mutation is very unlikely to be a phenotypically 
silent polymorphism. The substitution occured as a new germinal change, not present 
in either parent, that was retained after reduction to homozygosity during formation 
of the tumour. Furthermore, the retinoblastoma protein is known to be 
phosphorylated in vivo at one of several serine residues, and this phosphorylation is 
probably a critical event in the normal cellular role of the retinoblastoma protein. 
Kato et al. (1994) has also reported another missense mutation. In the current study, 
a missense mutation namely H502~>Q (Tj 5g7 ~>G)(patient PC) was found.This 
changes codon CAU (CAT) to CAG thus substituting conserved amino acid, histidine 
for glutamine. In this mutation, the charge and type of amino acid was changed. Since 
the patient was the only affected member of the family, the substitution has occurred 
as a new germinal. This mutation was likely to be the cause of Rb in these individuals. 
Data (Figure 31 ) suggesting that more than 94% of the RB gene mutations will 
create one way or another, a shorter transcript.
The possibility that other genes are involved in the genesis of this tumour can not be 
ruled out. For example, there seems to be variable resistance to tumour development 
even in patients inheriting retinoblastoma susceptibility. Further, heterozygous RB 
null mice do not develop retinoblastoma, but develop a characteristic brain tumour 
instead (Goodrich et al., 1993). The precise mechanism of action of RB is unknown,
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but a broad outline is beginning to emerge RB seems to influence negatively tumour 
cell growth by participating in regulation of the cell division cycle. RB has also been 
implicated in differentiation; its effect on the cell division cycle and its effects on 
differentiation may be different manifestations of the same function. In the current 
study, analysis of mutations in RB gene could also help to understanding of the 
function of the gene.
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APPENDIX A
SEQUENCE OF THE RETINOBLASTOMA cDNA
5'.........................TTC CGG TTT TTC TCA GGG GAC GTT GAA ATT ATT TTT
GTA ACG GGA GTC GGG AGA GGA CGG GGC GTG CCC CGC GTG CGC 
GCG CGT CGT CCT CCC CGG CGC TCC TCC ACA GCT CGC TGG CTC 
CCG CCG CGG AAA GGC GTC ATG CCG CCC AAA ACC CCC CGA AAA 
ACG GCC GCC ACC GCC GCC GCT GCC GCC GCG GAA CCC CCG GCA 
CCG CCG CCG CCG CCC CCT CCT GAG GAG GAC CCA GAG CAG GAC 
AGC GGC CCG GAG GAC CTG CCT CTC GTC AGG{275/2)CTT GAG TTT 
GAA GAA ACA GAA GAA CCT GAT TTT ACT GCA TTA TGT CAG AAA 
TTA AAG ATA CCA GAT CAT GTC AGA GAG AGA GCT TGG TTA ACT 
TGG GAG AAA GTT TCA TCT GTG GAT GGA GTA TTG(402/3) GGA GGT 
TAT ATT CAA AAG AAA AAG GAA CT(primer A5Kj TGG GGA ATC TGT 
ATC TTT ATT GCA CGA GTT GAC CTA GAT GAG ATG TCG TTC ACT 
TTA CTG AGC TAC AGA AAA ACA TAC GAA ATC AG(518/4)T GTC CAT 
AAA TTC TTT AAC TTA CTA AAA GAA ATT GAT ACC AGT ACC AAA 
GTT GAT AAT GCT ATG TCA AGA CTG TTG AAG AAG TAT GAT GTA 
TTG TTT GCA CTC TTC AGC AAA TTG GAA AG(638/5)G ACA TGT GAA 
CTT ATA TAT TTG ACA CAA CCC AGC AGT TC(677/6)G ATA TCT ACT 
GAA ATA AAT TCT GCA TTG GTG CTA AAA GTT TCT TGG ATC ACA 
TTT T(primer A3YTA TTA GCT AAA G(745/7^GG GAA GTA TTA CAA ATG 
GAA GAT GAT CTG GTG ATT TCA TTT CAG TTA A(primer B5YTG CTA 
TGT GTC CTT GAC TAT TTT ATT AAA CTC TCA CCT CCC ATG TTG 
CTC AAA GAA CCA TAT A(856/8)AA ACA GCT GTT ATA CCC ATT AAT 
GGT TCA CCT CGA ACA CCC AGG CGA GGT CAG AAC AGG AGT GCA
172
CGG ATA GCA AAA CAA CTA GAA AAT GAT ACA AGA ATT ATT GAA 
GTT CTC TGT AAA GAA CAT GAA TGT AAT ATA GAT GAG(999/9) G TG 
AAA AAT GTT TAT TTC AAA AAT TTT ATA CCT TTT ATG AAT TCT 
CTT GGA CTT GTA ACA TCT AAT GGA CTT CCA GAG(1077/10) G TT 
GAA AAT CTT TCT AAA CGA TAC GAA GAA ATT TAT CTT AAA AAT 
AAA GAT CTA GAT CGA AGA TTA TTT TTG GAT CAT GAT AAA ACT 
CTT CAG ACT GAT TCT ATA GAC AG(1187/11)T TTT GAA ACA C(primer 
B3)AG AGA ACA CCA CGA AAA AGT AAC CTT GAT GAA GAG GTG 
AAT ATA ATT CCT CCA CAC ACT CCA GTT AG(1265/12)G A C T GTT 
ATG AAC ACT ATC CAA CAA TTA ATG ATG ATT TTA AAT TCT GCA 
AGT GAT CAA CCT TCA GAA AAT CTG ATT TCC TAT TTT 
AA(1353/13)C AAC TGC A(primer C51CA GTG AAT CCA AAA GAA AGT 
ATA CTG AAA AGA GTG AAG GAT ATA GGA TAC ATC TTT AAA GAG 
AAA TTT GCT AAA GCT GTG GGA CAG GGT TGT GTC GAA ATT GGA 
TCA CAG(1470/14) CGA TAC AAA CTT GGA GTT CGC TTG TAT TAC 
CGA GTA ATG GAA TCC ATG CTT AAA TCA(1527/15) GAA GAA GAA 
CGA TTA TCC ATT CAA AAT TTT AG(1559/16)C AAA CTT CTG AAT 
GAC AAC ATT TTT CAT ATG TCT TTA TTG GCG TGC GCT CTT GAG 
GTT GTA ATG GCC ACA TAT AGC A(1636/17)GA A G T ACA TCT CAG 
AAT CTT GAT TCT GGA ACA GAT TTG TCT TTC CCA TGG ATT CTG 
AAT GTG CTT AAT TTA AAA GCC TTT GAT TTT TAC AAA GTG ATC 
GAA AGT TTT ATC AAA GCA GAA GGC AAC TTG ACA AGA GAA ATG 
ATA AAA CAT TTA GAA CGA TGT GAA CAT CGA ATC ATG GAA TCC 
CTT GCA TGG CTC TCA(1833/18) GAT TCA CCT TTA TTT GAT CTT AT 
(primer D5VT AAA CAA TCA AAG GAC CGA GAA GGA CCA ACT GAT 
CAC CTT GAA TCT GCT TGT CCT CTT AAT CTT CCT CTC CAG AAT
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AAT CAC ACT GCA GCA GAT AT(1952/19)G TA T CTT TCT CCT GTA 
AGA TCT CCA AAG AAA AAA GGT TCA ACT ACG CGT GTA AAT TCT 
ACT GCA AAT GCA GAG ACA CAA GCA ACC TCA GCC TTC CAG ACC 
CAG AAG CCA TTG AAA (primer C3VTCT ACC T C T  C T T TCA CTG  TT T 
TAT AAA AAA G(2098/20)TG TAT CGG CTA GCC TAT CTC CGG CTA 
AAT ACA CTT TGT GAA CGC CTT CTG TCT GAG CAC CCA GAA TTA 
GAA CAT ATC ATC TGG ACC CTT TTC CAG CAC ACC CTG CAG AAT 
GAG TAT GAA CTC ATG AGA GAC AGG CAT TTG GAC CAA(2244/21) 
A TT ATG ATG TGT TCC ATG TAT GGC ATA TGC AAA GTG AAG AAT 
ATA GAC CTT AAA TTC AAA ATC ATT GTA ACA GCA TAC AAG GAT 
CTT CCT CAT GCT GTT CAG GAG(2349/22) ACA TTC AAA CGT GTT 
TTG ATC AAA GAA GAG GAG TAT GAT TCT ATT ATA GTA TTC TAT 
AAC TCG GTC TTC ATG CAG AGA CTG AAA ACA AAT ATT TTG CAG 
TAT GCT TCC ACC AGG(2463/23) CCC CCT ACC TTG TCA CCA ATA 
CCT CAC ATT CCT CGA AGC CCT TAC AAG TTT CCT AGT TCA CCC 
TTA CGG ATT CCT GGA GGG AAC ATC TAT ATT TCA CCC CTG AAG 
AGT CCA TAT AAA ATT TCA GAA GGT CTG CCA ACA CCA ACA AAA 
ATG ACT CCA AGA TCA AG(2627/24)A ATC TTA GTA TCA ATT GGT 
GAA TCA TTC GGG(2658/25) A CT TCT GAG AAG TTC CAG AAA ATA 
AAT CAG ATG GTA TGT AAC AGC GAC CGT GTG CTC AAA AGA AGT 
GCT GAA GGA AGC AAC CCT CCT AAA CCA CTG AAA AAA CTA CGC 
TTT GAT ATT GAA GGA TCA GAT GAA GCA GAT GGA AG(2801/26)T 
AAA CAT CTC CCA GGA GAG TCC AAA TTT CAG CAG AAA CTG GCA 
GAA ATG A(2851/27)CT TCT ACT CGA ACA CGA ATG CAA AAG CAG AAA 
ATG AAT GAT AGC ATG GAT ACC TCA AAC AAG GAA GAG AAA TGA GGA 
TCT CAG GAC CTT GGT GGA CAC TGT GTA CAC CTC TGG ATT CAT TGT
174
CTC TCA CAG ATG TGA CTG TAT AAC TTT CCC AGG TTC TGT TTA TGG 
CCA CAT TTA ATA TCT TCA GCT CTT TTT GTG GAT ATA AAA TGT GCA 
GAT GCA ATT GTT TGG GTG AGT CCT AAG CCA CTT GAA ATG TTA GTC 
ATT GTT ATT TAT ACA AGA (primer E5VTTG AAA ATC TTG TGT AAA TCC 
TGC CAT TTA AAA AGT TGT AGC AGA TTG TTT CCT CTT CCA AAG TAA 
AAT TGC TGT GCT TTA TGG ATA GTA AGA ATG GCC CTA GAG TGG GAG 
TCC TGA TAA CCC AGG CCT GTC TGA CTA CTT TGC CTT CTT TTG TAG CAT 
ATA G (primer D31GT GAT GTT TGC TCT TGT TTT TAT TAA TTT ATA TGT 
ATA TTT TTT TAA TTT AAC ATG AAC ACC CTT AGA AAA TGT GTC CTA TCT 
ATC TTC CAA ATG CAA TTT GAT TGA CTG CCC ATT CAC CAA AAT TAT 
CCT GAA CTC TTC TGC AAA AAT GGA TAT TAT TAG AAA TTA GAA AAA 
AAT TAC TAA TTT TAC ACA TTA GAT TTT ATT TTA CTA TTG GAA TCT GAT 
ATA CTG TGT GCT TGT TTT ATA AAA TTT TGC TTT TAA TTA AAT AAA 
AGC TGG AAG CAA AGT ATA ACC ATA TGA TAC TAT CAT ACT ACT GAA 
ACA GAT TTC ATA CCT CAG AAT GTA AAA GAA CTT ACT GAT TAT TTT 
CTT CAT CCA ACT TAT GTT TTT AAA TGA GGA TTA TTG ATA GTA CTC 
TTG GTT TTT ATA CCA TTC AGA TCA CTG AAT TTA TAA AGT ACC CAT 
CTA GTA CTT GAA AAA GTA AAG TGT TCT GCC AGA TCT TAG GTA TAG 
AGG ACC CTA ACA CAG TAT ATC CCA AGT GCA CTT TCT AAT GTT TCT 
GGG TCC TGA AGA ATT AAG ATA CAA ATT AAT TTT ACT CCA TAA ACA 
GAC TGT TAA TTA TAG GAG CCT TAA TTT TTT TTT CAT AGA GAT TTG TCT 
AAT TGC ATC TCA AAA TTA TTC TGC CCT CCT TAA TTT GGG AAG GTT 
TGT GTT TTC TCT GGA ATG GTA CAT GTC TTC CAT GTA TCT TTT GAA CTG 
GCA ATT GTC TAT TTA TCT TTT ATT TTT TTA AGT CAG TAT GGT CTA ACA 
CTG GCA TGT TCA AAG CCA CAT TAT TTC TAG TCC AAA ATT ACA AGT 
AAT CAA GGG TCA TTA TGG GTT AGG CAT TAA TGT TTC TAT CTG ATT
175
TTG TGC AAA AGC TTC AAA TTA AAA CAG CTG CAT TAG AAA AAG AGG 
CGC TTC TCC CCT CCC CTA CAC CTA AAG GTG TAT TTA AAC TAT CTT 
GTG TGA TTA ACT TAT TTA GAG ATG CTG TAA CTT AAA ATA GGG GAT 
ATT TAA GGT AGC TTC AGC TAG CTT TTA GGA AAA TCA CTT TGT CTA 
ACT CAG AAT TAT TTT TAA AAA GAA ATC TGG TCT TGT TAG AAA ACA 
AAA TTT TAT TTT GTG CTC ATT TAA GTT TCA AAC TTA CTA TTT TGA CAG 
TTA TTT TGA TAA CAA TGA CAC TAG AAA ACT TGA CTC CAT TTC ATC 
ATT GTT TCT GCA TGA ATA TCA TAC AAA TC (primer E3)A GTT AGT TTT 
TAG GTC AAG GGC TTA CTA TTT CTG GGT CTT TTG CTA CTA AGT TCA 
CAT TAG AAT TAG TGC CAG AAT TTT AGG AAC TTC AGA GAT CGT GTA 
TTG AGA TTT CTT AAA TAA TGC TTC AGA TAT TAT TGC TTT ATT GCT TTT 
TTG TAT TGG TTA AAA CTG TAC ATT TAA AAT TGC TAT GTT ACT ATT TTC 
TAC AAT TAA TAG TTT GTC TAT TTT AAA ATA AAT TAG TTG TTA AGA 
GTC......................3'
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APPENDIX B
Reported mutations of the RB gene in Rb patients and other tumours
MUTATION LOCATION OF
MUTATION
Exon bp codon
RESULTING CHANGE Material 
or type of 
mutation
TECHNIQUE AUTHOR
1 a G deletion 24 2657 840 fiameshift in exon 24 leads to 
a stop codon in exon 25
Rb
tumour
germline?
direct
sequencing
Yandell et al., 
1989
2 T-»C transition intron
19
loss of splice-donor site for 
exon 19
Rb
tumour
unilateral
direct
sequencing
Yandell et al., 
1989
3 C—»T transition 14 1462 445 arginine—»a new stop codon Rb
tumour
germline
direct
sequencing
Yandell et al., 
1989
4 C—>T transition 18 1838 567 serine—^leucine Rb
tumour
germline
direct
sequencing
Yandell et al., 
1989
5 C—>T transition 23 2498 787 arginine—»a new stop codon Rb
tumour
germline
direct
sequencing
Yandell et al., 
1989
6 1-bp deletion 22 2381 748 fiameshift in exon 22 leads to 
a stop codon in exon 22
Rb
tumour
somatic
direct
sequencing
Yandell et al., 
1989
7 G-»T intron
10
loss of splice-donor site for 
exon 10
Rb
tumour
somatic
direct
sequencing
Yandell et al., 
1989
8 C—»T transition 11 1119 358 arginine—>a new stop codon ? direct
sequencing
Yandell et al., 
1989
9 A—>G 21 loss splice-acceptor site for 
exon 21
somatic
(bladder)
direct
sequencing
Yandell et al., 
1989
10 G->T 22 2379 748 glutamic acid—>a new stop 
codon
somatic
(SCLC
direct
sequencing
Yandell et al., 
1989
11 G-»A intron
11
splice donor site of exonl2 somatic RNase
protection
Dunn et al., 
1989
12 a 5 bp deletion 8 a fiameshift causing 
termination codon
germline RNase
protection
Dunnetal.,
1989
13 55 bp 
duplication
10 a fiameshift causing 
termination codon
germline RNase
protection
Dunnetal.,
1989
14 a 10 bp deletion 18 a fiameshift causing 
termination codon
germline RNase
protection
Dunnetal.,
1989
15 a 9 bp deletion 19 a fiameshift causing 
termination codon
germline RNase
protection
Dunn et al., 
1989
16 GC—»TT 22 2307 absence of exon 22 somatic
(SCLC
RT-PCR Mori et al., 
1990
17 A4 20 1979 fiameshift in exon 20—»stop 
codon in exon 20
somatic
(SCLC
RT-PCR Mori et al., 
1990
18 A1 23 2326 fiameshift in exon 23—> stop 
codon in exon 23
somatic
(SCLC
RT-PCR Mori et al., 
1990
19 G-»T
transversion
21 (cysteine to phenylalanine) at 
codon 706.
somatic
(SCLC
RNase
protection
Kaye et al., 
1990
20 G—>T 
transversion
promo
ter
causes no change germline SSCP Sakai et al., 
1991
21 G-» A transition promo
ter
causes no change germline SSCP Sakai et al., 
1991
22 G—>A intron
21
missing exon 21 somatic
(SCLC
AMD
analysis
Thompson et 
al., 1991
23 C->T 2 premature stop codon at 
codon 82
somatic
(SCLC
SSCP Murakami et 
al., 1991
24 T insertion 20 52
(exon)
premature stop codon at 
codon 672
germline SSCP Hogg et al., 
1992
25 C-»T transition 14 31
(exon)
Arginine(CGA)-»stop
codon(TGA)
germline SSCP Hogg et al., 
1992
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MUTATION LOCATION OF
MUTATION
Exon bp codon
RESULTING CHANGE Material 
or type of 
mutation
TECHNIQUE AUTHOR
26 2A 2 57 frameshift in exon 2 leads a 
stop codon at codon 109
Rb
tumour, ?
DGGE
27 2bp deletion 3 24
(exon)
frameshift in exon 3 leads a 
stop codon at codon 109
Rb
tumour, ?
DGGE Blanqued et 
al., 1993
28 1 bp deletion intron
2
affected splicing site Rb
tumour, ?
DGGE Blanqued et 
al., 1993
29 A —»T transition 4 31
(exon)
glutamic acid-»aspartic acid Rb
tumour, ?
DGGE Blanqued et 
al., 1993
30 1 bp insetion 6 (15) frameshift in exon 6 leads to 
a stop codon at codon 192
Rb
tumour, ?
DGGE Blanqued et 
al., 1993
31 G-* A transition intron
5
affected splicing site Rb
tumour, ?
DGGE Blanqued et 
al., 1993
32 Ibp deletion 7 70
(exon)
frameshift inexon 7 leads to a 
stop codon at codon 228
Rb
tumour, ?
DGGE Blanqued et 
al., 1993
33 T->C transition intron
8
affected splicing site Rb
tumour, ?
DGGE Blanqued et 
al., 1993
34 lbp deletion 18 12
(exon)
frameshift in exon 18 leads to 
a stop codon at codon 642
Rb
tumour, ?
DGGE Blanqued et 
al., 1993
35 T-»C intron
18
affected splicing site Rb
tumour, ?
DGGE Blanqued et 
al., 1993
36 A22 13 1353 a frameshift causing 
termination codon
somatic SSCP Hogg et al., 
1993
37 C-»T 1 179 splicing ? somatic SSCP Hogg et aL, 
1993
38 A2 19 2076 a frameshift causing 
termination codon
somatic SSCP Hogg et al., 
1993
39 T-»G 14 1508 causing splice acceptor site or 
stop codon
? SSCP Hogg et al., 
1993
40 C->T 11 1210 arginine-»stop codon somatic SSCP Hogg et al., 
1993
41 C-»T 14 1501 arginine—»stop codon somatic SSCP Hogg et al., 
1993
42 Al 4 638 splice donor deletion of exon 
4
? SSCP Hogg et al., 
1993
43 TTT-»C 4 622 a frameshift causing 
termination codon
somatic SSCP Hogg et al., 
1993
44 A4 24 2658 splice donor—^frameshift—» 
stop codon
somatic SSCP Hogg et al., 
1993
45 C —»T 17 1804 arginine—fcstop codon somatic SSCP Hogg et al., 
1993
46
47
C —>T 10 1096 arginine—wtop codon ? SSCP Hogg et al., 
1993
C-»T 12 1173 glutamine—»stop codon somatic SSCP Hogg et al., 
1993
48 A4 4 538 a frameshift causing 
termination codon
somatic SSCP Hogg et al., 
1993
49 G —»T 10 1105 glutamic acid—«top codon somatic SSCP Hoggetal.,
1993
50 C->T 17 1791 arginine—»stop codon somatic SSCP Hogg et al., 
1993
51 01 16 1576 a frameshift causing 
termination codon
somatic SSCP Hogg et aL, 
1993
52 A2 3 422 a frameshift causing 
termination codon
leukocyte
DNA,
germline
SSCP Onadimet 
al., 1993
53 A l 17 a frameshift causing 
termination codon
leukocyte
DNA,
germline
SSCP Onadimet 
al., 1993
54 01 13 a frameshift causing 
termination codon
leukocyte 
DNA, 
germ line
SSCP Onadimet 
al., 1993
178
MUTATION LOCATION OF
MUTATION
Exon bp codon
RESULTING CHANGE Material 
or type of 
mutation
TECHNIQUE AUTHOR
55 A7&020 17 502 a frameshift causing 
termination codon
Rb
tumour
bilateral
SSCP Schmizu et 
al., 1994
56 A - * } 11 acceptor site Rb
tumour
bilateral
SSCP Schmizu et 
al., 1994
57 T-»G 17 donor site Rb
tumour
bilateral
SSCP Schmizu et 
al., 1994
58 1A 13 444 stop in xon 14 Rb
tumour
bilateral
SSCP Schmizu et 
al., 1994
59 C—>T 12 384 Glutamine—wtop Rb
tumour
bilateral
SSCP Schmizu et 
al., 1994
60 1A 24 833 stop in exon 25 Rb
tumour
bilateral
SSCP Schmizu et 
al., 1994
61 C—»T 14 455 Arginine—»stop Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
62 10 2 71 stop in exon 3 Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
63 1A 13 412 stop in exon 13 Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
64 C—»A 16 489 cysteine—*stop Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
65 T-»A 12 389 leusine—«top Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
66 10 22 771 stop in exon 23 Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
67 40 15 472 stop in exon 16 Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
68 20 19 646 stop in exon 19 Rb
tumour
unilateral
SSCP Schmizu et 
al., 1994
69 A-»C intron
16
splice acceptor site mutation, 
trucated RNA transcript, 
skipping exon 17
leukocyte
DNA
germ line
RT-PCR,
AMD
Dundar, 1994
70 A—>G inton
19
does not result any change leukocyte
DNA 
germ line
SSCP Dundar, 1994
71 T—»G 16 1587 483 Histidine—^glutamine leukocyte
DNA
germline
AMD DGndar, 1994
72 OG 21 2251 a fiameshift in exon 21 leads 
to a stop codon 719
leukocyte
DNA
germline
SSCP Dundar, 1994
73 A->C 16 1636 500 affecting splice site leukocyte
DNA
germline
SSCP Dfindar, 1994
74 T-^C 16 493 causes no change in the 
amino acid pattern
leukocyte
DNA
germ line
SSCP DQndar, 1994
75 G—>C intron
12
splice donor site mutation tumour,
bladder
SSCP DOndar, 1994
0: insertion, A: deletion
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